{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sqlalchemy as db\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "engine = db.create_engine(\"sqlite:///../COVID-Clinical-Trials.sqlite\")\n",
    "connection = engine.connect()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "insp = db.inspect(engine)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['COVID_ClinicalTrials',\n",
       " 'Conditions',\n",
       " 'Exclusion_Criteria',\n",
       " 'Inclusion_Criteria',\n",
       " 'Interventions',\n",
       " 'Keywords',\n",
       " 'Phase_Recordings',\n",
       " 'lat_long']"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "insp.get_table_names()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "querylist = engine.execute('Select * From Interventions')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'index': 0,\n",
       "  'nctid': 'NCT04332380',\n",
       "  'interventionname': 'Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 1,\n",
       "  'nctid': 'NCT04387929',\n",
       "  'interventionname': 'Detection of anti-COVID-19 antibody level',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 2,\n",
       "  'nctid': 'NCT04332835',\n",
       "  'interventionname': 'Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 3,\n",
       "  'nctid': 'NCT04332835',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400 milligrams each 12 hours for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 4,\n",
       "  'nctid': 'NCT04330261',\n",
       "  'interventionname': 'Exposure (not intervention) - SARS-CoV-2 infection',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Exposure is infection with the virus. There is no intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 5,\n",
       "  'nctid': 'NCT04392323',\n",
       "  'interventionname': 'COVID-19 PCR and Serology',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 6,\n",
       "  'nctid': 'NCT04352764',\n",
       "  'interventionname': 'CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': \"The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 7,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Hydroxychloroquine - Daily Dosing',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.\\n\\nAll treatment groups will receive placebo pills to have the patients take 2 pills a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 8,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Hydroxychloroquine - Weekly Dosing',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria\\n\\nAll treatment groups will receive placebo pills to have the patients take 2 pills a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 9,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..\\n\\nParticipants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.\\n\\nAdditional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 10,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Monitoring Visit - Baseline',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 11,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Monitoring Visit - Week 4',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 12,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Monitoring Visit - Week 8',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 13,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Weekly Assessment',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 &7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 14,\n",
       "  'nctid': 'NCT04377425',\n",
       "  'interventionname': 'COVID-19 swap test PCR',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'COVID-19 swap test PCR performed according to hospital standard operating procedures',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 15,\n",
       "  'nctid': 'NCT04349202',\n",
       "  'interventionname': 'EUROIMMUN assay',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Serology testing to detect SARS-CoV-2 antibodies',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 16,\n",
       "  'nctid': 'NCT04336462',\n",
       "  'interventionname': 'oxyhydrogen',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 17,\n",
       "  'nctid': 'NCT04336462',\n",
       "  'interventionname': 'Oxygen',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'oxygen inhaled,3 L/min . 6 hour a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 18,\n",
       "  'nctid': 'NCT04388683',\n",
       "  'interventionname': 'Nitric Oxide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (\"day 1\"), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 19,\n",
       "  'nctid': 'NCT04353206',\n",
       "  'interventionname': 'Multiple Doses of Anti-SARS-CoV-2 convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 20,\n",
       "  'nctid': 'NCT04347174',\n",
       "  'interventionname': 'Suspension of heat killed (autoclaved) Mycobacterium w',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 21,\n",
       "  'nctid': 'NCT04347174',\n",
       "  'interventionname': 'Standard therapy of COVID-19',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 22,\n",
       "  'nctid': 'NCT04380532',\n",
       "  'interventionname': 'V-SARS',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 23,\n",
       "  'nctid': 'NCT04397757',\n",
       "  'interventionname': 'COVID-19 Convalescent Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '2 units of COVID-19 convalescent plasma compatible with their blood type',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 24,\n",
       "  'nctid': 'NCT04352348',\n",
       "  'interventionname': 'blood samples',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'All arms:\\n\\n1 blood sample at inclusion (T0)\\n\\nCOVID-19 positive, severe only:\\n\\n1 blood sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms and, eventually, at discharge from hospital if the last blood sample was more than 3 days old',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 25,\n",
       "  'nctid': 'NCT04367402',\n",
       "  'interventionname': 'BioMedomics COVID-19 IgM-IgG Rapid Test',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 26,\n",
       "  'nctid': 'NCT04350073',\n",
       "  'interventionname': 'Q-NRG Metobolic Cart Device',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 27,\n",
       "  'nctid': 'NCT04350073',\n",
       "  'interventionname': 'MuscleSound Ultrasound',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 28,\n",
       "  'nctid': 'NCT04350073',\n",
       "  'interventionname': 'Multifrequency Bioimpedance Spectroscopy',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 29,\n",
       "  'nctid': 'NCT04344457',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200 mg PO BID 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 30,\n",
       "  'nctid': 'NCT04344457',\n",
       "  'interventionname': 'Indomethacin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '50 mg PO TID 14 Days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 31,\n",
       "  'nctid': 'NCT04344457',\n",
       "  'interventionname': 'Zithromax Oral Product',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '500 mg PO QD 3 Days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 32,\n",
       "  'nctid': 'NCT04385017',\n",
       "  'interventionname': 'COVID-19 patients',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 33,\n",
       "  'nctid': 'NCT04384588',\n",
       "  'interventionname': 'Convalescent Plasma from COVID-19 donors',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 34,\n",
       "  'nctid': 'NCT04379310',\n",
       "  'interventionname': 'ACE Inhibitors and Calcium Channel Blockers',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'effect of drugs on patients with covid-19 pneumonia',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 35,\n",
       "  'nctid': 'NCT04374526',\n",
       "  'interventionname': 'COVID-19 Convalescent Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 36,\n",
       "  'nctid': 'NCT04366271',\n",
       "  'interventionname': 'Mesenchymal cells',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 37,\n",
       "  'nctid': 'NCT04366271',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Best treatment option for COVID-19 according to investigator criteria',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 38,\n",
       "  'nctid': 'NCT04393961',\n",
       "  'interventionname': 'Premier Biotech COVID-19 IgG/IgM Rapid test Cassette',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': \"Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.\\n\\nThe protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.\\n\\nWe chose the Precision Bio test for 4 reasons\\n\\nIt is available as a single use test kit in one sealed unit.\\nIt's a rapid test, with results available in 10 minutes.\\nIt has clear and easy to read instructions already included\\nIt has one of the lowest false positive rates of known tests at the moment\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 39,\n",
       "  'nctid': 'NCT04365985',\n",
       "  'interventionname': 'Naltrexone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 40,\n",
       "  'nctid': 'NCT04365985',\n",
       "  'interventionname': 'Ketamine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 41,\n",
       "  'nctid': 'NCT04365985',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 42,\n",
       "  'nctid': 'NCT04390165',\n",
       "  'interventionname': 'Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': \"This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 43,\n",
       "  'nctid': 'NCT04388527',\n",
       "  'interventionname': 'COVID-19 Convalescent Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 44,\n",
       "  'nctid': 'NCT04355897',\n",
       "  'interventionname': 'Convalescent COVID 19 Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 45,\n",
       "  'nctid': 'NCT04354831',\n",
       "  'interventionname': 'anti-SARS-CoV-2 convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL maximum dose as 7 ml/kg adjusted IBW )\\nStudy drug will be administered as a single intravenous infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 46,\n",
       "  'nctid': 'NCT04370288',\n",
       "  'interventionname': 'MCN (Methylene blue, vitamin C, N-acetyl cysteine)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'A mixture of MCN will be injected to covid-19 patients.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 47,\n",
       "  'nctid': 'NCT04343755',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Fresh plasma will be infused one time to hospitalized patients with COVID-19 infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 48,\n",
       "  'nctid': 'NCT04252274',\n",
       "  'interventionname': 'Darunavir and Cobicistat',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 49,\n",
       "  'nctid': 'NCT04322682',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 50,\n",
       "  'nctid': 'NCT04322682',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 51,\n",
       "  'nctid': 'NCT04345692',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 52,\n",
       "  'nctid': 'NCT04345523',\n",
       "  'interventionname': 'Blood and derivatives.',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Administration of fresh plasma from donor immunized against COVID-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 53,\n",
       "  'nctid': 'NCT04345523',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care for the treatment of COVID-19 in hospitalized patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 54,\n",
       "  'nctid': 'NCT04370808',\n",
       "  'interventionname': 'Exposure',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 55,\n",
       "  'nctid': 'NCT04321811',\n",
       "  'interventionname': 'Observation of patients with known, suspected, or at risk for COVID-19 infection',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 56,\n",
       "  'nctid': 'NCT04369859',\n",
       "  'interventionname': 'Examine the impact of COVID-19 during pregnancy',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'clinical data collection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 57,\n",
       "  'nctid': 'NCT04379284',\n",
       "  'interventionname': 'Biospecimen collection',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.\\n\\nNeonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 58,\n",
       "  'nctid': 'NCT04358783',\n",
       "  'interventionname': 'Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 59,\n",
       "  'nctid': 'NCT04358783',\n",
       "  'interventionname': 'Best Available Therapy',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 60,\n",
       "  'nctid': 'NCT04324463',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral medication',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 61,\n",
       "  'nctid': 'NCT04324463',\n",
       "  'interventionname': 'Hydoxychloroquine or Chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral medication',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 62,\n",
       "  'nctid': 'NCT04324463',\n",
       "  'interventionname': 'Interferon-Beta',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'subcutaneous injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 63,\n",
       "  'nctid': 'NCT04384497',\n",
       "  'interventionname': 'SARS-CoV-2 convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 64,\n",
       "  'nctid': 'NCT04384042',\n",
       "  'interventionname': 'Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': \"This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 65,\n",
       "  'nctid': 'NCT04325061',\n",
       "  'interventionname': 'Dexamethasone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 66,\n",
       "  'nctid': 'NCT04387279',\n",
       "  'interventionname': 'Interview',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': \"Surveys on medical use patterns and patient's perceptions about COVID-19\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 67,\n",
       "  'nctid': 'NCT04388618',\n",
       "  'interventionname': 'NHANES smell and taste tests',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 68,\n",
       "  'nctid': 'NCT04313023',\n",
       "  'interventionname': 'PUL-042 Inhalation Solution',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 69,\n",
       "  'nctid': 'NCT04313023',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sterile saline for inhalation',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 70,\n",
       "  'nctid': 'NCT04256395',\n",
       "  'interventionname': 'mobile internet survey on self-test',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '1. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 71,\n",
       "  'nctid': 'NCT04359095',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Generic drug distributed by the Colombian Health System for autoimmune and infectious diseases. It is classified as an anti infectious drug and its current indications include treatment of malaria, lupus erythematosus and rheumatoid arthritis.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 72,\n",
       "  'nctid': 'NCT04359095',\n",
       "  'interventionname': 'Lopinavir / Ritonavir Pill',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': \"Generic drug distributed by the Colombian Health System as an insurance treatment for Human Immunodeficiency Virus (HIV) and Acquired immunodeficiency syndrome (AIDS). It belongs to the group of drugs intended for infectious disease. It contains a combination of protease inhibitors, with a synergic effect in the lopinavir's blood and tissue concentration to inhibit viral replication.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 73,\n",
       "  'nctid': 'NCT04359095',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Generic drug distributed by the Colombian Health System for the treatment of infectious diseases. It is currently used to treat susceptible microorganisms, including respiratory tract infections, sinusitis, pharyngitis, pneumonia, skin infections and sexually transmitted diseases.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 74,\n",
       "  'nctid': 'NCT04359095',\n",
       "  'interventionname': 'Standard treatment',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Standard treatment which does not contain Hydroxychloroquine, Lopinavir/ritonavir or Azithromycin. It is defined as treatment aimed to control symptoms including fever and pain, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 75,\n",
       "  'nctid': 'NCT04333355',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 76,\n",
       "  'nctid': 'NCT04376853',\n",
       "  'interventionname': 'Apple Watch Series 5',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Digital monitoring via Apple Watch',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 77,\n",
       "  'nctid': 'NCT04382794',\n",
       "  'interventionname': 'Retrospective case-control analysis',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 78,\n",
       "  'nctid': 'NCT04341168',\n",
       "  'interventionname': 'this study is non- interventional',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'this study is non- interventional',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 79,\n",
       "  'nctid': 'NCT04363450',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 80,\n",
       "  'nctid': 'NCT04363450',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 81,\n",
       "  'nctid': 'NCT04389710',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 82,\n",
       "  'nctid': 'NCT04344015',\n",
       "  'interventionname': 'Plasma Donation',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Previously infected COVID-19 patients will be recruited to donate convalescent plasma.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 83,\n",
       "  'nctid': 'NCT04331600',\n",
       "  'interventionname': 'Chloroquine phosphate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral chloroquine phosphate for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 84,\n",
       "  'nctid': 'NCT04331600',\n",
       "  'interventionname': 'Telemedicine',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Telemedical supervision for 42 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 85,\n",
       "  'nctid': 'NCT04362176',\n",
       "  'interventionname': 'pathogen reduced SARS-CoV-2 convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 86,\n",
       "  'nctid': 'NCT04362176',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': \"Lactated Ringer's solution with multivitamins\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 87,\n",
       "  'nctid': 'NCT04390503',\n",
       "  'interventionname': 'Convalescent Plasma (anti-SARS-CoV-2 plasma)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Convalescent Plasma that contains antibody titers against SARS-CoV-2.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 88,\n",
       "  'nctid': 'NCT04390503',\n",
       "  'interventionname': 'Control (albumin 5%)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Albumin (Human) 5% is a sterile aqueous solution for intravenous use containing the albumin component human plasma.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 89,\n",
       "  'nctid': 'NCT04329611',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'COVID19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 90,\n",
       "  'nctid': 'NCT04331509',\n",
       "  'interventionname': 'No Intervention',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'No Intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 91,\n",
       "  'nctid': 'NCT04395664',\n",
       "  'interventionname': 'C3+ Holter Monitor',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'ECG monitoring',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 92,\n",
       "  'nctid': 'NCT04393558',\n",
       "  'interventionname': 'ADAM Sensor',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 93,\n",
       "  'nctid': 'NCT04352751',\n",
       "  'interventionname': 'convalescent plasma',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Plasmapheresis, 900 - 1000 mL each time.\\nStandard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.\\nIsovolumic saline replacement should be done.\\nEach donor can donate convalescent plasma again after an interval of every 2 weeks',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 94,\n",
       "  'nctid': 'NCT04312997',\n",
       "  'interventionname': 'PUL-042 Inhalation Solution',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 95,\n",
       "  'nctid': 'NCT04312997',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sterile saline for inhalation',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 96,\n",
       "  'nctid': 'NCT04364802',\n",
       "  'interventionname': 'Povidone-Iodine Nasal Spray and Gargle',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 97,\n",
       "  'nctid': 'NCT04364802',\n",
       "  'interventionname': 'Povidone-Iodine Nasal Spray and Gargle',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 98,\n",
       "  'nctid': 'NCT04343690',\n",
       "  'interventionname': 'Crisis management coaching',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 99,\n",
       "  'nctid': 'NCT04348864',\n",
       "  'interventionname': 'COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'An immunodiagnostic rapid (5-20 minute) test detects circulating antibodies (IgM and IgG) in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 in the past.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 100,\n",
       "  'nctid': 'NCT04348864',\n",
       "  'interventionname': 'Telemedicine',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Imaging of the test and upload to server by the subject and phone, video or messaging consult with a clinician for interpretation and instructions establishes the telemedicine (i.e. virtual point-of-care).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 101,\n",
       "  'nctid': 'NCT04394208',\n",
       "  'interventionname': 'Silymarin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Silymarin Oral at a dose of 420 mg/day in 3 divided doses.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 102,\n",
       "  'nctid': 'NCT04394208',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo comparator',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 103,\n",
       "  'nctid': 'NCT04366024',\n",
       "  'interventionname': 'other',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'clinical diagnosis',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 104,\n",
       "  'nctid': 'NCT04372602',\n",
       "  'interventionname': 'Duvelisib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 105,\n",
       "  'nctid': 'NCT04372602',\n",
       "  'interventionname': 'Peripheral blood draw',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'First 10 patients enrolled\\nScreening, Day 2, Day 4, Day 8, Day 15, and Day 29',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 106,\n",
       "  'nctid': 'NCT04335123',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 107,\n",
       "  'nctid': 'NCT04400305',\n",
       "  'interventionname': 'Digital Health Online Platform',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:\\n\\nLesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 108,\n",
       "  'nctid': 'NCT04365231',\n",
       "  'interventionname': 'Hydroxychloroquine and azithromycin treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.\\n\\n- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 109,\n",
       "  'nctid': 'NCT04365231',\n",
       "  'interventionname': 'conventional management of patients',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'conventional management of patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 110,\n",
       "  'nctid': 'NCT04360538',\n",
       "  'interventionname': 'Quality of Life',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Physical disability assessment tool',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 111,\n",
       "  'nctid': 'NCT04360538',\n",
       "  'interventionname': 'Impact Event Score',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Psychological Sequelae assessment tool',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 112,\n",
       "  'nctid': 'NCT04360538',\n",
       "  'interventionname': 'Hospital anxiety and depression scale',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Psychological Sequelae assessment tool',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 113,\n",
       "  'nctid': 'NCT04331899',\n",
       "  'interventionname': 'Peginterferon Lambda-1a',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 114,\n",
       "  'nctid': 'NCT04331899',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 115,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Hidroxicloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hidroxicloroquine 200 mg BID oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 116,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir 200/50 mg BID oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 117,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Imatinib tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Imatinib 400 mg QD oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 118,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Baricitinib Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib 4 mg QD oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 119,\n",
       "  'nctid': 'NCT04323332',\n",
       "  'interventionname': 'Traditional Chinese Medicine Prescription',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 120,\n",
       "  'nctid': 'NCT04381819',\n",
       "  'interventionname': 'SARS-CoV-2 PCR',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'SARS-CoV-2 E gene',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 121,\n",
       "  'nctid': 'NCT04365699',\n",
       "  'interventionname': 'AT-001',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 122,\n",
       "  'nctid': 'NCT04367857',\n",
       "  'interventionname': 'COVID-19 Serology',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 123,\n",
       "  'nctid': 'NCT04367857',\n",
       "  'interventionname': 'Health Care Worker Survey',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 124,\n",
       "  'nctid': 'NCT04379336',\n",
       "  'interventionname': 'Bacille Calmette-Guérin (BCG)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'BCG vaccine will be given intradermally in the upper arm after randomization.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 125,\n",
       "  'nctid': 'NCT04379336',\n",
       "  'interventionname': 'Placebo Comparator',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Placebo injection will be given intradermally in the upper arm after randomization.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 126,\n",
       "  'nctid': 'NCT04381988',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 127,\n",
       "  'nctid': 'NCT04381988',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '400mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 128,\n",
       "  'nctid': 'NCT04381988',\n",
       "  'interventionname': 'Radiation therapy',\n",
       "  'interventiontype': 'Radiation',\n",
       "  'interventiondesc': \"Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 129,\n",
       "  'nctid': 'NCT04371510',\n",
       "  'interventionname': 'blood sample',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 130,\n",
       "  'nctid': 'NCT04378595',\n",
       "  'interventionname': 'During COVID-19 Pandemic',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Assessing status of food insecurity during the COVID-19 pandemic',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 131,\n",
       "  'nctid': 'NCT04378595',\n",
       "  'interventionname': 'After COVID-19 Pandemic',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Assessing status of food insecurity after the COVID-19 pandemic',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 132,\n",
       "  'nctid': 'NCT04372017',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 133,\n",
       "  'nctid': 'NCT04372017',\n",
       "  'interventionname': 'Vitamin D',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 134,\n",
       "  'nctid': 'NCT04360122',\n",
       "  'interventionname': 'Levamisole',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Levamisole (150 mg/day for two days per week for 2 months',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 135,\n",
       "  'nctid': 'NCT04360122',\n",
       "  'interventionname': 'Isoprinosine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Isoprinosine (1 g 3 times per day daily) for two months',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 136,\n",
       "  'nctid': 'NCT04360122',\n",
       "  'interventionname': 'Levamisole and Isoprinosine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 137,\n",
       "  'nctid': 'NCT04382586',\n",
       "  'interventionname': 'Zanubrutinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '320 mg (4 x 80 mg) capsules administered orally once daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 138,\n",
       "  'nctid': 'NCT04382586',\n",
       "  'interventionname': 'Supportive Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Supportive care treatment is selected and administered as deemed appropriate by the study investigator.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 139,\n",
       "  'nctid': 'NCT04382586',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo to match zanubrutinib',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 140,\n",
       "  'nctid': 'NCT04363346',\n",
       "  'interventionname': 'FT516',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 141,\n",
       "  'nctid': 'NCT04331665',\n",
       "  'interventionname': 'Ruxolitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 142,\n",
       "  'nctid': 'NCT04340232',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will receive a 2 mg oral dose of baricitinib.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 143,\n",
       "  'nctid': 'NCT04370262',\n",
       "  'interventionname': 'HCQ + Intravenous Famotidine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'IV famotidine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 144,\n",
       "  'nctid': 'NCT04370262',\n",
       "  'interventionname': 'HCQ + Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'IV placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 145,\n",
       "  'nctid': 'NCT04318444',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 146,\n",
       "  'nctid': 'NCT04318444',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 147,\n",
       "  'nctid': 'NCT04352946',\n",
       "  'interventionname': 'Hydroxychloroquine Pre-Exposure Prophylaxis',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'HCQ PreP 400mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 148,\n",
       "  'nctid': 'NCT04352946',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo tablets 400mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 149,\n",
       "  'nctid': 'NCT04395391',\n",
       "  'interventionname': 'SARS-CoV-2',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Determine usability of study materials and kit',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 150,\n",
       "  'nctid': 'NCT04392427',\n",
       "  'interventionname': 'Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.\\n\\nSample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.\\nRandomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)\\nIntervention:\\n\\nA) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 151,\n",
       "  'nctid': 'NCT04362137',\n",
       "  'interventionname': 'Ruxolitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ruxolitinib 5 mg tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 152,\n",
       "  'nctid': 'NCT04362137',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Matching-image placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 153,\n",
       "  'nctid': 'NCT04354701',\n",
       "  'interventionname': 'Web-based REDCap survey',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 154,\n",
       "  'nctid': 'NCT04374032',\n",
       "  'interventionname': 'metenkefalin + tridecactide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 155,\n",
       "  'nctid': 'NCT04374032',\n",
       "  'interventionname': 'The standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 156,\n",
       "  'nctid': 'NCT04379544',\n",
       "  'interventionname': 'Observation only',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 157,\n",
       "  'nctid': 'NCT04350931',\n",
       "  'interventionname': 'intradermal injection of BCG Vaccine',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 158,\n",
       "  'nctid': 'NCT04350931',\n",
       "  'interventionname': 'placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 159,\n",
       "  'nctid': 'NCT04327206',\n",
       "  'interventionname': 'BCG Vaccine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.\\n\\nEach 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 160,\n",
       "  'nctid': 'NCT04327206',\n",
       "  'interventionname': '0.9%NaCl',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.9% Sodium Chloride Injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 161,\n",
       "  'nctid': 'NCT04359810',\n",
       "  'interventionname': 'Convalescent Plasma (anti-SARS-CoV-2 plasma)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Convalescent Plasma that contains antibody titers against SARS-CoV-2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 162,\n",
       "  'nctid': 'NCT04359810',\n",
       "  'interventionname': 'Non-convalescent Plasma (control plasma)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 163,\n",
       "  'nctid': 'NCT04362189',\n",
       "  'interventionname': 'HB-adMSC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hope Biosciences allogeneic adipose-derived mesenchymal stem cells',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 164,\n",
       "  'nctid': 'NCT04362189',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Saline',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 165,\n",
       "  'nctid': 'NCT04377620',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo administered BID approximately 12 hours apart',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 166,\n",
       "  'nctid': 'NCT04377620',\n",
       "  'interventionname': 'Ruxolitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ruxolitinb administered BID approximately 12 hours apart',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 167,\n",
       "  'nctid': 'NCT04394117',\n",
       "  'interventionname': 'Angiotensin Receptor Blockers',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Angiotensin Receptor Blockers class have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin II by competitive antagonism of the angiotensin receptor. ARBs displace angiotensin II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of angiotensin II-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response.\\n\\nThe virus causing COVID-19, the SARS-CoV-2 virus binds to the extracellular portion of ACE2 expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 168,\n",
       "  'nctid': 'NCT04329832',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 169,\n",
       "  'nctid': 'NCT04329832',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization, the prior doses will count toward the 5-day total.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 170,\n",
       "  'nctid': 'NCT04331795',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.\\n\\nSecond dose is provisioned if:\\n\\nIncreasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND\\nCRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 171,\n",
       "  'nctid': 'NCT04331795',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.\\n\\nSecond dose is provisioned if:\\n\\nIncreasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND\\nCRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 172,\n",
       "  'nctid': 'NCT04346615',\n",
       "  'interventionname': 'Vazegepant (BHV-3500)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '10 mg intranasal (IN) for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 173,\n",
       "  'nctid': 'NCT04346615',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo Q8h for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 174,\n",
       "  'nctid': 'NCT04328961',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 175,\n",
       "  'nctid': 'NCT04328961',\n",
       "  'interventionname': 'Ascorbic Acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 176,\n",
       "  'nctid': 'NCT04352634',\n",
       "  'interventionname': 'Exposure to the SARS-CoV-2 and its consequences',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 177,\n",
       "  'nctid': 'NCT04337918',\n",
       "  'interventionname': 'NORS (Nitric Oxide Releasing Solution)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 178,\n",
       "  'nctid': 'NCT04337918',\n",
       "  'interventionname': 'NORS (Nitric Oxide Releasing Solution)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.\\n\\nAny participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 179,\n",
       "  'nctid': 'NCT04339426',\n",
       "  'interventionname': 'Atovaquone/Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 180,\n",
       "  'nctid': 'NCT04362813',\n",
       "  'interventionname': 'Canakinumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 181,\n",
       "  'nctid': 'NCT04362813',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 182,\n",
       "  'nctid': 'NCT04348656',\n",
       "  'interventionname': 'Convalescent plasma',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': \"Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 183,\n",
       "  'nctid': 'NCT04368988',\n",
       "  'interventionname': 'SARS-CoV-2 rS',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 184,\n",
       "  'nctid': 'NCT04368988',\n",
       "  'interventionname': 'Matrix-M Adjuvant',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment assigned.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 185,\n",
       "  'nctid': 'NCT04368988',\n",
       "  'interventionname': 'NSS Saline Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Phase 1: Study vaccinations will comprise 2 IM injections at a 21-day interval (Day 0 and Day 21), ideally in alternate deltoids with the study treatment assigned (ie, saline).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 186,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 400 mg twice a day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial compound',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 187,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 600 mg twice a day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial compound',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 188,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 600 mg once a day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial compound',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 189,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 190,\n",
       "  'nctid': 'NCT04306497',\n",
       "  'interventionname': 'TCM prescriptions',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 191,\n",
       "  'nctid': 'NCT04397614',\n",
       "  'interventionname': 'mHealth Assessments',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Daily symptom tracker',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 192,\n",
       "  'nctid': 'NCT04345315',\n",
       "  'interventionname': 'serological test',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'serological test assessing IgM and IgG directed against SARS-CoV-2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 193,\n",
       "  'nctid': 'NCT04345315',\n",
       "  'interventionname': 'Rapid molecular test',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 194,\n",
       "  'nctid': 'NCT04345315',\n",
       "  'interventionname': 'Next generation Sequencing (NGS) analysis',\n",
       "  'interventiontype': 'Genetic',\n",
       "  'interventiondesc': 'analysis of genetic variability of virus and host',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 195,\n",
       "  'nctid': 'NCT04345315',\n",
       "  'interventionname': 'serum chemistry analysis',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Analysis of serum chemistry factors and coagulation panel in blood samples',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 196,\n",
       "  'nctid': 'NCT04339660',\n",
       "  'interventionname': 'UC-MSCs',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '1*10E6 UC-MSCs /kg body weight suspended in 100mL saline',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 197,\n",
       "  'nctid': 'NCT04339660',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '100mL saline intravenously',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 198,\n",
       "  'nctid': 'NCT04350476',\n",
       "  'interventionname': 'VitalConnect Vital Sign Patch',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.\\n\\nThis patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 199,\n",
       "  'nctid': 'NCT04371640',\n",
       "  'interventionname': 'Sirolimus 1 MG/ML',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 200,\n",
       "  'nctid': 'NCT04371640',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 201,\n",
       "  'nctid': 'NCT04382066',\n",
       "  'interventionname': 'Plitidepsin 1.5 mg/day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 202,\n",
       "  'nctid': 'NCT04382066',\n",
       "  'interventionname': 'Plitidepsin 2.0 mg/day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 203,\n",
       "  'nctid': 'NCT04382066',\n",
       "  'interventionname': 'Plitidepsin 2.5 mg/day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 204,\n",
       "  'nctid': 'NCT04368260',\n",
       "  'interventionname': 'Control swab',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'FDA-cleared nasopharyngeal swab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 205,\n",
       "  'nctid': 'NCT04368260',\n",
       "  'interventionname': 'Prototype swab',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Injection molded polypropylene flocked nylon nasopharyngeal swab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 206,\n",
       "  'nctid': 'NCT04335084',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Prophylaxis treatment for COVID-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 207,\n",
       "  'nctid': 'NCT04335084',\n",
       "  'interventionname': 'Vitamin C',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Prophylaxis treatment for COVID-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 208,\n",
       "  'nctid': 'NCT04335084',\n",
       "  'interventionname': 'Vitamin D',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Prophylaxis treatment for COVID-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 209,\n",
       "  'nctid': 'NCT04335084',\n",
       "  'interventionname': 'Zinc',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Prophylaxis treatment for COVID-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 210,\n",
       "  'nctid': 'NCT04361214',\n",
       "  'interventionname': 'Leflunomide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 211,\n",
       "  'nctid': 'NCT04394104',\n",
       "  'interventionname': 'Survey',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'No intervention is being administered.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 212,\n",
       "  'nctid': 'NCT04357327',\n",
       "  'interventionname': 'rapid salivary test',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 213,\n",
       "  'nctid': 'NCT04373759',\n",
       "  'interventionname': 'Cardiopulmonary resuscitation',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Cardiopulmonary resuscitation',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 214,\n",
       "  'nctid': 'NCT04373759',\n",
       "  'interventionname': 'Modified Rankin score',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '0 - no symptoms at all\\n\\n- no significant disability despite symptoms; able to carry out all usual duties and activities\\n- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance\\n- Moderate disability; requiring some help, but able to walk without assistance\\n- Moderately severe disability; unable to walk and attend to bodily needs without assistance\\n- Severe disability; bedridden, incontinent and requiring constant nursing care and attention\\n- Dead',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 215,\n",
       "  'nctid': 'NCT04369794',\n",
       "  'interventionname': 'BCG',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 216,\n",
       "  'nctid': 'NCT04369794',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '0.9% saline in the same volume as the BCG vaccine in a single dose',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 217,\n",
       "  'nctid': 'NCT04382417',\n",
       "  'interventionname': 'Observational study',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Not required',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 218,\n",
       "  'nctid': 'NCT04353674',\n",
       "  'interventionname': 'Control group',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Patients randomized into this group will receive standard of care for COVID-19 infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 219,\n",
       "  'nctid': 'NCT04353674',\n",
       "  'interventionname': 'SLEDD with a L-MOD',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 220,\n",
       "  'nctid': 'NCT04374461',\n",
       "  'interventionname': 'N-acetylcysteine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 221,\n",
       "  'nctid': 'NCT04374565',\n",
       "  'interventionname': 'High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Pathogen reduced SARS-CoV-2 convalescent plasma (2 units; ~200 mL each for a total of 400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 222,\n",
       "  'nctid': 'NCT04384250',\n",
       "  'interventionname': 'Whole Exome Sequencing',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Genetic study of patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 223,\n",
       "  'nctid': 'NCT04351620',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 224,\n",
       "  'nctid': 'NCT04315298',\n",
       "  'interventionname': 'Sarilumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Single intravenous (IV) dose of sarilumab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 225,\n",
       "  'nctid': 'NCT04315298',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Single intravenous (IV) dose of placebo to match sarilumab administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 226,\n",
       "  'nctid': 'NCT04355936',\n",
       "  'interventionname': 'Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Control arm will receive standard care.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 227,\n",
       "  'nctid': 'NCT04350593',\n",
       "  'interventionname': 'Dapagliflozin 10 MG',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Active Comparator: Dapagliflozin 10mg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 228,\n",
       "  'nctid': 'NCT04350593',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo Comparator',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 229,\n",
       "  'nctid': 'NCT04321993',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir tablet 200mg/50mg 2 tables by mouth twice daily for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 230,\n",
       "  'nctid': 'NCT04321993',\n",
       "  'interventionname': 'Hydroxychloroquine sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine sulfate tablet 200 mg 2 tablets by mouth twice daily for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 231,\n",
       "  'nctid': 'NCT04321993',\n",
       "  'interventionname': 'Baricitinib (janus kinase inhibitor)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib 2 mg po daily for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 232,\n",
       "  'nctid': 'NCT04352491',\n",
       "  'interventionname': 'No intervention',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'No intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 233,\n",
       "  'nctid': 'NCT04359537',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 200 MG',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 234,\n",
       "  'nctid': 'NCT04359537',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Control group will receive a Placebo tablet. Placebo 200mg will be given on Day 1 followed by Placebo 200mg every three weeks.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 235,\n",
       "  'nctid': 'NCT04356937',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:\\n\\nTocilizumab 8mg x 1 (n=185)\\nStandard of care/Placebo (n=93)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 236,\n",
       "  'nctid': 'NCT04356937',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:\\n\\nTocilizumab 8mg x 1 (n=185)\\nStandard of care/Placebo (n=93)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 237,\n",
       "  'nctid': 'NCT04317040',\n",
       "  'interventionname': 'CD24Fc',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'CD24Fc is given on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 238,\n",
       "  'nctid': 'NCT04317040',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo is given on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 239,\n",
       "  'nctid': 'NCT04385251',\n",
       "  'interventionname': 'Data Collection',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Data collection at Screening\\n\\nDemographics\\nSymptoms and health status\\nCo-morbidities\\nTargeted medications Specimen Collection (substudy at selected sites)\\nNasopharyngeal or oropharyngeal swab\\nBlood for serum storage Day 7\\nVital and hospitalization status\\nSymptoms and health status Day 14\\nVital and hospitalization status\\nSymptoms and health status Day 28\\nVital and hospitalization status\\nSymptoms and health status',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 240,\n",
       "  'nctid': 'NCT04308668',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 241,\n",
       "  'nctid': 'NCT04308668',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 242,\n",
       "  'nctid': 'NCT04353180',\n",
       "  'interventionname': 'Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment\\n\\nStandard treatment is according to the protocol of treatment of 2019-nCoV infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 243,\n",
       "  'nctid': 'NCT04353180',\n",
       "  'interventionname': 'Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment\\n\\nStandard treatment is according to the protocol of treatment of 2019-nCoV infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 244,\n",
       "  'nctid': 'NCT04353180',\n",
       "  'interventionname': 'Standard treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard treatment is according to the protocol of treatment of 2019-nCoV infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 245,\n",
       "  'nctid': 'NCT04344600',\n",
       "  'interventionname': 'Peginterferon lambda alfa-1a subcutaneous injection',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon lambda-1a 180 micrograms by subcutaneous injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 246,\n",
       "  'nctid': 'NCT04344600',\n",
       "  'interventionname': 'Saline',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Saline subcutaneous injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 247,\n",
       "  'nctid': 'NCT04389294',\n",
       "  'interventionname': 'SARS-CoV2 serum antibody testing',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 248,\n",
       "  'nctid': 'NCT04341480',\n",
       "  'interventionname': 'Chemotherapy',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Routine chemotherapy for individual tumor type.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 249,\n",
       "  'nctid': 'NCT04321421',\n",
       "  'interventionname': 'hyperimmune plasma',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 250,\n",
       "  'nctid': 'NCT04369742',\n",
       "  'interventionname': 'Hydroxychloroquine (HCQ)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 251,\n",
       "  'nctid': 'NCT04369742',\n",
       "  'interventionname': 'Pacebo: Calcium citrate',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 252,\n",
       "  'nctid': 'NCT04363866',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 253,\n",
       "  'nctid': 'NCT04363866',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'A placebo is a pill that looks like the study drug but has no real medicine in it.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 254,\n",
       "  'nctid': 'NCT04299724',\n",
       "  'interventionname': 'Pathogen-specific aAPC',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 255,\n",
       "  'nctid': 'NCT04374279',\n",
       "  'interventionname': 'Bicalutamide 150 Mg Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Bicalutamide 150 mg by mouth daily for 7 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 256,\n",
       "  'nctid': 'NCT04374279',\n",
       "  'interventionname': 'Ivermectin 3Mg Tab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ivermectin 600 µg/kg (up to a maximum dose of 60mg) by mouth daily for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 257,\n",
       "  'nctid': 'NCT04280705',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 258,\n",
       "  'nctid': 'NCT04280705',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 259,\n",
       "  'nctid': 'NCT04391309',\n",
       "  'interventionname': 'IC14',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '4 mg/kg on Day 1, 2 mg/kg on Days 2-4 in normal saline intravenously',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 260,\n",
       "  'nctid': 'NCT04391309',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Normal saline intravenously on Days 1-4',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 261,\n",
       "  'nctid': 'NCT04381273',\n",
       "  'interventionname': 'No intervention',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'questionnaire-based assessment',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 262,\n",
       "  'nctid': 'NCT04368000',\n",
       "  'interventionname': 'Intermittent prone positioning instructions',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 263,\n",
       "  'nctid': 'NCT04368000',\n",
       "  'interventionname': 'Usual care positioning with no instructions',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Participants will not be given instructions to lie in the prone position for any duration.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 264,\n",
       "  'nctid': 'NCT04323839',\n",
       "  'interventionname': 'Pregnant women under investigation for Coronavirus or diagnosed with COVID-19',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'This is an observational study with no intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 265,\n",
       "  'nctid': 'NCT04323839',\n",
       "  'interventionname': 'Postpartum women under investigation for Coronavirus or diagnosed with COVID-19',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'This is an observational study with no intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 266,\n",
       "  'nctid': 'NCT04400838',\n",
       "  'interventionname': 'ChAdOx1 nCoV-19',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'A single dose of 5x10^10vp of ChAdOx1 nCoV-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 267,\n",
       "  'nctid': 'NCT04400838',\n",
       "  'interventionname': 'MenACWY vaccine',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Standard single dose of MenACWY vaccine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 268,\n",
       "  'nctid': 'NCT04400838',\n",
       "  'interventionname': 'ChAdOx1 nCoV-19 + boost',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two doses of 5x10^10vp of ChAdOx1 nCoV-19 4 weeks apart',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 269,\n",
       "  'nctid': 'NCT04400838',\n",
       "  'interventionname': 'MenACWY vaccine + boost',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two standard doses of MenACWY vaccine 4 weeks apart',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 270,\n",
       "  'nctid': 'NCT04400838',\n",
       "  'interventionname': 'ChAdox1 n-CoV vaccine low dose',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'A single dose of 2.5x10^10vp of ChAdOx1 nCoV-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 271,\n",
       "  'nctid': 'NCT04360551',\n",
       "  'interventionname': 'Telmisartan 40mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Angiotensin Receptor Blocker (ARB)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 272,\n",
       "  'nctid': 'NCT04360551',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo once daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 273,\n",
       "  'nctid': 'NCT04346212',\n",
       "  'interventionname': 'Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also follow clinical complications at 6 months.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 274,\n",
       "  'nctid': 'NCT04334382',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 275,\n",
       "  'nctid': 'NCT04334382',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 276,\n",
       "  'nctid': 'NCT04373044',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given PO',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 277,\n",
       "  'nctid': 'NCT04373044',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given PO',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 278,\n",
       "  'nctid': 'NCT04373044',\n",
       "  'interventionname': 'Placebo Administration',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given Po',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 279,\n",
       "  'nctid': 'NCT04373148',\n",
       "  'interventionname': 'There is no intervention',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'There is no intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 280,\n",
       "  'nctid': 'NCT04382625',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 281,\n",
       "  'nctid': 'NCT04354870',\n",
       "  'interventionname': 'Hydroxychloroquine (HCQ)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 282,\n",
       "  'nctid': 'NCT04380688',\n",
       "  'interventionname': 'Acalabrutinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Acalabrutinib administered orally',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 283,\n",
       "  'nctid': 'NCT04305457',\n",
       "  'interventionname': 'Nitric Oxide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 284,\n",
       "  'nctid': 'NCT04362124',\n",
       "  'interventionname': 'vaccine BCG',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 285,\n",
       "  'nctid': 'NCT04362124',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'A single dose intradermal application of normal saline solution.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 286,\n",
       "  'nctid': 'NCT04374487',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 287,\n",
       "  'nctid': 'NCT04374487',\n",
       "  'interventionname': 'Standard Care Therapy',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 288,\n",
       "  'nctid': 'NCT04334980',\n",
       "  'interventionname': 'bacTRL-Spike',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1A), 3 billion (Group 2A) or 10 billion (Group 3A) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 289,\n",
       "  'nctid': 'NCT04334980',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Placebo consists of bacterial medium without bacteria.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 290,\n",
       "  'nctid': 'NCT04400032',\n",
       "  'interventionname': 'Mesenchymal Stromal Cells',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'The Mesenchymal Stromal Cells will be administered intravenously',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 291,\n",
       "  'nctid': 'NCT04397718',\n",
       "  'interventionname': 'Degarelix',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Degarelix is an FDA-approved drug for prostate cancer',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 292,\n",
       "  'nctid': 'NCT04397718',\n",
       "  'interventionname': 'Saline',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '09% Saline',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 293,\n",
       "  'nctid': 'NCT04365257',\n",
       "  'interventionname': 'Prazosin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants in this arm will receive the study drug as outlined in the arm description.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 294,\n",
       "  'nctid': 'NCT04365257',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants in this arm will receive standard of care.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 295,\n",
       "  'nctid': 'NCT04347538',\n",
       "  'interventionname': 'Saline Nasal Irrigation',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Saline nasal irrigation BID',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 296,\n",
       "  'nctid': 'NCT04347538',\n",
       "  'interventionname': 'Saline with Baby Shampoo Nasal Irrigation',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 297,\n",
       "  'nctid': 'NCT04353596',\n",
       "  'interventionname': 'ACE inhibitor, angiotensin receptor blocker',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 298,\n",
       "  'nctid': 'NCT04384458',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 299,\n",
       "  'nctid': 'NCT04349241',\n",
       "  'interventionname': 'favipiravir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 300,\n",
       "  'nctid': 'NCT04349241',\n",
       "  'interventionname': 'Standard of care therapy',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 301,\n",
       "  'nctid': 'NCT04330690',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir will be administered 400 mg/100 mg orally for a 14-day course plus supportive care, or until discharge from hospital, whichever occurs first',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 302,\n",
       "  'nctid': 'NCT04330690',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 800mg BID for 1 day then 400mg BID for 10 days plus optimized supportive care or until discharge from hospital, whichever occurs first',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 303,\n",
       "  'nctid': 'NCT04330690',\n",
       "  'interventionname': 'remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care or until discharge from hospital, whichever occurs first',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 304,\n",
       "  'nctid': 'NCT04377308',\n",
       "  'interventionname': 'Fluoxetine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 305,\n",
       "  'nctid': 'NCT04343183',\n",
       "  'interventionname': 'Hyperbaric Oxygen Therapy',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 306,\n",
       "  'nctid': 'NCT04304313',\n",
       "  'interventionname': 'Sildenafil citrate tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.1g/day for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 307,\n",
       "  'nctid': 'NCT04292899',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered as an intravenous infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 308,\n",
       "  'nctid': 'NCT04292899',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of Care Treatment for COVID-19 Infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 309,\n",
       "  'nctid': 'NCT04359277',\n",
       "  'interventionname': 'Enoxaparin Higher Dose',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Enoxaparin will be preferred in non-intubated patients with a Cr Clearance of > 30\\nEnoxaparin 1mg/kg q12 SQ hours for weight 50-150kg\\nEnoxaparin 0.75mg/kg q12 SQ hours for weight >150kg or BMI >40\\nUnfractionated IV heparin titrated to a goal antiXa of 0.3-0.5 unit/mL (will be preferred in intubated patients)\\n\\nFor Enoxaparin, AntiXA testing will be done after fourth injection only for participants with BMI >40 or weight > 150 kg as per institutional policy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 310,\n",
       "  'nctid': 'NCT04359277',\n",
       "  'interventionname': 'Lower-dose prophylactic anticoagulation',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Heparin 5000 units every 12 or every 8 hours or 7500 units every 8 hours for BMI > 40 or weight > 150 kg, or\\nEnoxaparin 40mg every 24 hours or 30mg every 12 hours or every 24 hours (with CrCl < 30mL/min) SQ or\\nEnoxaparin 40mg every 12 hours SQ for weight >150kg or BMI >40-50\\nEnoxaparin 60 mg every 12 hours SQ for BMI >50 For Enoxaparin, AntiXA testing will be done after fourth injection only for participants with BMI >40 or weight > 150kg as per institutional policy.\\n\\nFor patients that develop acute kidney injury, and received enoxaparin, transition to IV unfractionated heparin by checking antiXa when next dose of enoxaparin would be due and initiating IV heparin when antiXa <0.7 IU/mL',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 311,\n",
       "  'nctid': 'NCT04378452',\n",
       "  'interventionname': 'COM-COVID anonimous survey',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 312,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 313,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 314,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Zinc Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Zinc sulfate 220mg once daily for 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 315,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Doxycycline',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Doxycycline 200 mg once daily for 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 316,\n",
       "  'nctid': 'NCT04341038',\n",
       "  'interventionname': 'Tacrolimus',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'the necessary dose to obtain blood levels of 8-10 ng / ml',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 317,\n",
       "  'nctid': 'NCT04341038',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '120mg of methylprednisolone daily for 3 consecutive days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 318,\n",
       "  'nctid': 'NCT04398004',\n",
       "  'interventionname': 'Clarithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with 500 mg Clarithromycin orally twice daily for seven days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 319,\n",
       "  'nctid': 'NCT04332107',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will be shipped a single 1.2 g dose of oral azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 320,\n",
       "  'nctid': 'NCT04332107',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will be shipped a dose of matching placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 321,\n",
       "  'nctid': 'NCT04292730',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered as an intravenous infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 322,\n",
       "  'nctid': 'NCT04292730',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of Care Treatment for COVID-19 Infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 323,\n",
       "  'nctid': 'NCT04339998',\n",
       "  'interventionname': 'Point-of-Care Ultrasonography (POCUS)',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:\\n\\nPulmonary POCUS Evaluation:\\n\\nB lines: absent (< 3 lines), present (> 3 lines), fused\\n\\nConsolidation: yes or no\\n\\na. Bilateral: yes or no\\n\\nPleural Effusion: yes or no\\nOther pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities\\n\\nCardiac POCUS Evaluation:\\n\\nParasternal long axis\\n\\nParasternal short axis\\n\\nQualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed\\nEPSS (E-point septal separation): normal (<10 mm), abnormal (>10 mm)\\nLeft ventricular (LV) mass approximation by septal thickness\\nLeft Ventricular Chamber Size by internal diameter at diastole',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 324,\n",
       "  'nctid': 'NCT04385199',\n",
       "  'interventionname': 'Convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'One 200mL transfusion of ABO compatible convalescent plasma over 3 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 325,\n",
       "  'nctid': 'NCT04347239',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebos',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 326,\n",
       "  'nctid': 'NCT04347239',\n",
       "  'interventionname': 'Leronlimab (700mg)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 327,\n",
       "  'nctid': 'NCT04377568',\n",
       "  'interventionname': 'Convalescent plasma (CP)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 328,\n",
       "  'nctid': 'NCT04343976',\n",
       "  'interventionname': 'Pegylated interferon lambda',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '180 mcg subcutaneous injection of pegylated interferon lambda',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 329,\n",
       "  'nctid': 'NCT04356690',\n",
       "  'interventionname': 'Etoposide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4. If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 330,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'Low-dose chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate) weekly\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 331,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'Mid-dose chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate) twice weekly\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 332,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'High-dose chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'chloroquine base 150mg (equivalent to 250mg chloroquine phosphate or 200mg chloroquine sulphate) daily\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 333,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The placebo equivalent of low, medium and high arm. Low- once weekly Medium - twice weekly High - daily\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine or base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 334,\n",
       "  'nctid': 'NCT04336332',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate + Azithromycin',\n",
       "  'interventiontype': 'Combination Product',\n",
       "  'interventiondesc': 'Given PO',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 335,\n",
       "  'nctid': 'NCT04336332',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given PO',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 336,\n",
       "  'nctid': 'NCT04384900',\n",
       "  'interventionname': 'Prone position ventilation',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Patients are placed in a prone position using specialized equipment.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 337,\n",
       "  'nctid': 'NCT04377659',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 338,\n",
       "  'nctid': 'NCT04396353',\n",
       "  'interventionname': 'Electronic questionnaire',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 339,\n",
       "  'nctid': 'NCT04327804',\n",
       "  'interventionname': 'Odd/Even birth year intervention groups',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'The nostril used and order of testing will be different in each arm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 340,\n",
       "  'nctid': 'NCT04368728',\n",
       "  'interventionname': 'BNT162a1',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '0.5 mL intramuscular injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 341,\n",
       "  'nctid': 'NCT04368728',\n",
       "  'interventionname': 'BNT162b1',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '0.5 mL intramuscular injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 342,\n",
       "  'nctid': 'NCT04368728',\n",
       "  'interventionname': 'BNT162b2',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '0.5 mL intramuscular injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 343,\n",
       "  'nctid': 'NCT04368728',\n",
       "  'interventionname': 'BNT162c2',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '0.5 mL intramuscular injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 344,\n",
       "  'nctid': 'NCT04368728',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '0.5 mL Intramuscular injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 345,\n",
       "  'nctid': 'NCT04331366',\n",
       "  'interventionname': 'GO2 PEEP MOUTHPIECE',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 346,\n",
       "  'nctid': 'NCT04319445',\n",
       "  'interventionname': 'Mindfulness session(s)',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 347,\n",
       "  'nctid': 'NCT04320615',\n",
       "  'interventionname': 'Tocilizumab (TCZ)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 348,\n",
       "  'nctid': 'NCT04320615',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 349,\n",
       "  'nctid': 'NCT04342182',\n",
       "  'interventionname': 'Convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.\\n\\nPlasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 350,\n",
       "  'nctid': 'NCT04338568',\n",
       "  'interventionname': 'Lung ultrasound',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 351,\n",
       "  'nctid': 'NCT04344236',\n",
       "  'interventionname': 'Saline oral/nasal rinse',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 352,\n",
       "  'nctid': 'NCT04344236',\n",
       "  'interventionname': '0.5% Povidone/Iodine oral/nasal rinse',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 353,\n",
       "  'nctid': 'NCT04344236',\n",
       "  'interventionname': '0.12% Chlorhexidine oral/nasal rinse',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 354,\n",
       "  'nctid': 'NCT04385264',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 355,\n",
       "  'nctid': 'NCT04385264',\n",
       "  'interventionname': 'Mannitol',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 356,\n",
       "  'nctid': 'NCT04355143',\n",
       "  'interventionname': 'Colchicine Tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 357,\n",
       "  'nctid': 'NCT04355143',\n",
       "  'interventionname': 'Current care per UCLA treating physicians',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Current care',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 358,\n",
       "  'nctid': 'NCT04344444',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'tablets provided as described in Arm B',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 359,\n",
       "  'nctid': 'NCT04344444',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'tablets provided as described in Arm C',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 360,\n",
       "  'nctid': 'NCT04379089',\n",
       "  'interventionname': 'Observational study only',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'No Intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 361,\n",
       "  'nctid': 'NCT04341675',\n",
       "  'interventionname': 'Sirolimus',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 362,\n",
       "  'nctid': 'NCT04341675',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Matching placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 363,\n",
       "  'nctid': 'NCT04338828',\n",
       "  'interventionname': 'Nitric Oxide Gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 364,\n",
       "  'nctid': 'NCT04338828',\n",
       "  'interventionname': 'Inhaled Supplemental Oxygen',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '2 L/min oxygen therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 365,\n",
       "  'nctid': 'NCT04326387',\n",
       "  'interventionname': 'SAMBA II (Diagnostic for the Real World)',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Point of care Isothermal-PCR Viral RNA Amplication for virus detection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 366,\n",
       "  'nctid': 'NCT04326387',\n",
       "  'interventionname': 'Public Health England Gold Standard',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Reverse Transcription PCR',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 367,\n",
       "  'nctid': 'NCT04326387',\n",
       "  'interventionname': 'Cambridge Validated Viral Detection Method',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Reverse Transcription PCR',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 368,\n",
       "  'nctid': 'NCT04326387',\n",
       "  'interventionname': 'Radiological Detection',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Chest X-ray & CT Scan detection of viral infection in the lungs',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 369,\n",
       "  'nctid': 'NCT04355728',\n",
       "  'interventionname': 'Umbilical Cord Mesenchymal Stem Cells',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 370,\n",
       "  'nctid': 'NCT04355728',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Standard of care treatment per the treating hospital protocol.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 371,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Escalating doses of SnPP Protoporphyrin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 372,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Escalating doses of SnPP Protoporphyrin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 373,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Escalating doses of SnPP Protoporphyrin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 374,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'SnPP Protoporphyrin plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 375,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'SnPP Protoporphyrin plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 376,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'SnPP Protoporphyrin plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 377,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'Sulfonatoporphyrin(TPPS)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sulfonatoporphyrin(TPPS) plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.\\n\\nArm: Experimental: Administer 9mg TAnthPS dose in subjects with with COVID-19 7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will be administered a single dose of 9 mg of sulfonated tetra-anthracenyl porphyrin (TAnthPS), after 1 houre patients will be followed by Exposure to A computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 378,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'Sulfonatoporphyrin(TPPS)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sulfonatoporphyrin(TPPS)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 379,\n",
       "  'nctid': 'NCT04332991',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.\\n\\nFor this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 380,\n",
       "  'nctid': 'NCT04332991',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 381,\n",
       "  'nctid': 'NCT04383574',\n",
       "  'interventionname': 'Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 300SU/ml',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 382,\n",
       "  'nctid': 'NCT04383574',\n",
       "  'interventionname': 'Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 600SU/ml',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 383,\n",
       "  'nctid': 'NCT04383574',\n",
       "  'interventionname': 'Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 1200SU/ml',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 384,\n",
       "  'nctid': 'NCT04383574',\n",
       "  'interventionname': 'Two doses of placebo at the schedule of day 0,28',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The placebo contains no active ingredient and manufactured by Sinovac Research & Development Co., Ltd.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 385,\n",
       "  'nctid': 'NCT04342897',\n",
       "  'interventionname': 'LY3127804',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered IV',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 386,\n",
       "  'nctid': 'NCT04342897',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered IV',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 387,\n",
       "  'nctid': 'NCT04363008',\n",
       "  'interventionname': 'serum inflammatory biomarkers',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Serum biomarkers measured (IL-1 beta, IL-2, IL-6, IL-10, TNF alpha)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 388,\n",
       "  'nctid': 'NCT04351581',\n",
       "  'interventionname': 'Discontinuation of ACEi/ARB',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Discontinuation of ACEi/ARB',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 389,\n",
       "  'nctid': 'NCT04351581',\n",
       "  'interventionname': 'Continuation of ACEi/ARB',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Continuation of ACEi/ARB',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 390,\n",
       "  'nctid': 'NCT04338074',\n",
       "  'interventionname': 'Tranexamic acid tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 391,\n",
       "  'nctid': 'NCT04338074',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '2 tablets p.o. three times per day x 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 392,\n",
       "  'nctid': 'NCT04401410',\n",
       "  'interventionname': 'Partially HLA-matched Virus Specific T cells (VSTs)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Patients will receive 4 x 10^7 partially HLA-matched Virus Specific T cells (VSTs) as a single infusion.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 393,\n",
       "  'nctid': 'NCT04381052',\n",
       "  'interventionname': 'Clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dose is 25mg intravenously over 30 minutes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 394,\n",
       "  'nctid': 'NCT04381052',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Intravenously administered over 30 minutes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 395,\n",
       "  'nctid': 'NCT04305106',\n",
       "  'interventionname': 'Bevacizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 396,\n",
       "  'nctid': 'NCT04396106',\n",
       "  'interventionname': 'AT-527',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One or two 550 mg tablet(s) of AT-527 administered on Day 1 followed by 1 tablet every ~12 hours (twice a day) + SOC for a total of 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 397,\n",
       "  'nctid': 'NCT04396106',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'One or two placebo tablet(s) administered on Day 1 followed by 1 tablet every ~12 hours (twice a day) + SOC for a total of 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 398,\n",
       "  'nctid': 'NCT04332081',\n",
       "  'interventionname': 'hyperbaric oxygen therapy (HBOT)',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 399,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Chloroquine or Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 400,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Lopinavir/Ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/Ritonavir 200mg/50mg 2-0-2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 401,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Best standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'best standard of care',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 402,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Rivaroxaban',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 403,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Thromboprophylaxis',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'as local standard, most likely to be low molecular weight heparin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 404,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Candesartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'starting dose 4mg once daily, titrated to normotension',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 405,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'non-RAS blocking antihypertensives',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 406,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '25mg i.v. single dose, possibly a repeated dose',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 407,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'placebo for clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'sodium chloride bolus infusions as placebo for clazakizumab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 408,\n",
       "  'nctid': 'NCT04352517',\n",
       "  'interventionname': 'Online Survey',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Online survey completion through google app.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 409,\n",
       "  'nctid': 'NCT04342663',\n",
       "  'interventionname': 'Fluvoxamine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 410,\n",
       "  'nctid': 'NCT04342663',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 411,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'MSTT1041A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of MSTT1041A.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 412,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'MSTT1041A-matched Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of MSTT1041A-matched placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 413,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'UTTR1147A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of UTTR1147A.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 414,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'UTTR1147A-matched Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of UTTR1147A-matched placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 415,\n",
       "  'nctid': 'NCT04343989',\n",
       "  'interventionname': 'Clazakizumab 25 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 416,\n",
       "  'nctid': 'NCT04343989',\n",
       "  'interventionname': 'Clazakizumab 12.5 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 417,\n",
       "  'nctid': 'NCT04343989',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 418,\n",
       "  'nctid': 'NCT04351152',\n",
       "  'interventionname': 'Lenzilumab',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Administered as an intravenous (IV) infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 419,\n",
       "  'nctid': 'NCT04351152',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care therapy per local written policies or guidelines',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 420,\n",
       "  'nctid': 'NCT04399252',\n",
       "  'interventionname': 'Lactobaciltus rhamnosus GG',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Participants will take 2 capsules per day of either LGG or placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 421,\n",
       "  'nctid': 'NCT04399252',\n",
       "  'interventionname': 'Lactobaciltus rhamnosus GG Placebo',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Participants will take 2 capsules per day of LGG placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 422,\n",
       "  'nctid': 'NCT04398290',\n",
       "  'interventionname': 'Inhaled nitric oxide (iNO)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 423,\n",
       "  'nctid': 'NCT04398290',\n",
       "  'interventionname': 'Nitrogen gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '250 mcg/kg ideal body weight (IBW)/hour',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 424,\n",
       "  'nctid': 'NCT04398290',\n",
       "  'interventionname': 'Oxygen gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Supplemental oxygen administered via nasal cannula',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 425,\n",
       "  'nctid': 'NCT04375709',\n",
       "  'interventionname': 'Physical exercise',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 426,\n",
       "  'nctid': 'NCT04375709',\n",
       "  'interventionname': 'Education sessions',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 427,\n",
       "  'nctid': 'NCT04377750',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The placebo treatment arm will include 100 ml of normal saline administered along 60 min',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 428,\n",
       "  'nctid': 'NCT03891420',\n",
       "  'interventionname': 'Galidesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Galidesivir IV infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 429,\n",
       "  'nctid': 'NCT03891420',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo IV infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 430,\n",
       "  'nctid': 'NCT04334148',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral self administered tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 431,\n",
       "  'nctid': 'NCT04334148',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral self administered tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 432,\n",
       "  'nctid': 'NCT04365127',\n",
       "  'interventionname': 'Progesterone 100 MG',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subcutaneous administration twice daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 433,\n",
       "  'nctid': 'NCT04390022',\n",
       "  'interventionname': 'Ivermectin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Single dose of STROMECTOL® tablets at 400mcg/kg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 434,\n",
       "  'nctid': 'NCT04390022',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 435,\n",
       "  'nctid': 'NCT04347226',\n",
       "  'interventionname': 'BMS-986253',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 436,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'Chat-based support',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, social support and behavioral capacity of quitting, and improve mental health during COVID-19 isolation or quarantine.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 437,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'AWARD plus COVID-specific advice',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 438,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'AWARD advice',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 439,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'COVID-19 related health warning leaflet',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking; hygienic advice related to COVID-19, and the most important messages to motivate smoking cessation',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 440,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'Health warning leaflet',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 441,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'SMS-based support',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 442,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'Referral card',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The 3-folded \"Smoking Cessation Services\" card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 443,\n",
       "  'nctid': 'NCT04399967',\n",
       "  'interventionname': 'COSH Self-help smoking cessation booklet',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'A general smoking cessation self-help booklet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 444,\n",
       "  'nctid': 'NCT04393246',\n",
       "  'interventionname': 'EDP1815',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 445,\n",
       "  'nctid': 'NCT04393246',\n",
       "  'interventionname': 'Dapagliflozin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 446,\n",
       "  'nctid': 'NCT04393246',\n",
       "  'interventionname': 'Ambrisentan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 447,\n",
       "  'nctid': 'NCT04393246',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Regular standard of care for COVID-19 patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 448,\n",
       "  'nctid': 'NCT04352608',\n",
       "  'interventionname': 'Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 449,\n",
       "  'nctid': 'NCT04352608',\n",
       "  'interventionname': 'Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 450,\n",
       "  'nctid': 'NCT04352608',\n",
       "  'interventionname': 'Two doses of placebo at the emergency vaccination schedule',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two doses of placebo at the schedule of day 0,14',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 451,\n",
       "  'nctid': 'NCT04352608',\n",
       "  'interventionname': 'Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 452,\n",
       "  'nctid': 'NCT04352608',\n",
       "  'interventionname': 'Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 453,\n",
       "  'nctid': 'NCT04352608',\n",
       "  'interventionname': 'Two doses of placebo at the routine vaccination schedule',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Two doses of placebo at the schedule of day 0,28',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 454,\n",
       "  'nctid': 'NCT04379661',\n",
       "  'interventionname': 'Online support Group',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': '12 one-hour, once-weekly online support groups for people with Multiple Sclerosis to address anxiety related to the COVID-19 outbreak and its effects on them.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 455,\n",
       "  'nctid': 'NCT04354259',\n",
       "  'interventionname': 'Peginterferon Lambda-1A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 456,\n",
       "  'nctid': 'NCT04354259',\n",
       "  'interventionname': 'placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 457,\n",
       "  'nctid': 'NCT04360759',\n",
       "  'interventionname': 'Chloroquine or hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 458,\n",
       "  'nctid': 'NCT04351243',\n",
       "  'interventionname': 'Gimsilumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Gimsilumab is a fully human monoclonal antibody (mAb).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 459,\n",
       "  'nctid': 'NCT04351243',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Normal saline',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 460,\n",
       "  'nctid': 'NCT04386694',\n",
       "  'interventionname': 'Active PBMT/sMF',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 461,\n",
       "  'nctid': 'NCT04386694',\n",
       "  'interventionname': 'Placebo PBMT/sMF',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 462,\n",
       "  'nctid': 'NCT04359121',\n",
       "  'interventionname': 'Questionnaires for specific phobia',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Questionnaires will be used.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 463,\n",
       "  'nctid': 'NCT04365101',\n",
       "  'interventionname': 'CYNK-001',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 464,\n",
       "  'nctid': 'NCT04346186',\n",
       "  'interventionname': 'IgM and IgG diagnostic kits to SARS-CoV-2',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 465,\n",
       "  'nctid': 'NCT04346186',\n",
       "  'interventionname': 'Elisa-test for IgM and IgG to SARS-CoV-2',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Elisa-test for IgM and IgG to SARS-CoV-2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 466,\n",
       "  'nctid': 'NCT04401579',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 467,\n",
       "  'nctid': 'NCT04401579',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 468,\n",
       "  'nctid': 'NCT04401579',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 469,\n",
       "  'nctid': 'NCT04322565',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cochicine 1mg/day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 470,\n",
       "  'nctid': 'NCT04368013',\n",
       "  'interventionname': 'Extended sampling and procedures',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 471,\n",
       "  'nctid': 'NCT04341116',\n",
       "  'interventionname': 'TJ003234',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'patients receive a single infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 472,\n",
       "  'nctid': 'NCT04341116',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'patients receive a single infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 473,\n",
       "  'nctid': 'NCT04382729',\n",
       "  'interventionname': 'Neuromuscular Electrical Stimulation',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 474,\n",
       "  'nctid': 'NCT04382729',\n",
       "  'interventionname': 'Physical Therapy Exercise',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 475,\n",
       "  'nctid': 'NCT04328480',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The colchicine dosage schedule will vary according to the following scenarios:\\n\\nIn patients not receiving Lopinavir/Ritonavir\\n\\nLoading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)\\nThe next day 0.5 mg bid for 14 days or until discharge.\\n\\nIn patients receiving Lopinavir/Ritonavir\\n\\nLoading dose of 0.5 mg (day 1)\\nAfter 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.\\n\\nPatients under treatment with Colchicine that are starting with Lopinavir/Ritonavir\\n\\nDose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.\\nContinue with 0.5 mg every 72 hours for 14 days or until discharge.\\n\\nOnly the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 476,\n",
       "  'nctid': 'NCT04328480',\n",
       "  'interventionname': 'Local standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Local standard of care for COVID-19 SARS moderate /high-risk patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 477,\n",
       "  'nctid': 'NCT04380766',\n",
       "  'interventionname': 'Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 478,\n",
       "  'nctid': 'NCT04366986',\n",
       "  'interventionname': 'Tested for SARS-CoV-2 (regardless of the result)',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'This is an observational study with no intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 479,\n",
       "  'nctid': 'NCT04366986',\n",
       "  'interventionname': 'Clinical diagnosis of COVID-19 by a health care professional',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'This is an observational study with no intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 480,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered for minimum of 5 days, up to 14 days if supply available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 481,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered for minimum of 5 days, up to 14 days if supply available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 482,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered for minimum of 5 days, up to 14 days if supply available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 483,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 484,\n",
       "  'nctid': 'NCT04387240',\n",
       "  'interventionname': 'Artemisinin / Artesunate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 485,\n",
       "  'nctid': 'NCT04387240',\n",
       "  'interventionname': 'placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'placebo or sham drug will be given to the second arm',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 486,\n",
       "  'nctid': 'NCT04341207',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 200 mg 3 times a day for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 487,\n",
       "  'nctid': 'NCT04341207',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 488,\n",
       "  'nctid': 'NCT04288102',\n",
       "  'interventionname': 'MSCs',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '3 times of MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 489,\n",
       "  'nctid': 'NCT04288102',\n",
       "  'interventionname': 'Saline containing 1% Human serum albumin（solution of MSC）',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '3 times of placebo（intravenously at Day 0, Day 3, Day 6）',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 490,\n",
       "  'nctid': 'NCT04335188',\n",
       "  'interventionname': 'Prospective oberservational registry',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Non interventional study.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 491,\n",
       "  'nctid': 'NCT04335552',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Standard of care',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 492,\n",
       "  'nctid': 'NCT04335552',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 493,\n",
       "  'nctid': 'NCT04335552',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 494,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Enoxaparin Prophylactic Dose',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):\\n\\nIf eGFR ≥30 mL/min (stable kidney function):\\n\\nBMI < 40 kg/m2: Enoxaparin 40 mg SC daily\\nBMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h\\nBMI > 50 kg/m2: Enoxaparin 60 mg SC q12h',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 495,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Heparin Infusion',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 496,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Heparin SC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 497,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Enoxaparin/Lovenox Intermediate Dose',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 498,\n",
       "  'nctid': 'NCT04346368',\n",
       "  'interventionname': 'BM-MSCs',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 499,\n",
       "  'nctid': 'NCT04346368',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 500,\n",
       "  'nctid': 'NCT04311177',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Losartan; 25 mg daily; oral administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 501,\n",
       "  'nctid': 'NCT04311177',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 502,\n",
       "  'nctid': 'NCT04342195',\n",
       "  'interventionname': 'Blood draw',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 503,\n",
       "  'nctid': 'NCT04347382',\n",
       "  'interventionname': 'Honey',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '30ml Natural Honey orally BD',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 504,\n",
       "  'nctid': 'NCT04347382',\n",
       "  'interventionname': 'Nigella Sativa / Black Cumin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Capsule 2gm seed powder orally BD',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 505,\n",
       "  'nctid': 'NCT04347382',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Empty capsule with 250ml of distilled water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 506,\n",
       "  'nctid': 'NCT04273646',\n",
       "  'interventionname': 'UC-MSCs',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 507,\n",
       "  'nctid': 'NCT04273646',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 508,\n",
       "  'nctid': 'NCT04334005',\n",
       "  'interventionname': 'Vitamin D',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 509,\n",
       "  'nctid': 'NCT04374552',\n",
       "  'interventionname': 'Hydroxychloroquine sulfate &Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug - Hydroxychloroquine sulfate &Azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 510,\n",
       "  'nctid': 'NCT04374552',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug - placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 511,\n",
       "  'nctid': 'NCT04312100',\n",
       "  'interventionname': 'oxygen treatment',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'different kinds of oxygen treatments will be given to patients according to their state of illness',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 512,\n",
       "  'nctid': 'NCT04345640',\n",
       "  'interventionname': 'no intervention',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'no intervention',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 513,\n",
       "  'nctid': 'NCT04382040',\n",
       "  'interventionname': 'ArtemiC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment will be sprayed orally twice a day for the first 2 days in the treatment period',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 514,\n",
       "  'nctid': 'NCT04382040',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment will be sprayed orally twice a day for the first 2 days in the treatment period',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 515,\n",
       "  'nctid': 'NCT04383652',\n",
       "  'interventionname': 'Biological sample and clinical data collection',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 516,\n",
       "  'nctid': 'NCT04390477',\n",
       "  'interventionname': 'Probiotic',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 517,\n",
       "  'nctid': 'NCT04377100',\n",
       "  'interventionname': 'Computer task questionnaires',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 518,\n",
       "  'nctid': 'NCT04344756',\n",
       "  'interventionname': 'Tinzaparin or unfractionated heparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 519,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'DAS181',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'DAS181 4.5mg nebulized qd x 7 OR 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 520,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo nebulized qd x 7 OR 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 521,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'DAS181 COVID-19',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'DAS181 4.5mg nebulized q12h/day x 7 OR 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 522,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'DAS181 OL',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days < 40kg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 523,\n",
       "  'nctid': 'NCT04321174',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 524,\n",
       "  'nctid': 'NCT04361253',\n",
       "  'interventionname': 'High-Titer COVID-19 Convalescent Plasma (HT-CCP)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '250mL HT-CCP x2 doses given sequentially.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 525,\n",
       "  'nctid': 'NCT04361253',\n",
       "  'interventionname': 'Standard Plasma (FFP)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': '250mL FFP or FP24 x2 doses given sequentially.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 526,\n",
       "  'nctid': 'NCT04334460',\n",
       "  'interventionname': 'BLD-2660',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 527,\n",
       "  'nctid': 'NCT04283461',\n",
       "  'interventionname': 'mRNA-1273',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 528,\n",
       "  'nctid': 'NCT04356482',\n",
       "  'interventionname': 'convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.\\n\\nIn phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 529,\n",
       "  'nctid': 'NCT04343651',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 530,\n",
       "  'nctid': 'NCT04343651',\n",
       "  'interventionname': 'Leronlimab (700mg)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 531,\n",
       "  'nctid': 'NCT04373811',\n",
       "  'interventionname': 'Lung ultrasound',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.\\n\\nLung Ultrasound Score (lung aeration) will be recorded using a linear probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 532,\n",
       "  'nctid': 'NCT04373811',\n",
       "  'interventionname': 'Muscle ultrasound',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.\\n\\nThickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 533,\n",
       "  'nctid': 'NCT04382391',\n",
       "  'interventionname': 'gammaCore® Sapphire (non-invasive vagus nerve stimulator)',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.\\n\\nFor acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 534,\n",
       "  'nctid': 'NCT04382391',\n",
       "  'interventionname': 'Standard of care therapies',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 535,\n",
       "  'nctid': 'NCT04318366',\n",
       "  'interventionname': 'Observational Study',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Not required',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 536,\n",
       "  'nctid': 'NCT04399109',\n",
       "  'interventionname': 'TCC-COVID mHealth solution',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 537,\n",
       "  'nctid': 'NCT04353037',\n",
       "  'interventionname': 'Group A HCQ',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Enrolled participants randomized in Group A receive the HCQ drug',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 538,\n",
       "  'nctid': 'NCT04353037',\n",
       "  'interventionname': 'Group B Control',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Enrolled participants randomized in Group B will receive a placebo drug',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 539,\n",
       "  'nctid': 'NCT04385186',\n",
       "  'interventionname': 'Inactivated convalescent plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol\\n\\nDay 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 540,\n",
       "  'nctid': 'NCT04385186',\n",
       "  'interventionname': 'Support treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: Start of support treatment selected by medical staff according to each each institutional protocol',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 541,\n",
       "  'nctid': 'NCT04320472',\n",
       "  'interventionname': 'Follow up',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 542,\n",
       "  'nctid': 'NCT04390464',\n",
       "  'interventionname': 'Ravulizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement‐mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 543,\n",
       "  'nctid': 'NCT04390464',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 544,\n",
       "  'nctid': 'NCT04390464',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Regular standard of care for COVID-19 patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 545,\n",
       "  'nctid': 'NCT04398277',\n",
       "  'interventionname': 'Daily Coping Toolkit',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Emotion Labelling Activity: Participants rate 10 discrete negative and positive emotional words on a likert scale (0-4).\\nExpressive Writing and Self Distancing Activity: Participants respond to an open-ended prompt to write about their day in an open text box in response to the prompt: \"What was today like for you?\" After this is completed, they are prompted that if the experience was very challenging, to revisit that experience in their mind by taking a \"fly on the wall\" perspective (Kross & Ayduk, 2016).\\nPositive Emotion Generation Activity (1 v. 2 prompts) Participants are prompted to take a deep breath and then respond to 1 (or 2) of 8 possible prompts in which they can generate positive emotions. In response to each, they are asked to describe their thoughts or memories in open-ended text box.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 546,\n",
       "  'nctid': 'NCT04334512',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with hydroxychloroquine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 547,\n",
       "  'nctid': 'NCT04334512',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 548,\n",
       "  'nctid': 'NCT04334512',\n",
       "  'interventionname': 'Vitamin C',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Treatment with vitamin C',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 549,\n",
       "  'nctid': 'NCT04334512',\n",
       "  'interventionname': 'Vitamin D',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Treatment with vitamin D',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 550,\n",
       "  'nctid': 'NCT04334512',\n",
       "  'interventionname': 'Zinc',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Treatment with Zinc',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 551,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Low-dose radiotherapy',\n",
       "  'interventiontype': 'Radiation',\n",
       "  'interventiondesc': 'Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 552,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200 mg/12h for 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 553,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Ritonavir/lopinavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400/100 mg/12h for 7-10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 554,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Tocilizumab Injection [Actemra]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '600 mg/day for 1-2 doses',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 555,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '500 mg/24h for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 556,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Corticosteroid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Corticosteroids (methylprednisolone/dexamethasone/prednisone)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 557,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Low molecular weight heparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 558,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Oxygen supply',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Oxygen',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 559,\n",
       "  'nctid': 'NCT04366232',\n",
       "  'interventionname': 'Anakinra alone (stages 2b/3)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Anakinra 300 mg 1/d Intravenous 5 days then dose tapering',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 560,\n",
       "  'nctid': 'NCT04366232',\n",
       "  'interventionname': 'Anakinra and Ruxolitinib (overcome stage 3)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 561,\n",
       "  'nctid': 'NCT04366232',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Routine clinical care for Covid-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 562,\n",
       "  'nctid': 'NCT04371419',\n",
       "  'interventionname': 'Messaging',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.\\n\\nRacial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.\\nWhether the message includes an acknowledgment of \"elephant in the room\" issues for each target group: trust in the medical system or fear of deportation.\\nWhether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.\\nWhether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.\\nSome individuals in a control group will see messages later.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 563,\n",
       "  'nctid': 'NCT04367883',\n",
       "  'interventionname': 'ACE inhibitor',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If evolution is favorable in patients treated with ACE as assessed at the first step of the study, this treatment would be added in a random selection of new incoming patients suffering Covid19, and results would be compared to a control group of incoming patients.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 564,\n",
       "  'nctid': 'NCT04367883',\n",
       "  'interventionname': 'ARB',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If evolution is favorable in patients treated with ARB as assessed at the first step of the study, this treatment would be added in a random selection of new incoming patients suffering Covid19, and results would be compared to a control group of incoming patients.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 565,\n",
       "  'nctid': 'NCT04346589',\n",
       "  'interventionname': 'Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 566,\n",
       "  'nctid': 'NCT04394793',\n",
       "  'interventionname': 'Low dose radiation therapy',\n",
       "  'interventiontype': 'Radiation',\n",
       "  'interventiondesc': 'Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 567,\n",
       "  'nctid': 'NCT04340479',\n",
       "  'interventionname': 'Ultrasound lung imaging as part of FAST+ evaluation',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:\\n\\nAnterior midclavicular right and left (apical, medial, basal)\\n\\nPosterior paraspinal right and left* (apical, medial, basal)\\n\\n*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.\\n\\nLateral axillary medial right and left (apical and basal)\\n\\nSpecifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 568,\n",
       "  'nctid': 'NCT04349098',\n",
       "  'interventionname': 'Selinexor',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive 20 mg of selinexor.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 569,\n",
       "  'nctid': 'NCT04349098',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants will receive 20 mg of placebo matched to selinexor.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 570,\n",
       "  'nctid': 'NCT04379492',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 571,\n",
       "  'nctid': 'NCT04379492',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 572,\n",
       "  'nctid': 'NCT04371523',\n",
       "  'interventionname': 'Apo-Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 573,\n",
       "  'nctid': 'NCT04371523',\n",
       "  'interventionname': 'Matched Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Matching Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 574,\n",
       "  'nctid': 'NCT04320277',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 575,\n",
       "  'nctid': 'NCT04342169',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 576,\n",
       "  'nctid': 'NCT04342169',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo to be taken on the same schedule as HCQ.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 577,\n",
       "  'nctid': 'NCT04336774',\n",
       "  'interventionname': 'Caption AI',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 578,\n",
       "  'nctid': 'NCT04339712',\n",
       "  'interventionname': 'Anakinra',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'In case of diagnosis of MAS treatment with anakinra',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 579,\n",
       "  'nctid': 'NCT04339712',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'In case of diagnosis of immune dysregulation treatment with tocilizumab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 580,\n",
       "  'nctid': 'NCT04344548',\n",
       "  'interventionname': 'Allogeneic NK transfer',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Three doses of allogeneic NK cell transfer',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 581,\n",
       "  'nctid': 'NCT04329533',\n",
       "  'interventionname': '\"Calm\" is a mindfulness meditation mobile app',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the \"Calm\" app, can be used to help manage stress, especially during this uncertain time.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 582,\n",
       "  'nctid': 'NCT04364737',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'SARS-CoV-2 convalescent plasma (1-2 units; ~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 583,\n",
       "  'nctid': 'NCT04364737',\n",
       "  'interventionname': \"Lactated ringer's solution or sterile saline\",\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': \"Equivalent volume of Lactated ringer's or sterile saline solution will be administered to eligible candidate as a control group\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 584,\n",
       "  'nctid': 'NCT04377412',\n",
       "  'interventionname': 'Pandemic control measures',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 585,\n",
       "  'nctid': 'NCT04346797',\n",
       "  'interventionname': 'Eculizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous administration as follows:\\n\\nInduction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 586,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Ivermectine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 587,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine Sulfate 400mg/daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 588,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '(0.2 mg /kg=12 mg ) lactose single dose at once/ weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 589,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Azithromycin 500 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin capsules 500mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 590,\n",
       "  'nctid': 'NCT04380870',\n",
       "  'interventionname': 'Chinese Herbal Medicine',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 591,\n",
       "  'nctid': 'NCT04392232',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '• Investigational Product\\n\\no COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 592,\n",
       "  'nctid': 'NCT04312009',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Losartan; 50 mg daily; oral administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 593,\n",
       "  'nctid': 'NCT04312009',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 594,\n",
       "  'nctid': 'NCT04307459',\n",
       "  'interventionname': 'standard operating procedures',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 595,\n",
       "  'nctid': 'NCT04333654',\n",
       "  'interventionname': 'Hydroxychloroquine SAR321068',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Pharmaceutical form:Tablet Route of administration: Oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 596,\n",
       "  'nctid': 'NCT04333654',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Pharmaceutical form:Tablet Route of administration: Oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 597,\n",
       "  'nctid': 'NCT04374786',\n",
       "  'interventionname': 'Calm Meditation App',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the \"Calm\" app, can be used to help manage stress, especially during this uncertain time.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 598,\n",
       "  'nctid': 'NCT04354155',\n",
       "  'interventionname': 'Enoxaparin Prefilled Syringe [Lovenox]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 599,\n",
       "  'nctid': 'NCT04399980',\n",
       "  'interventionname': 'Mavrilimumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 600,\n",
       "  'nctid': 'NCT04399980',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 601,\n",
       "  'nctid': 'NCT04325906',\n",
       "  'interventionname': 'high flow nasal cannula (HFNC)',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': \"HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 602,\n",
       "  'nctid': 'NCT04325906',\n",
       "  'interventionname': 'Prone positioning (PP)',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': \"PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 603,\n",
       "  'nctid': 'NCT04384445',\n",
       "  'interventionname': 'Organicell Flow',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': \"Biological: Organicell Flow. Organicell Flow will be administered intravenously with 1ml, containing 2-5 x 10^11 particles/mL in addition to the Standard Care. The Organicell Flow dose will be diluted in 100 mL of sterile saline at subject's bedside.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 604,\n",
       "  'nctid': 'NCT04384445',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': \"Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 605,\n",
       "  'nctid': 'NCT04276896',\n",
       "  'interventionname': 'Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 606,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Ascorbic Acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive ascorbic acid and folic acid therapy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 607,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 608,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 609,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Folic Acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household will receive folic acid and an additional intervention drug',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 610,\n",
       "  'nctid': 'NCT04331613',\n",
       "  'interventionname': 'CAStem',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'CAStem will be administered intravenously.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 611,\n",
       "  'nctid': 'NCT04401293',\n",
       "  'interventionname': 'Enoxaparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Full Dose LMWH anticoagulation therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 612,\n",
       "  'nctid': 'NCT04401293',\n",
       "  'interventionname': 'Prophylactic/Intermediate Dose Enoxaparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Prophylactic/Intermediate Dose LMWH or UFH therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 613,\n",
       "  'nctid': 'NCT04388709',\n",
       "  'interventionname': 'Peginterferon Lambda-1A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 614,\n",
       "  'nctid': 'NCT04366791',\n",
       "  'interventionname': 'Low Dose Radiation Therapy',\n",
       "  'interventiontype': 'Radiation',\n",
       "  'interventiondesc': 'Undergo low-dose radiation therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 615,\n",
       "  'nctid': 'NCT04345601',\n",
       "  'interventionname': 'Mesenchymal Stromal Cells',\n",
       "  'interventiontype': 'Genetic',\n",
       "  'interventiondesc': 'Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 616,\n",
       "  'nctid': 'NCT04370938',\n",
       "  'interventionname': 'Coping strategies video',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'No additional description',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 617,\n",
       "  'nctid': 'NCT04395716',\n",
       "  'interventionname': 'ResCure™',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Patients will be treated with nebulized ResCure™',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 618,\n",
       "  'nctid': 'NCT04372589',\n",
       "  'interventionname': 'Heparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).\\n\\nUnfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 619,\n",
       "  'nctid': 'NCT04341935',\n",
       "  'interventionname': 'Linagliptin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 mg Linagliptin administered by mouth once daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 620,\n",
       "  'nctid': 'NCT04341935',\n",
       "  'interventionname': 'Insulin regimen',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care insulin regimen as per hospital protocol',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 621,\n",
       "  'nctid': 'NCT04357730',\n",
       "  'interventionname': 'Alteplase 50 MG [Activase]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hours. Immediately following the Alteplase infusion, 5000 IU of unfracionated heparin (UFH) will be delivered intravenously and the heparin drip will be continued to maintain the activated partial thromboplastin time at 60-80sec (2.0 to 2.5 times the upper limit of normal).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 622,\n",
       "  'nctid': 'NCT04357730',\n",
       "  'interventionname': 'Alteplase 100 MG [Activase]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients randomized to Alteplase-100 group will receive 100 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 90 mgs over a total time of 2 hours. Immediately following the Alteplase infusion, 5000 IU of unfracionated heparin (UFH) will be delivered intravenously and the heparin drip will be continued to maintain the activated partial thromboplastin time at 60-80sec (2.0 to 2.5 times the upper limit of normal).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 623,\n",
       "  'nctid': 'NCT04357366',\n",
       "  'interventionname': 'Anakinra',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 624,\n",
       "  'nctid': 'NCT04357366',\n",
       "  'interventionname': 'trimethoprim/sulfamethoxazole',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with 80/400 mgTrimethoprime/sulfamethoxazole orally once daily for ten days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 625,\n",
       "  'nctid': 'NCT04373005',\n",
       "  'interventionname': 'Nasopharyngeal (NP) swab',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 626,\n",
       "  'nctid': 'NCT04380935',\n",
       "  'interventionname': 'Convalescent plasma',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Convalescent plasma of recovered COVID-19 patients (donor)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 627,\n",
       "  'nctid': 'NCT04380935',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'According to national or hospital guidelines \"COVID-19 Management Protocol\"',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 628,\n",
       "  'nctid': 'NCT04359836',\n",
       "  'interventionname': 'There is no intervention in this study',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'There is no intervention in this study',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 629,\n",
       "  'nctid': 'NCT04390139',\n",
       "  'interventionname': 'XCEL-UMC-BETA',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administration on top of the standard administered treatment',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 630,\n",
       "  'nctid': 'NCT04390139',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Administration on top of the standard administered treatment',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 631,\n",
       "  'nctid': 'NCT04378686',\n",
       "  'interventionname': 'dialysis',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 632,\n",
       "  'nctid': 'NCT04397692',\n",
       "  'interventionname': 'Nitric Oxide delivered via LungFit system',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Patients will receive inhalations of 80 ppm for 40 min 4 times a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 633,\n",
       "  'nctid': 'NCT04372628',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 200 mg tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 634,\n",
       "  'nctid': 'NCT04372628',\n",
       "  'interventionname': 'Lopinavir/ritonavir 400 mg/100 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'lopinavir/ritonavir tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 635,\n",
       "  'nctid': 'NCT04372628',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'matched placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 636,\n",
       "  'nctid': 'NCT04336215',\n",
       "  'interventionname': 'Non-Interventional',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'This non-interventional study poses no additional risks to people with pre-existing conditions.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 637,\n",
       "  'nctid': 'NCT04345614',\n",
       "  'interventionname': 'CM4620-Injectable Emulsion',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'CM4620-IE 2.0 mg/kg on Day 1 and then 1.6 mg/kg on Days 2 and 3. All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 638,\n",
       "  'nctid': 'NCT04391179',\n",
       "  'interventionname': 'Dipyridamole 100 Milligram(mg)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug will be given for 14 days while in the hospital.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 639,\n",
       "  'nctid': 'NCT04391179',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo will be given for 14 days while in the hospital.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 640,\n",
       "  'nctid': 'NCT04356443',\n",
       "  'interventionname': 'AirGo Respiratory Monitor',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 641,\n",
       "  'nctid': 'NCT04328272',\n",
       "  'interventionname': 'Hydroxychloroquine 200 Mg Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine administered orally with water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 642,\n",
       "  'nctid': 'NCT04328272',\n",
       "  'interventionname': 'Azithromycin 500Mg Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin administered orally with water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 643,\n",
       "  'nctid': 'NCT04328272',\n",
       "  'interventionname': 'Glucose tablets',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'administered orally with water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 644,\n",
       "  'nctid': 'NCT04335279',\n",
       "  'interventionname': 'SPIN-CHAT Program',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 645,\n",
       "  'nctid': 'NCT04346446',\n",
       "  'interventionname': 'Convalescent Plasma Transfusion',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Convalescent Plasma Transfusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 646,\n",
       "  'nctid': 'NCT04346446',\n",
       "  'interventionname': 'Supportive Care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Supportive Care',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 647,\n",
       "  'nctid': 'NCT04346446',\n",
       "  'interventionname': 'Random Donor Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 648,\n",
       "  'nctid': 'NCT04367077',\n",
       "  'interventionname': 'MultiStem',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'intravenous infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 649,\n",
       "  'nctid': 'NCT04367077',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'intravenous infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 650,\n",
       "  'nctid': 'NCT04397497',\n",
       "  'interventionname': 'Mavrilimumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'human monoclonal antibody targeting GM-CSF receptor-alpha',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 651,\n",
       "  'nctid': 'NCT04397497',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'matching volume of diluent',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 652,\n",
       "  'nctid': 'NCT04323592',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 653,\n",
       "  'nctid': 'NCT04323592',\n",
       "  'interventionname': 'standard care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'usual standard of care:\\n\\noxygen therapy (regular or high-flow) and monitoring\\nempiric antibiotic therapy\\nmechanical ventilation (invasive or noninvasive)\\nECMO when needed and available\\npronation when possible\\nother treatment which can be used are: antivirals, chloroquine, vitamins',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 654,\n",
       "  'nctid': 'NCT04348370',\n",
       "  'interventionname': 'BCG Vaccine',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 655,\n",
       "  'nctid': 'NCT04348370',\n",
       "  'interventionname': 'Placebo Vaccine',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 656,\n",
       "  'nctid': 'NCT04251871',\n",
       "  'interventionname': 'Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.\\n\\nTraditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 657,\n",
       "  'nctid': 'NCT04251871',\n",
       "  'interventionname': 'Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 658,\n",
       "  'nctid': 'NCT04363827',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 659,\n",
       "  'nctid': 'NCT04359329',\n",
       "  'interventionname': 'Estradiol patch',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 660,\n",
       "  'nctid': 'NCT04306705',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered as an intravenous infusion.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 661,\n",
       "  'nctid': 'NCT04306705',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 662,\n",
       "  'nctid': 'NCT04306705',\n",
       "  'interventionname': 'Continuous renal replacement therapy',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Catheter insertion site is femoral vein.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 663,\n",
       "  'nctid': 'NCT04363437',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 664,\n",
       "  'nctid': 'NCT04363437',\n",
       "  'interventionname': 'Usual Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 665,\n",
       "  'nctid': 'NCT03042143',\n",
       "  'interventionname': 'Human umbilical cord derived CD362 enriched MSCs',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Infusion of Human umbilical cord derived CD362 enriched MSCs',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 666,\n",
       "  'nctid': 'NCT03042143',\n",
       "  'interventionname': 'Placebo (Plasma-Lyte 148)',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Infusion of placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 667,\n",
       "  'nctid': 'NCT04390191',\n",
       "  'interventionname': 'Continuous Positive Airway Pressure',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 668,\n",
       "  'nctid': 'NCT04319731',\n",
       "  'interventionname': 'Human Amniotic Fluid',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Administration of amniotic fluid in SARS-CoV-2 positive patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 669,\n",
       "  'nctid': 'NCT04338126',\n",
       "  'interventionname': 'Tranexamic acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'previously described',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 670,\n",
       "  'nctid': 'NCT04338126',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'previously described',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 671,\n",
       "  'nctid': 'NCT03648372',\n",
       "  'interventionname': 'TAK-981',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous infusion.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 672,\n",
       "  'nctid': 'NCT03648372',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care for COVID-19.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 673,\n",
       "  'nctid': 'NCT04373824',\n",
       "  'interventionname': 'Ivermectin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ivermectin 200 to 400 mcg per kg body weight',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 674,\n",
       "  'nctid': 'NCT04328467',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine; 200mg tablet; oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 675,\n",
       "  'nctid': 'NCT04328467',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Placebo; tablet; oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 676,\n",
       "  'nctid': 'NCT04341519',\n",
       "  'interventionname': 'PTSD',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days\\n\\nPatients:\\n\\npost-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 677,\n",
       "  'nctid': 'NCT04341519',\n",
       "  'interventionname': 'Burnout',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Symptoms of burnout as assessed by the Maslash Burnout Inventory',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 678,\n",
       "  'nctid': 'NCT04350450',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400 mg tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 679,\n",
       "  'nctid': 'NCT04381364',\n",
       "  'interventionname': 'Ciclesonide Inhalation Aerosol',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ciclesonide 320 µg twice daily for 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 680,\n",
       "  'nctid': 'NCT04357782',\n",
       "  'interventionname': 'L-ascorbic acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 681,\n",
       "  'nctid': 'NCT04385238',\n",
       "  'interventionname': 'This is an online survey with no intervention.',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'As this is an online survey about health and wellbeing, there is no intervention.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 682,\n",
       "  'nctid': 'NCT04361019',\n",
       "  'interventionname': 'On-Line Survey',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'A survey has been sent by email to the students of the participating universities',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 683,\n",
       "  'nctid': 'NCT04320511',\n",
       "  'interventionname': 'CT-V',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 684,\n",
       "  'nctid': 'NCT04366089',\n",
       "  'interventionname': 'Oxygen-ozone therapy, probiotic supplementation and Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': '- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 685,\n",
       "  'nctid': 'NCT04366089',\n",
       "  'interventionname': 'SivoMixx (200 billion)',\n",
       "  'interventiontype': 'Dietary Supplement',\n",
       "  'interventiondesc': 'Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 686,\n",
       "  'nctid': 'NCT04366089',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 687,\n",
       "  'nctid': 'NCT04366089',\n",
       "  'interventionname': 'hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'dose: 200 mg, 1 cp x 2 / day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 688,\n",
       "  'nctid': 'NCT04393792',\n",
       "  'interventionname': 'Povidone-Iodine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.23% three times daily (tds) for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 689,\n",
       "  'nctid': 'NCT04393792',\n",
       "  'interventionname': 'Normal saline',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.9% three times daily (tds) for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 690,\n",
       "  'nctid': 'NCT04358081',\n",
       "  'interventionname': 'HCQ',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine Monotherapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 691,\n",
       "  'nctid': 'NCT04358081',\n",
       "  'interventionname': 'HCQ+AZT',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine with azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 692,\n",
       "  'nctid': 'NCT04358081',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 693,\n",
       "  'nctid': 'NCT04333914',\n",
       "  'interventionname': 'Chloroquine analog (GNS651)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cohort 1 (arm B): 200mg bid loading dose for 2 days then, 200 qd orally for 14 consecutive days.\\n\\nCohorte 2 (arm E): 200mg bid loading dose for 2 days then, 200 qd/day orally, per os, for 14 consecutive days.\\n\\nIf for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 694,\n",
       "  'nctid': 'NCT04333914',\n",
       "  'interventionname': 'Nivolumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cohorte 1 (arm C): 0.3mg/Kg, intravenously, single infusion at Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 695,\n",
       "  'nctid': 'NCT04333914',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cohorte 2 (arm F): 400mg flat dose, intravenously, single infusion at Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 696,\n",
       "  'nctid': 'NCT04333914',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': \"In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.\\n\\nAdditional care and medications should be administered in the patient's best interest.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 697,\n",
       "  'nctid': 'NCT04402060',\n",
       "  'interventionname': 'APL-9',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Complement (C3) Inhibitor',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 698,\n",
       "  'nctid': 'NCT04402060',\n",
       "  'interventionname': 'Vehicle Control',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Normal saline of equal volume to active arm',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 699,\n",
       "  'nctid': 'NCT04373135',\n",
       "  'interventionname': 'Brief educational video',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': \"A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 700,\n",
       "  'nctid': 'NCT04343963',\n",
       "  'interventionname': 'Pyridostigmine Bromide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One 60mg tablet P.O. once per day for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 701,\n",
       "  'nctid': 'NCT04343963',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One tablet P.O. once per day for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 702,\n",
       "  'nctid': 'NCT04371393',\n",
       "  'interventionname': 'Remestemcel-L',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 703,\n",
       "  'nctid': 'NCT04371393',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 704,\n",
       "  'nctid': 'NCT04345276',\n",
       "  'interventionname': 'Danoprevir+Ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 705,\n",
       "  'nctid': 'NCT04365153',\n",
       "  'interventionname': 'Canakinumab Injection 600mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients </= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 706,\n",
       "  'nctid': 'NCT04365153',\n",
       "  'interventionname': 'Canakinumab Injection 300mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients </= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 707,\n",
       "  'nctid': 'NCT04365153',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '250 mL of 5% dextrose infused IV over 2 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 708,\n",
       "  'nctid': 'NCT04381000',\n",
       "  'interventionname': 'Exercise Group',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 709,\n",
       "  'nctid': 'NCT04306393',\n",
       "  'interventionname': 'Nitric Oxide Gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.\\n\\nWeaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 710,\n",
       "  'nctid': 'NCT04343898',\n",
       "  'interventionname': 'No intervention',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Observational',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 711,\n",
       "  'nctid': 'NCT04373382',\n",
       "  'interventionname': 'Peer Resilience Champion',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 712,\n",
       "  'nctid': 'NCT04373382',\n",
       "  'interventionname': 'Enriched Survey Feedback',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 713,\n",
       "  'nctid': 'NCT04395807',\n",
       "  'interventionname': 'Helmet CPAP',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': \"Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 714,\n",
       "  'nctid': 'NCT04395807',\n",
       "  'interventionname': 'HFNC',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': \"Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 715,\n",
       "  'nctid': 'NCT04397471',\n",
       "  'interventionname': 'Bone Marrow Harvest',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Healthy volunteer bone marrow harvest',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 716,\n",
       "  'nctid': 'NCT04358003',\n",
       "  'interventionname': 'Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': \"Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.\\n\\nStudy Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 717,\n",
       "  'nctid': 'NCT04384965',\n",
       "  'interventionname': 'MagPro X100 Stimulator, B70 Fluid-Cooled Coil',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': \"Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~3 minutes) at a target of 110% of the subject's resting MT.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 718,\n",
       "  'nctid': 'NCT04344184',\n",
       "  'interventionname': 'L-ascorbic acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '100 mg/kg intravenous vitamin C infusion every 8 hours for up to 72 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 719,\n",
       "  'nctid': 'NCT04344184',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Dextrose 5% Water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 720,\n",
       "  'nctid': 'NCT04351906',\n",
       "  'interventionname': 'ECCO2R',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'ECCO2R integrated into the multiFiltrate device',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 721,\n",
       "  'nctid': 'NCT04385797',\n",
       "  'interventionname': 'Telephone interview',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 722,\n",
       "  'nctid': 'NCT04363502',\n",
       "  'interventionname': 'Clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 723,\n",
       "  'nctid': 'NCT04363502',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 724,\n",
       "  'nctid': 'NCT04391166',\n",
       "  'interventionname': 'Non invasive visual acuity testing',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 725,\n",
       "  'nctid': 'NCT04389333',\n",
       "  'interventionname': 'non-contact magnetically-controlled capsule endoscopy',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 726,\n",
       "  'nctid': 'NCT04245631',\n",
       "  'interventionname': 'Recombinase aided amplification (RAA) assay',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 727,\n",
       "  'nctid': 'NCT04395144',\n",
       "  'interventionname': 'Awake Prone Positioning',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 728,\n",
       "  'nctid': 'NCT04395144',\n",
       "  'interventionname': 'Standard care',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Patients will not receive any special instructions with regards to proning.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 729,\n",
       "  'nctid': 'NCT04367636',\n",
       "  'interventionname': 'Behavioral: OCAT-sham',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Placebo version of the online contingent attention training preceded by psycho-education movieclip.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 730,\n",
       "  'nctid': 'NCT04367636',\n",
       "  'interventionname': 'Behavioral: OCAT',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Online contingent attention training preceded by psycho-education movieclip.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 731,\n",
       "  'nctid': 'NCT04367636',\n",
       "  'interventionname': 'psycho-education video',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Both groups get to see a psycho-education video before the smartphone training starts.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 732,\n",
       "  'nctid': 'NCT04360954',\n",
       "  'interventionname': 'Diagnostic test',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'There is no intervention. This study will test deidentified archived biosamples.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 733,\n",
       "  'nctid': 'NCT04349371',\n",
       "  'interventionname': 'Chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 734,\n",
       "  'nctid': 'NCT04349371',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 735,\n",
       "  'nctid': 'NCT04061382',\n",
       "  'interventionname': 'Venepuncture',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'One study visit will be conducted by research study staff and blood sampling will be carried out. The blood sample will initially focus on looking at population immunity to Diphtheria, Group C invasive Meningococcal disease and COVID-19.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 736,\n",
       "  'nctid': 'NCT04383613',\n",
       "  'interventionname': 'Prone positioning',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for >24 hours or study outcome.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 737,\n",
       "  'nctid': 'NCT04388657',\n",
       "  'interventionname': 'Echo-Doppler',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Utrasound Doppler of the lower limbs',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 738,\n",
       "  'nctid': 'NCT04335630',\n",
       "  'interventionname': 'Electrocardiogram, telemetry, echocardiogram, laboratory values',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 739,\n",
       "  'nctid': 'NCT04279782',\n",
       "  'interventionname': 'Comprehensive treatment',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 740,\n",
       "  'nctid': 'NCT04311398',\n",
       "  'interventionname': 'New QIAstat-Dx fully automatic multiple PCR detection platform',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 741,\n",
       "  'nctid': 'NCT04388826',\n",
       "  'interventionname': 'Veru-111',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Respiratory Distress Syndrome, Adult',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 742,\n",
       "  'nctid': 'NCT04280224',\n",
       "  'interventionname': 'NK Cells',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'twice a week of NK cells (0.1-2*10E7 cells/kg body weight)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 743,\n",
       "  'nctid': 'NCT04269525',\n",
       "  'interventionname': 'UC-MSCs',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 744,\n",
       "  'nctid': 'NCT04279197',\n",
       "  'interventionname': 'N-acetylcysteine+ Fuzheng Huayu Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 745,\n",
       "  'nctid': 'NCT04279197',\n",
       "  'interventionname': 'N-acetylcysteine+Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The subjects will be taking 1 N-acetylcysteine capcule and 4 Placebo tablets three times a day for 24 weeks.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 746,\n",
       "  'nctid': 'NCT04374474',\n",
       "  'interventionname': 'Olfactory retraining',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 747,\n",
       "  'nctid': 'NCT04374474',\n",
       "  'interventionname': 'corticosteroid nasal irrigation',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 748,\n",
       "  'nctid': 'NCT04374474',\n",
       "  'interventionname': 'smell household Items',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 749,\n",
       "  'nctid': 'NCT04374474',\n",
       "  'interventionname': 'Nasal Irrigation',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 750,\n",
       "  'nctid': 'NCT04327479',\n",
       "  'interventionname': 'Assessment of cardiovascular diseases and cardiovascular risk factors',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 751,\n",
       "  'nctid': 'NCT04341012',\n",
       "  'interventionname': 'Collection of breath sample',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Analysis of volatile organic compounds in breath',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 752,\n",
       "  'nctid': 'NCT04386291',\n",
       "  'interventionname': 'Anxiety Reduction Training',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 753,\n",
       "  'nctid': 'NCT04386291',\n",
       "  'interventionname': 'Kundalini Yoga and Anxiety Reduction Training',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 754,\n",
       "  'nctid': 'NCT04386291',\n",
       "  'interventionname': 'Meditation and Anxiety Reduction Training',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 755,\n",
       "  'nctid': 'NCT04346420',\n",
       "  'interventionname': 'Standard interface',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 756,\n",
       "  'nctid': 'NCT04346420',\n",
       "  'interventionname': 'Double-Trunk Mask',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 757,\n",
       "  'nctid': 'NCT04360850',\n",
       "  'interventionname': 'online survey',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'A brief survey for therapists to fill out',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 758,\n",
       "  'nctid': 'NCT04342650',\n",
       "  'interventionname': 'Chloroquine Diphosphate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '150mg tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 759,\n",
       "  'nctid': 'NCT04342650',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '150mg placebo tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 760,\n",
       "  'nctid': 'NCT04397705',\n",
       "  'interventionname': 'Patient Status Engine',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Wearable sensors',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 761,\n",
       "  'nctid': 'NCT04343729',\n",
       "  'interventionname': 'Methylprednisolone Sodium Succinate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'injectable solution at a dose of 0.5mg/kg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 762,\n",
       "  'nctid': 'NCT04343729',\n",
       "  'interventionname': 'Placebo solution',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'injectable saline solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 763,\n",
       "  'nctid': 'NCT04359225',\n",
       "  'interventionname': '3D Telemedicine',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Telemedicine using 3D broadcast to clinician',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 764,\n",
       "  'nctid': 'NCT04359225',\n",
       "  'interventionname': '2D Telemedicine',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Standard care with 2D telemedicine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 765,\n",
       "  'nctid': 'NCT04340557',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 766,\n",
       "  'nctid': 'NCT04254874',\n",
       "  'interventionname': 'Abidol hydrochloride',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.2g once, 3 times a day,two weeks',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 767,\n",
       "  'nctid': 'NCT04254874',\n",
       "  'interventionname': 'Abidol Hydrochloride combined with Interferon atomization',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 768,\n",
       "  'nctid': 'NCT04261270',\n",
       "  'interventionname': 'ASC09F+Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 769,\n",
       "  'nctid': 'NCT04261270',\n",
       "  'interventionname': 'Ritonavir+Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 770,\n",
       "  'nctid': 'NCT04261270',\n",
       "  'interventionname': 'Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '75mg ,once a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 771,\n",
       "  'nctid': 'NCT04336410',\n",
       "  'interventionname': 'INO-4800',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'INO-4800 will be administered ID on Day 0 and Week 4.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 772,\n",
       "  'nctid': 'NCT04336410',\n",
       "  'interventionname': 'CELLECTRA® 2000',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Week 4.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 773,\n",
       "  'nctid': 'NCT04385576',\n",
       "  'interventionname': 'Aerosol Box',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 774,\n",
       "  'nctid': 'NCT04385576',\n",
       "  'interventionname': 'Intubation Box',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 775,\n",
       "  'nctid': 'NCT04255017',\n",
       "  'interventionname': 'Abidol hydrochloride',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 776,\n",
       "  'nctid': 'NCT04255017',\n",
       "  'interventionname': 'Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 777,\n",
       "  'nctid': 'NCT04255017',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 778,\n",
       "  'nctid': 'NCT04263402',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 779,\n",
       "  'nctid': 'NCT04263402',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 780,\n",
       "  'nctid': 'NCT04334265',\n",
       "  'interventionname': 'Anluohuaxian',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '6g each time, twice a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 781,\n",
       "  'nctid': 'NCT04355637',\n",
       "  'interventionname': 'Inhaled budesonide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'adding budesonide to standard of care for pneumonia in COVID19 positive patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 782,\n",
       "  'nctid': 'NCT04361552',\n",
       "  'interventionname': 'Best Practice',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Receive standard of care',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 783,\n",
       "  'nctid': 'NCT04361552',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Given IV',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 784,\n",
       "  'nctid': 'NCT04337983',\n",
       "  'interventionname': 'Transpulmonary thermodilution',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 785,\n",
       "  'nctid': 'NCT04337983',\n",
       "  'interventionname': 'Echocardiography',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'Daily echocardiography evaluation',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 786,\n",
       "  'nctid': 'NCT04323527',\n",
       "  'interventionname': 'Chloroquine diphosphate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '150mg chloroquine diphosphate tablets.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 787,\n",
       "  'nctid': 'NCT04401150',\n",
       "  'interventionname': 'Vitamin C',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 788,\n",
       "  'nctid': 'NCT04401150',\n",
       "  'interventionname': 'Control',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 789,\n",
       "  'nctid': 'NCT04368676',\n",
       "  'interventionname': 'Sudarshan Kriya Yoga (SKY)',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Sudarshan Kriya Yoga (SKY) is a standardized, easy to learn breath based yogic intervention program consisting of breath control techniques followed by a timed rhythmic breathing practice consisting of fast, medium and slow breaths. SKY, once learnt, takes between 10-25 minutes to practice daily at home.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 790,\n",
       "  'nctid': 'NCT04368676',\n",
       "  'interventionname': 'Health Enhancement Program',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'HEP will consist of time-matched online self-paced modules, comprised of de-stressing guided exercises such as gentle stretch and yoga asanas and progressive muscle relaxation. In addition, mindfulness-based meditation sessions will be offered.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 791,\n",
       "  'nctid': 'NCT04396600',\n",
       "  'interventionname': 'MinnRAP Peer Support Program',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The behavioral intervention consists of 1) pairing healthcare workers into \"Battle Buddies\" who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 792,\n",
       "  'nctid': 'NCT04380961',\n",
       "  'interventionname': 'Sirukumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive sirukumab 5 mg/kg IV single dose infusion on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 793,\n",
       "  'nctid': 'NCT04380961',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive placebo IV single dose infusion on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 794,\n",
       "  'nctid': 'NCT04380961',\n",
       "  'interventionname': 'Standard of Care (SOC)',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'SOC treatment will be determined by the investigator based on local practice and consists of supportive care.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 795,\n",
       "  'nctid': 'NCT04264533',\n",
       "  'interventionname': 'VC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 796,\n",
       "  'nctid': 'NCT04264533',\n",
       "  'interventionname': 'Sterile Water for Injection',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 797,\n",
       "  'nctid': 'NCT04399005',\n",
       "  'interventionname': 'after-each-case room disinfection',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'After-each-case room disinfection was defined as after completing each case.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 798,\n",
       "  'nctid': 'NCT04399005',\n",
       "  'interventionname': 'daily room disinfection',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 799,\n",
       "  'nctid': 'NCT04376034',\n",
       "  'interventionname': 'Convalescent Plasma 1 Unit',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.\\n\\nEach pediatric recipient will receive 10mL/kg up to 1 unit of plasma.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 800,\n",
       "  'nctid': 'NCT04376034',\n",
       "  'interventionname': 'Convalescent Plasma 2 Units',\n",
       "  'interventiontype': 'Biological',\n",
       "  'interventiondesc': 'Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.\\n\\nThose that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.\\n\\nEach pediatric recipient will receive 10mL/kg up to 2 units of plasma.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 801,\n",
       "  'nctid': 'NCT04376034',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 802,\n",
       "  'nctid': 'NCT04275245',\n",
       "  'interventionname': 'Meplazumab for Injection',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'humanized MAb against CD147',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 803,\n",
       "  'nctid': 'NCT04281693',\n",
       "  'interventionname': 'Standard screening strategy',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 804,\n",
       "  'nctid': 'NCT04281693',\n",
       "  'interventionname': 'New screening strategy',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 805,\n",
       "  'nctid': 'NCT04333589',\n",
       "  'interventionname': 'Favipiravir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 806,\n",
       "  'nctid': 'NCT04310228',\n",
       "  'interventionname': 'Favipiravir Combined With Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\\n\\nTocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 807,\n",
       "  'nctid': 'NCT04310228',\n",
       "  'interventionname': 'Favipiravir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 808,\n",
       "  'nctid': 'NCT04310228',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 809,\n",
       "  'nctid': 'NCT04341727',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'anti-rheumatic drug (DMARD)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 810,\n",
       "  'nctid': 'NCT04341727',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antibiotic',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 811,\n",
       "  'nctid': 'NCT04341727',\n",
       "  'interventionname': 'Chloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 812,\n",
       "  'nctid': 'NCT04392219',\n",
       "  'interventionname': 'EIDD-2801',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Part 1:\\n\\nSubjects will be randomized to receive a single oral dose of EIDD-2801 or Placebo.\\n\\nPart 2:\\n\\nTwo single oral doses of EIDD-2801 will be administered to subjects, in an open-label manner.\\n\\nPart 3:\\n\\nSubjects will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 813,\n",
       "  'nctid': 'NCT04392219',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Part 1:\\n\\nSubjects will be randomized to receive a single oral dose of EIDD-2801 or Placebo.\\n\\nPart 3:\\n\\nSubjects will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 814,\n",
       "  'nctid': 'NCT04357977',\n",
       "  'interventionname': 'RBA-2',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 815,\n",
       "  'nctid': 'NCT04378803',\n",
       "  'interventionname': 'Mindfulness training (MT) Connect',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': \"MT Connect will involve instructor-led weekly sessions and mindfulness exercises over a 4-week interval for a total of 8 to 10 hours. There will be one instructor-led session per week that will last between 2 and 2.5 hours. Participants will also be asked to complete three categories of mindfulness exercises (formal and informal mindfulness exercises, and reflective practices) as part of their daily 'out-of-class' homework. The daily homework will require between 10 to 30 minutes to complete.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 816,\n",
       "  'nctid': 'NCT04353531',\n",
       "  'interventionname': 'High-flow nasal cannula',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'High-flow nasal cannula is a modality of oxygen device that can provide gas flow meets or exceeds patient inspiratory flow demand (flow can be set at 10-60 L/min), it has been proven to improve oxygenation and reduce intubation rate in hypoxemic patients.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 817,\n",
       "  'nctid': 'NCT04353531',\n",
       "  'interventionname': 'Surgical mask',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': \"A procedure mask will be used to cover patient's face after HFNC is initiated.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 818,\n",
       "  'nctid': 'NCT04353531',\n",
       "  'interventionname': 'bronchoscopy examination',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'is a procedure that allows a doctor to examine the inside of the lungs, including the bronchi, which are the main pathways into the lungs. During a bronchoscopy, a doctor inserts a thin tube containing a light and camera into the lungs through the nose or mouth or via artificial airway such as intubation or tracheotomy tube',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 819,\n",
       "  'nctid': 'NCT04353531',\n",
       "  'interventionname': 'intubation',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'Intubation is the process of inserting a tube, called an endotracheal tube (ET), through the mouth and then into the airway. This is done so that a patient can be placed on a ventilator to assist with breathing during anesthesia, sedation, or severe illness.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 820,\n",
       "  'nctid': 'NCT04353531',\n",
       "  'interventionname': 'tracheostomy',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': \"A tracheostomy is a medical procedure — either temporary or permanent — that involves creating an opening in the neck in order to place a tube into a person's windpipe. The tube is inserted through a cut in the neck below the vocal cords. This allows air to enter the lungs.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 821,\n",
       "  'nctid': 'NCT04353531',\n",
       "  'interventionname': 'nebulization',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'A nebulizer is a piece of medical equipment that a person with asthma or another respiratory condition can use to administer medication directly and quickly to the lungs',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 822,\n",
       "  'nctid': 'NCT04340414',\n",
       "  'interventionname': 'Low flow ECMO driving by CVVH machine',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 823,\n",
       "  'nctid': 'NCT04393649',\n",
       "  'interventionname': 'ESOGER',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Questionnaire',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 824,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': 'F-FMISO PET/CT Scan',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'Every participant will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 825,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': '30 Gy over 3 weeks',\n",
       "  'interventiontype': 'Radiation',\n",
       "  'interventiondesc': 'Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the postoperative bed, all subclinical areas at risk for disease will receive the same dose at 30Gy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 826,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': 'Cisplatin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 827,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': 'Carboplatin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 828,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': '5Fluorouracil',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 829,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': 'Proton Therapy',\n",
       "  'interventiontype': 'Radiation',\n",
       "  'interventiondesc': 'Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 830,\n",
       "  'nctid': 'NCT03680274',\n",
       "  'interventionname': 'Vitamin C',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 831,\n",
       "  'nctid': 'NCT03680274',\n",
       "  'interventionname': 'Control',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 832,\n",
       "  'nctid': 'NCT04297904',\n",
       "  'interventionname': 'Sedentary behaviour',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'To assess sedentary behaviour each participant will wear an activity monitor (PAL Technologies, Scotland). The resident will wear the monitor on their right thigh for 24 hours per day over seven days continuously.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 833,\n",
       "  'nctid': 'NCT04297904',\n",
       "  'interventionname': 'Urinary Incontinence',\n",
       "  'interventiontype': 'Diagnostic Test',\n",
       "  'interventiondesc': 'The presence of IU, assessed by the Minimum Data Set (MDS) version 3.0, and used together with the International Consultation on Incontinence Questionnaire-Short Form to characterize the incontinence.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 834,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'Voraxaze',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 835,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'Methotrexate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m^2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 836,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'Rituximab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will be treated with rituximab 500 mg/m^2.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 837,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'leucovorin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 838,\n",
       "  'nctid': 'NCT04349332',\n",
       "  'interventionname': 'Helmet non-invasive ventilation (NIV)',\n",
       "  'interventiontype': 'Device',\n",
       "  'interventiondesc': 'After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate <30breaths/min and PaO2 >75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 839,\n",
       "  'nctid': 'NCT04350723',\n",
       "  'interventionname': 'Awake Proning',\n",
       "  'interventiontype': 'Procedure',\n",
       "  'interventiondesc': 'The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 840,\n",
       "  'nctid': 'NCT04367922',\n",
       "  'interventionname': 'Positive Emotion Skills Course',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 841,\n",
       "  'nctid': 'NCT04173663',\n",
       "  'interventionname': 'ASSIST',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The ASSIST program is a 12-week advocacy training to educate parents of youth with ASD about the adult service system. It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 842,\n",
       "  'nctid': 'NCT03827057',\n",
       "  'interventionname': 'Reconsolidation of Traumatic Memories (RTM)',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with \"traditional\" exposure therapies.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 843,\n",
       "  'nctid': 'NCT03827057',\n",
       "  'interventionname': 'Prolonged Exposure (PE)',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 844,\n",
       "  'nctid': 'NCT03710746',\n",
       "  'interventionname': 'Project Health',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 845,\n",
       "  'nctid': 'NCT03710746',\n",
       "  'interventionname': 'Response and Attention Training',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 846,\n",
       "  'nctid': 'NCT03398135',\n",
       "  'interventionname': 'risankizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'subcutaneous (SC) injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 847,\n",
       "  'nctid': 'NCT03398135',\n",
       "  'interventionname': 'placebo for risankizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'subcutaneous (SC) injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 848,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Placebo for Risankizumab SC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo for Risankizumab SC Subcutaneous (SC) Injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 849,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Risankizumab IV',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Risankizumab IV Intravenous (IV) infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 850,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Placebo for Risankizumab IV',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo for Risankizumab IV Intravenous (IV) infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 851,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Risankizumab SC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Risankizumab SC Subcutaneous (SC) injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 852,\n",
       "  'nctid': 'NCT02875301',\n",
       "  'interventionname': '150 Minutes Week',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'This group will walk 150 minutes per week. Participants will have 3 supervised exercise sessions per week. A walking duration of 30 minutes will be achieved by the third week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 853,\n",
       "  'nctid': 'NCT02875301',\n",
       "  'interventionname': '225 Minutes Week',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'This group will walk 225 minutes per week. Participants will have 3 supervised exercise sessions per week. A walking duration of 45 minutes will be achieved by the sixth week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 854,\n",
       "  'nctid': 'NCT02875301',\n",
       "  'interventionname': 'Stretch and Tone',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'The control condition will focus on improving balance, flexibility, and strength. This group will meet for supervised sessions 3 times per week for 12 months. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 855,\n",
       "  'nctid': 'NCT04144231',\n",
       "  'interventionname': 'iCBT-I',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 856,\n",
       "  'nctid': 'NCT04144231',\n",
       "  'interventionname': 'GCBT-I',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 857,\n",
       "  'nctid': 'NCT04278404',\n",
       "  'interventionname': 'The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 858,\n",
       "  'nctid': 'NCT04390542',\n",
       "  'interventionname': 'Psychoeducation',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': \"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:\\n\\nSession 1: Communication, Support, Self Care, Symptom Management\\n\\nSessions 2-4: Communication, Symptom Management, Support\\n\\nSessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 859,\n",
       "  'nctid': 'NCT04351880',\n",
       "  'interventionname': 'Medically Tailored Meals',\n",
       "  'interventiontype': 'Other',\n",
       "  'interventiondesc': 'Compare 2 and 4 weeks of meal delivery',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 860,\n",
       "  'nctid': 'NCT03261050',\n",
       "  'interventionname': 'Counter Attitudinal Therapy',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': '8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 861,\n",
       "  'nctid': 'NCT03261050',\n",
       "  'interventionname': 'Interpersonal Therapy',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': '8 weekly 60 minute sessions of interpersonal-based treatment wherein women with an eating disorder complete verbal, written, and behavioral activities.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 862,\n",
       "  'nctid': 'NCT03823469',\n",
       "  'interventionname': 'CCTP',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': \"Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 863,\n",
       "  'nctid': 'NCT03823469',\n",
       "  'interventionname': 'Nutritional counseling',\n",
       "  'interventiontype': 'Behavioral',\n",
       "  'interventiondesc': 'Two 30-minute nutritional counseling sessions',\n",
       "  'statusDate': '05/26/2020'}]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "d, a = {}, []\n",
    "for rowproxy in querylist:\n",
    "    # rowproxy.items() returns an array like [(key0, value0), (key1, value1)] > thank you stackoverflow!\n",
    "    for column, value in rowproxy.items():\n",
    "        # build up the dictionary\n",
    "        d = {**d, **{column: value}}\n",
    "    a.append(d)\n",
    "connection.close()\n",
    "a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'index': 0,\n",
       "  'nctid': 'NCT04332380',\n",
       "  'interventionname': 'Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 2,\n",
       "  'nctid': 'NCT04332835',\n",
       "  'interventionname': 'Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 3,\n",
       "  'nctid': 'NCT04332835',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400 milligrams each 12 hours for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 7,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Hydroxychloroquine - Daily Dosing',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.\\n\\nAll treatment groups will receive placebo pills to have the patients take 2 pills a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 8,\n",
       "  'nctid': 'NCT04341441',\n",
       "  'interventionname': 'Hydroxychloroquine - Weekly Dosing',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria\\n\\nAll treatment groups will receive placebo pills to have the patients take 2 pills a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 18,\n",
       "  'nctid': 'NCT04388683',\n",
       "  'interventionname': 'Nitric Oxide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (\"day 1\"), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 20,\n",
       "  'nctid': 'NCT04347174',\n",
       "  'interventionname': 'Suspension of heat killed (autoclaved) Mycobacterium w',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 21,\n",
       "  'nctid': 'NCT04347174',\n",
       "  'interventionname': 'Standard therapy of COVID-19',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 29,\n",
       "  'nctid': 'NCT04344457',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200 mg PO BID 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 30,\n",
       "  'nctid': 'NCT04344457',\n",
       "  'interventionname': 'Indomethacin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '50 mg PO TID 14 Days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 31,\n",
       "  'nctid': 'NCT04344457',\n",
       "  'interventionname': 'Zithromax Oral Product',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '500 mg PO QD 3 Days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 34,\n",
       "  'nctid': 'NCT04379310',\n",
       "  'interventionname': 'ACE Inhibitors and Calcium Channel Blockers',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'effect of drugs on patients with covid-19 pneumonia',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 37,\n",
       "  'nctid': 'NCT04366271',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Best treatment option for COVID-19 according to investigator criteria',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 39,\n",
       "  'nctid': 'NCT04365985',\n",
       "  'interventionname': 'Naltrexone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 40,\n",
       "  'nctid': 'NCT04365985',\n",
       "  'interventionname': 'Ketamine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 46,\n",
       "  'nctid': 'NCT04370288',\n",
       "  'interventionname': 'MCN (Methylene blue, vitamin C, N-acetyl cysteine)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'A mixture of MCN will be injected to covid-19 patients.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 48,\n",
       "  'nctid': 'NCT04252274',\n",
       "  'interventionname': 'Darunavir and Cobicistat',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 49,\n",
       "  'nctid': 'NCT04322682',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 50,\n",
       "  'nctid': 'NCT04322682',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 51,\n",
       "  'nctid': 'NCT04345692',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 53,\n",
       "  'nctid': 'NCT04345523',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care for the treatment of COVID-19 in hospitalized patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 60,\n",
       "  'nctid': 'NCT04324463',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral medication',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 61,\n",
       "  'nctid': 'NCT04324463',\n",
       "  'interventionname': 'Hydoxychloroquine or Chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral medication',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 62,\n",
       "  'nctid': 'NCT04324463',\n",
       "  'interventionname': 'Interferon-Beta',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'subcutaneous injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 65,\n",
       "  'nctid': 'NCT04325061',\n",
       "  'interventionname': 'Dexamethasone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 68,\n",
       "  'nctid': 'NCT04313023',\n",
       "  'interventionname': 'PUL-042 Inhalation Solution',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 69,\n",
       "  'nctid': 'NCT04313023',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sterile saline for inhalation',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 71,\n",
       "  'nctid': 'NCT04359095',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Generic drug distributed by the Colombian Health System for autoimmune and infectious diseases. It is classified as an anti infectious drug and its current indications include treatment of malaria, lupus erythematosus and rheumatoid arthritis.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 72,\n",
       "  'nctid': 'NCT04359095',\n",
       "  'interventionname': 'Lopinavir / Ritonavir Pill',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': \"Generic drug distributed by the Colombian Health System as an insurance treatment for Human Immunodeficiency Virus (HIV) and Acquired immunodeficiency syndrome (AIDS). It belongs to the group of drugs intended for infectious disease. It contains a combination of protease inhibitors, with a synergic effect in the lopinavir's blood and tissue concentration to inhibit viral replication.\",\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 73,\n",
       "  'nctid': 'NCT04359095',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Generic drug distributed by the Colombian Health System for the treatment of infectious diseases. It is currently used to treat susceptible microorganisms, including respiratory tract infections, sinusitis, pharyngitis, pneumonia, skin infections and sexually transmitted diseases.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 77,\n",
       "  'nctid': 'NCT04382794',\n",
       "  'interventionname': 'Retrospective case-control analysis',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 79,\n",
       "  'nctid': 'NCT04363450',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 80,\n",
       "  'nctid': 'NCT04363450',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 81,\n",
       "  'nctid': 'NCT04389710',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 83,\n",
       "  'nctid': 'NCT04331600',\n",
       "  'interventionname': 'Chloroquine phosphate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral chloroquine phosphate for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 89,\n",
       "  'nctid': 'NCT04329611',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'COVID19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 94,\n",
       "  'nctid': 'NCT04312997',\n",
       "  'interventionname': 'PUL-042 Inhalation Solution',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 95,\n",
       "  'nctid': 'NCT04312997',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sterile saline for inhalation',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 96,\n",
       "  'nctid': 'NCT04364802',\n",
       "  'interventionname': 'Povidone-Iodine Nasal Spray and Gargle',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 97,\n",
       "  'nctid': 'NCT04364802',\n",
       "  'interventionname': 'Povidone-Iodine Nasal Spray and Gargle',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 101,\n",
       "  'nctid': 'NCT04394208',\n",
       "  'interventionname': 'Silymarin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Silymarin Oral at a dose of 420 mg/day in 3 divided doses.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 102,\n",
       "  'nctid': 'NCT04394208',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo comparator',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 104,\n",
       "  'nctid': 'NCT04372602',\n",
       "  'interventionname': 'Duvelisib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 106,\n",
       "  'nctid': 'NCT04335123',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 108,\n",
       "  'nctid': 'NCT04365231',\n",
       "  'interventionname': 'Hydroxychloroquine and azithromycin treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.\\n\\n- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 113,\n",
       "  'nctid': 'NCT04331899',\n",
       "  'interventionname': 'Peginterferon Lambda-1a',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 115,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Hidroxicloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hidroxicloroquine 200 mg BID oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 116,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir 200/50 mg BID oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 117,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Imatinib tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Imatinib 400 mg QD oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 118,\n",
       "  'nctid': 'NCT04346147',\n",
       "  'interventionname': 'Baricitinib Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib 4 mg QD oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 119,\n",
       "  'nctid': 'NCT04323332',\n",
       "  'interventionname': 'Traditional Chinese Medicine Prescription',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 121,\n",
       "  'nctid': 'NCT04365699',\n",
       "  'interventionname': 'AT-001',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 126,\n",
       "  'nctid': 'NCT04381988',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 132,\n",
       "  'nctid': 'NCT04372017',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 134,\n",
       "  'nctid': 'NCT04360122',\n",
       "  'interventionname': 'Levamisole',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Levamisole (150 mg/day for two days per week for 2 months',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 135,\n",
       "  'nctid': 'NCT04360122',\n",
       "  'interventionname': 'Isoprinosine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Isoprinosine (1 g 3 times per day daily) for two months',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 136,\n",
       "  'nctid': 'NCT04360122',\n",
       "  'interventionname': 'Levamisole and Isoprinosine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 137,\n",
       "  'nctid': 'NCT04382586',\n",
       "  'interventionname': 'Zanubrutinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '320 mg (4 x 80 mg) capsules administered orally once daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 138,\n",
       "  'nctid': 'NCT04382586',\n",
       "  'interventionname': 'Supportive Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Supportive care treatment is selected and administered as deemed appropriate by the study investigator.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 139,\n",
       "  'nctid': 'NCT04382586',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo to match zanubrutinib',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 140,\n",
       "  'nctid': 'NCT04363346',\n",
       "  'interventionname': 'FT516',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 141,\n",
       "  'nctid': 'NCT04331665',\n",
       "  'interventionname': 'Ruxolitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 142,\n",
       "  'nctid': 'NCT04340232',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will receive a 2 mg oral dose of baricitinib.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 143,\n",
       "  'nctid': 'NCT04370262',\n",
       "  'interventionname': 'HCQ + Intravenous Famotidine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'IV famotidine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 144,\n",
       "  'nctid': 'NCT04370262',\n",
       "  'interventionname': 'HCQ + Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'IV placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 145,\n",
       "  'nctid': 'NCT04318444',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 146,\n",
       "  'nctid': 'NCT04318444',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 147,\n",
       "  'nctid': 'NCT04352946',\n",
       "  'interventionname': 'Hydroxychloroquine Pre-Exposure Prophylaxis',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'HCQ PreP 400mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 148,\n",
       "  'nctid': 'NCT04352946',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo tablets 400mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 150,\n",
       "  'nctid': 'NCT04392427',\n",
       "  'interventionname': 'Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.\\n\\nSample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.\\nRandomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)\\nIntervention:\\n\\nA) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 151,\n",
       "  'nctid': 'NCT04362137',\n",
       "  'interventionname': 'Ruxolitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ruxolitinib 5 mg tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 152,\n",
       "  'nctid': 'NCT04362137',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Matching-image placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 154,\n",
       "  'nctid': 'NCT04374032',\n",
       "  'interventionname': 'metenkefalin + tridecactide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 155,\n",
       "  'nctid': 'NCT04374032',\n",
       "  'interventionname': 'The standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 159,\n",
       "  'nctid': 'NCT04327206',\n",
       "  'interventionname': 'BCG Vaccine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.\\n\\nEach 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 160,\n",
       "  'nctid': 'NCT04327206',\n",
       "  'interventionname': '0.9%NaCl',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.9% Sodium Chloride Injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 163,\n",
       "  'nctid': 'NCT04362189',\n",
       "  'interventionname': 'HB-adMSC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hope Biosciences allogeneic adipose-derived mesenchymal stem cells',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 164,\n",
       "  'nctid': 'NCT04362189',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Saline',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 165,\n",
       "  'nctid': 'NCT04377620',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo administered BID approximately 12 hours apart',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 166,\n",
       "  'nctid': 'NCT04377620',\n",
       "  'interventionname': 'Ruxolitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ruxolitinb administered BID approximately 12 hours apart',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 167,\n",
       "  'nctid': 'NCT04394117',\n",
       "  'interventionname': 'Angiotensin Receptor Blockers',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Angiotensin Receptor Blockers class have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin II by competitive antagonism of the angiotensin receptor. ARBs displace angiotensin II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of angiotensin II-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response.\\n\\nThe virus causing COVID-19, the SARS-CoV-2 virus binds to the extracellular portion of ACE2 expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 168,\n",
       "  'nctid': 'NCT04329832',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 169,\n",
       "  'nctid': 'NCT04329832',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization, the prior doses will count toward the 5-day total.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 170,\n",
       "  'nctid': 'NCT04331795',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.\\n\\nSecond dose is provisioned if:\\n\\nIncreasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND\\nCRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 171,\n",
       "  'nctid': 'NCT04331795',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.\\n\\nSecond dose is provisioned if:\\n\\nIncreasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND\\nCRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 172,\n",
       "  'nctid': 'NCT04346615',\n",
       "  'interventionname': 'Vazegepant (BHV-3500)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '10 mg intranasal (IN) for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 173,\n",
       "  'nctid': 'NCT04346615',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo Q8h for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 174,\n",
       "  'nctid': 'NCT04328961',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 175,\n",
       "  'nctid': 'NCT04328961',\n",
       "  'interventionname': 'Ascorbic Acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 177,\n",
       "  'nctid': 'NCT04337918',\n",
       "  'interventionname': 'NORS (Nitric Oxide Releasing Solution)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 178,\n",
       "  'nctid': 'NCT04337918',\n",
       "  'interventionname': 'NORS (Nitric Oxide Releasing Solution)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.\\n\\nAny participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 179,\n",
       "  'nctid': 'NCT04339426',\n",
       "  'interventionname': 'Atovaquone/Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 180,\n",
       "  'nctid': 'NCT04362813',\n",
       "  'interventionname': 'Canakinumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 181,\n",
       "  'nctid': 'NCT04362813',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 186,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 400 mg twice a day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial compound',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 187,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 600 mg twice a day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial compound',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 188,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 600 mg once a day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial compound',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 189,\n",
       "  'nctid': 'NCT04329923',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 190,\n",
       "  'nctid': 'NCT04306497',\n",
       "  'interventionname': 'TCM prescriptions',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 199,\n",
       "  'nctid': 'NCT04371640',\n",
       "  'interventionname': 'Sirolimus 1 MG/ML',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 200,\n",
       "  'nctid': 'NCT04371640',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 201,\n",
       "  'nctid': 'NCT04382066',\n",
       "  'interventionname': 'Plitidepsin 1.5 mg/day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 202,\n",
       "  'nctid': 'NCT04382066',\n",
       "  'interventionname': 'Plitidepsin 2.0 mg/day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 203,\n",
       "  'nctid': 'NCT04382066',\n",
       "  'interventionname': 'Plitidepsin 2.5 mg/day',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 206,\n",
       "  'nctid': 'NCT04335084',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Prophylaxis treatment for COVID-19',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 210,\n",
       "  'nctid': 'NCT04361214',\n",
       "  'interventionname': 'Leflunomide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 220,\n",
       "  'nctid': 'NCT04374461',\n",
       "  'interventionname': 'N-acetylcysteine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 221,\n",
       "  'nctid': 'NCT04374565',\n",
       "  'interventionname': 'High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Pathogen reduced SARS-CoV-2 convalescent plasma (2 units; ~200 mL each for a total of 400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 223,\n",
       "  'nctid': 'NCT04351620',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 224,\n",
       "  'nctid': 'NCT04315298',\n",
       "  'interventionname': 'Sarilumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Single intravenous (IV) dose of sarilumab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 225,\n",
       "  'nctid': 'NCT04315298',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Single intravenous (IV) dose of placebo to match sarilumab administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 226,\n",
       "  'nctid': 'NCT04355936',\n",
       "  'interventionname': 'Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Control arm will receive standard care.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 227,\n",
       "  'nctid': 'NCT04350593',\n",
       "  'interventionname': 'Dapagliflozin 10 MG',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Active Comparator: Dapagliflozin 10mg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 228,\n",
       "  'nctid': 'NCT04350593',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo Comparator',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 229,\n",
       "  'nctid': 'NCT04321993',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir tablet 200mg/50mg 2 tables by mouth twice daily for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 230,\n",
       "  'nctid': 'NCT04321993',\n",
       "  'interventionname': 'Hydroxychloroquine sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine sulfate tablet 200 mg 2 tablets by mouth twice daily for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 231,\n",
       "  'nctid': 'NCT04321993',\n",
       "  'interventionname': 'Baricitinib (janus kinase inhibitor)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib 2 mg po daily for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 233,\n",
       "  'nctid': 'NCT04359537',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate 200 MG',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 235,\n",
       "  'nctid': 'NCT04356937',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:\\n\\nTocilizumab 8mg x 1 (n=185)\\nStandard of care/Placebo (n=93)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 236,\n",
       "  'nctid': 'NCT04356937',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:\\n\\nTocilizumab 8mg x 1 (n=185)\\nStandard of care/Placebo (n=93)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 237,\n",
       "  'nctid': 'NCT04317040',\n",
       "  'interventionname': 'CD24Fc',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'CD24Fc is given on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 238,\n",
       "  'nctid': 'NCT04317040',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo is given on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 240,\n",
       "  'nctid': 'NCT04308668',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 242,\n",
       "  'nctid': 'NCT04353180',\n",
       "  'interventionname': 'Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment\\n\\nStandard treatment is according to the protocol of treatment of 2019-nCoV infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 243,\n",
       "  'nctid': 'NCT04353180',\n",
       "  'interventionname': 'Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment\\n\\nStandard treatment is according to the protocol of treatment of 2019-nCoV infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 244,\n",
       "  'nctid': 'NCT04353180',\n",
       "  'interventionname': 'Standard treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard treatment is according to the protocol of treatment of 2019-nCoV infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 245,\n",
       "  'nctid': 'NCT04344600',\n",
       "  'interventionname': 'Peginterferon lambda alfa-1a subcutaneous injection',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon lambda-1a 180 micrograms by subcutaneous injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 248,\n",
       "  'nctid': 'NCT04341480',\n",
       "  'interventionname': 'Chemotherapy',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Routine chemotherapy for individual tumor type.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 250,\n",
       "  'nctid': 'NCT04369742',\n",
       "  'interventionname': 'Hydroxychloroquine (HCQ)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 252,\n",
       "  'nctid': 'NCT04363866',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 253,\n",
       "  'nctid': 'NCT04363866',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'A placebo is a pill that looks like the study drug but has no real medicine in it.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 255,\n",
       "  'nctid': 'NCT04374279',\n",
       "  'interventionname': 'Bicalutamide 150 Mg Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Bicalutamide 150 mg by mouth daily for 7 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 256,\n",
       "  'nctid': 'NCT04374279',\n",
       "  'interventionname': 'Ivermectin 3Mg Tab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ivermectin 600 µg/kg (up to a maximum dose of 60mg) by mouth daily for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 258,\n",
       "  'nctid': 'NCT04280705',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 271,\n",
       "  'nctid': 'NCT04360551',\n",
       "  'interventionname': 'Telmisartan 40mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Angiotensin Receptor Blocker (ARB)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 272,\n",
       "  'nctid': 'NCT04360551',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo once daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 274,\n",
       "  'nctid': 'NCT04334382',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 275,\n",
       "  'nctid': 'NCT04334382',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 276,\n",
       "  'nctid': 'NCT04373044',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given PO',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 277,\n",
       "  'nctid': 'NCT04373044',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given PO',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 278,\n",
       "  'nctid': 'NCT04373044',\n",
       "  'interventionname': 'Placebo Administration',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given Po',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 280,\n",
       "  'nctid': 'NCT04382625',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 281,\n",
       "  'nctid': 'NCT04354870',\n",
       "  'interventionname': 'Hydroxychloroquine (HCQ)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 282,\n",
       "  'nctid': 'NCT04380688',\n",
       "  'interventionname': 'Acalabrutinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Acalabrutinib administered orally',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 283,\n",
       "  'nctid': 'NCT04305457',\n",
       "  'interventionname': 'Nitric Oxide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 286,\n",
       "  'nctid': 'NCT04374487',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 291,\n",
       "  'nctid': 'NCT04397718',\n",
       "  'interventionname': 'Degarelix',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Degarelix is an FDA-approved drug for prostate cancer',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 293,\n",
       "  'nctid': 'NCT04365257',\n",
       "  'interventionname': 'Prazosin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants in this arm will receive the study drug as outlined in the arm description.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 297,\n",
       "  'nctid': 'NCT04353596',\n",
       "  'interventionname': 'ACE inhibitor, angiotensin receptor blocker',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 298,\n",
       "  'nctid': 'NCT04384458',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 299,\n",
       "  'nctid': 'NCT04349241',\n",
       "  'interventionname': 'favipiravir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 300,\n",
       "  'nctid': 'NCT04349241',\n",
       "  'interventionname': 'Standard of care therapy',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 301,\n",
       "  'nctid': 'NCT04330690',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir will be administered 400 mg/100 mg orally for a 14-day course plus supportive care, or until discharge from hospital, whichever occurs first',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 302,\n",
       "  'nctid': 'NCT04330690',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 800mg BID for 1 day then 400mg BID for 10 days plus optimized supportive care or until discharge from hospital, whichever occurs first',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 303,\n",
       "  'nctid': 'NCT04330690',\n",
       "  'interventionname': 'remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care or until discharge from hospital, whichever occurs first',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 304,\n",
       "  'nctid': 'NCT04377308',\n",
       "  'interventionname': 'Fluoxetine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 306,\n",
       "  'nctid': 'NCT04304313',\n",
       "  'interventionname': 'Sildenafil citrate tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.1g/day for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 307,\n",
       "  'nctid': 'NCT04292899',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered as an intravenous infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 308,\n",
       "  'nctid': 'NCT04292899',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of Care Treatment for COVID-19 Infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 309,\n",
       "  'nctid': 'NCT04359277',\n",
       "  'interventionname': 'Enoxaparin Higher Dose',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Enoxaparin will be preferred in non-intubated patients with a Cr Clearance of > 30\\nEnoxaparin 1mg/kg q12 SQ hours for weight 50-150kg\\nEnoxaparin 0.75mg/kg q12 SQ hours for weight >150kg or BMI >40\\nUnfractionated IV heparin titrated to a goal antiXa of 0.3-0.5 unit/mL (will be preferred in intubated patients)\\n\\nFor Enoxaparin, AntiXA testing will be done after fourth injection only for participants with BMI >40 or weight > 150 kg as per institutional policy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 310,\n",
       "  'nctid': 'NCT04359277',\n",
       "  'interventionname': 'Lower-dose prophylactic anticoagulation',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Heparin 5000 units every 12 or every 8 hours or 7500 units every 8 hours for BMI > 40 or weight > 150 kg, or\\nEnoxaparin 40mg every 24 hours or 30mg every 12 hours or every 24 hours (with CrCl < 30mL/min) SQ or\\nEnoxaparin 40mg every 12 hours SQ for weight >150kg or BMI >40-50\\nEnoxaparin 60 mg every 12 hours SQ for BMI >50 For Enoxaparin, AntiXA testing will be done after fourth injection only for participants with BMI >40 or weight > 150kg as per institutional policy.\\n\\nFor patients that develop acute kidney injury, and received enoxaparin, transition to IV unfractionated heparin by checking antiXa when next dose of enoxaparin would be due and initiating IV heparin when antiXa <0.7 IU/mL',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 312,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 313,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 314,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Zinc Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Zinc sulfate 220mg once daily for 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 315,\n",
       "  'nctid': 'NCT04370782',\n",
       "  'interventionname': 'Doxycycline',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Doxycycline 200 mg once daily for 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 316,\n",
       "  'nctid': 'NCT04341038',\n",
       "  'interventionname': 'Tacrolimus',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'the necessary dose to obtain blood levels of 8-10 ng / ml',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 317,\n",
       "  'nctid': 'NCT04341038',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '120mg of methylprednisolone daily for 3 consecutive days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 318,\n",
       "  'nctid': 'NCT04398004',\n",
       "  'interventionname': 'Clarithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with 500 mg Clarithromycin orally twice daily for seven days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 319,\n",
       "  'nctid': 'NCT04332107',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will be shipped a single 1.2 g dose of oral azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 320,\n",
       "  'nctid': 'NCT04332107',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will be shipped a dose of matching placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 321,\n",
       "  'nctid': 'NCT04292730',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered as an intravenous infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 322,\n",
       "  'nctid': 'NCT04292730',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of Care Treatment for COVID-19 Infection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 325,\n",
       "  'nctid': 'NCT04347239',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebos',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 326,\n",
       "  'nctid': 'NCT04347239',\n",
       "  'interventionname': 'Leronlimab (700mg)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 328,\n",
       "  'nctid': 'NCT04343976',\n",
       "  'interventionname': 'Pegylated interferon lambda',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '180 mcg subcutaneous injection of pegylated interferon lambda',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 329,\n",
       "  'nctid': 'NCT04356690',\n",
       "  'interventionname': 'Etoposide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4. If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 330,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'Low-dose chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate) weekly\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 331,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'Mid-dose chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate) twice weekly\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 332,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'High-dose chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'chloroquine base 150mg (equivalent to 250mg chloroquine phosphate or 200mg chloroquine sulphate) daily\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 333,\n",
       "  'nctid': 'NCT04333732',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The placebo equivalent of low, medium and high arm. Low- once weekly Medium - twice weekly High - daily\\n\\nIn all treatment arms, an induction dose of 1200mg chloroquine or base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine base per day for four days) before starting the low, medium, or high dose regimen.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 335,\n",
       "  'nctid': 'NCT04336332',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Given PO',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 337,\n",
       "  'nctid': 'NCT04377659',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 347,\n",
       "  'nctid': 'NCT04320615',\n",
       "  'interventionname': 'Tocilizumab (TCZ)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 348,\n",
       "  'nctid': 'NCT04320615',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 351,\n",
       "  'nctid': 'NCT04344236',\n",
       "  'interventionname': 'Saline oral/nasal rinse',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 352,\n",
       "  'nctid': 'NCT04344236',\n",
       "  'interventionname': '0.5% Povidone/Iodine oral/nasal rinse',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 353,\n",
       "  'nctid': 'NCT04344236',\n",
       "  'interventionname': '0.12% Chlorhexidine oral/nasal rinse',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 354,\n",
       "  'nctid': 'NCT04385264',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 355,\n",
       "  'nctid': 'NCT04385264',\n",
       "  'interventionname': 'Mannitol',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 356,\n",
       "  'nctid': 'NCT04355143',\n",
       "  'interventionname': 'Colchicine Tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 358,\n",
       "  'nctid': 'NCT04344444',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'tablets provided as described in Arm B',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 359,\n",
       "  'nctid': 'NCT04344444',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'tablets provided as described in Arm C',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 361,\n",
       "  'nctid': 'NCT04341675',\n",
       "  'interventionname': 'Sirolimus',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 362,\n",
       "  'nctid': 'NCT04341675',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Matching placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 363,\n",
       "  'nctid': 'NCT04338828',\n",
       "  'interventionname': 'Nitric Oxide Gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 371,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Escalating doses of SnPP Protoporphyrin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 372,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Escalating doses of SnPP Protoporphyrin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 373,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Escalating doses of SnPP Protoporphyrin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 374,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'SnPP Protoporphyrin plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 375,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'SnPP Protoporphyrin plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 376,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'SnPP Protoporphyrin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'SnPP Protoporphyrin plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 377,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'Sulfonatoporphyrin(TPPS)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sulfonatoporphyrin(TPPS) plus computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm.\\n\\nArm: Experimental: Administer 9mg TAnthPS dose in subjects with with COVID-19 7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will be administered a single dose of 9 mg of sulfonated tetra-anthracenyl porphyrin (TAnthPS), after 1 houre patients will be followed by Exposure to A computerized tomography (CT) scan type of chest x ray at wavelength light source of 630 nm',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 378,\n",
       "  'nctid': 'NCT04371822',\n",
       "  'interventionname': 'Sulfonatoporphyrin(TPPS)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Sulfonatoporphyrin(TPPS)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 379,\n",
       "  'nctid': 'NCT04332991',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.\\n\\nFor this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 380,\n",
       "  'nctid': 'NCT04332991',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 385,\n",
       "  'nctid': 'NCT04342897',\n",
       "  'interventionname': 'LY3127804',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered IV',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 386,\n",
       "  'nctid': 'NCT04342897',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered IV',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 390,\n",
       "  'nctid': 'NCT04338074',\n",
       "  'interventionname': 'Tranexamic acid tablets',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 391,\n",
       "  'nctid': 'NCT04338074',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '2 tablets p.o. three times per day x 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 393,\n",
       "  'nctid': 'NCT04381052',\n",
       "  'interventionname': 'Clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dose is 25mg intravenously over 30 minutes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 395,\n",
       "  'nctid': 'NCT04305106',\n",
       "  'interventionname': 'Bevacizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 396,\n",
       "  'nctid': 'NCT04396106',\n",
       "  'interventionname': 'AT-527',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One or two 550 mg tablet(s) of AT-527 administered on Day 1 followed by 1 tablet every ~12 hours (twice a day) + SOC for a total of 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 399,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Chloroquine or Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 400,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Lopinavir/Ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/Ritonavir 200mg/50mg 2-0-2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 402,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Rivaroxaban',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 403,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Thromboprophylaxis',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'as local standard, most likely to be low molecular weight heparin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 404,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Candesartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'starting dose 4mg once daily, titrated to normotension',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 405,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'non-RAS blocking antihypertensives',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 406,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'Clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '25mg i.v. single dose, possibly a repeated dose',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 407,\n",
       "  'nctid': 'NCT04351724',\n",
       "  'interventionname': 'placebo for clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'sodium chloride bolus infusions as placebo for clazakizumab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 409,\n",
       "  'nctid': 'NCT04342663',\n",
       "  'interventionname': 'Fluvoxamine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 410,\n",
       "  'nctid': 'NCT04342663',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 411,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'MSTT1041A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of MSTT1041A.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 412,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'MSTT1041A-matched Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of MSTT1041A-matched placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 413,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'UTTR1147A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of UTTR1147A.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 414,\n",
       "  'nctid': 'NCT04386616',\n",
       "  'interventionname': 'UTTR1147A-matched Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive up to 2 intravenous infusions of UTTR1147A-matched placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 415,\n",
       "  'nctid': 'NCT04343989',\n",
       "  'interventionname': 'Clazakizumab 25 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 416,\n",
       "  'nctid': 'NCT04343989',\n",
       "  'interventionname': 'Clazakizumab 12.5 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 419,\n",
       "  'nctid': 'NCT04351152',\n",
       "  'interventionname': 'Standard of Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care therapy per local written policies or guidelines',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 422,\n",
       "  'nctid': 'NCT04398290',\n",
       "  'interventionname': 'Inhaled nitric oxide (iNO)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 423,\n",
       "  'nctid': 'NCT04398290',\n",
       "  'interventionname': 'Nitrogen gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '250 mcg/kg ideal body weight (IBW)/hour',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 424,\n",
       "  'nctid': 'NCT04398290',\n",
       "  'interventionname': 'Oxygen gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Supplemental oxygen administered via nasal cannula',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 427,\n",
       "  'nctid': 'NCT04377750',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The placebo treatment arm will include 100 ml of normal saline administered along 60 min',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 428,\n",
       "  'nctid': 'NCT03891420',\n",
       "  'interventionname': 'Galidesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Galidesivir IV infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 429,\n",
       "  'nctid': 'NCT03891420',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo IV infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 430,\n",
       "  'nctid': 'NCT04334148',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral self administered tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 431,\n",
       "  'nctid': 'NCT04334148',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'oral self administered tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 432,\n",
       "  'nctid': 'NCT04365127',\n",
       "  'interventionname': 'Progesterone 100 MG',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subcutaneous administration twice daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 433,\n",
       "  'nctid': 'NCT04390022',\n",
       "  'interventionname': 'Ivermectin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Single dose of STROMECTOL® tablets at 400mcg/kg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 434,\n",
       "  'nctid': 'NCT04390022',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 435,\n",
       "  'nctid': 'NCT04347226',\n",
       "  'interventionname': 'BMS-986253',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 444,\n",
       "  'nctid': 'NCT04393246',\n",
       "  'interventionname': 'EDP1815',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 445,\n",
       "  'nctid': 'NCT04393246',\n",
       "  'interventionname': 'Dapagliflozin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 446,\n",
       "  'nctid': 'NCT04393246',\n",
       "  'interventionname': 'Ambrisentan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 455,\n",
       "  'nctid': 'NCT04354259',\n",
       "  'interventionname': 'Peginterferon Lambda-1A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 457,\n",
       "  'nctid': 'NCT04360759',\n",
       "  'interventionname': 'Chloroquine or hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 458,\n",
       "  'nctid': 'NCT04351243',\n",
       "  'interventionname': 'Gimsilumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Gimsilumab is a fully human monoclonal antibody (mAb).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 459,\n",
       "  'nctid': 'NCT04351243',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Normal saline',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 467,\n",
       "  'nctid': 'NCT04401579',\n",
       "  'interventionname': 'Remdesivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 468,\n",
       "  'nctid': 'NCT04401579',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 469,\n",
       "  'nctid': 'NCT04322565',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cochicine 1mg/day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 471,\n",
       "  'nctid': 'NCT04341116',\n",
       "  'interventionname': 'TJ003234',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'patients receive a single infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 472,\n",
       "  'nctid': 'NCT04341116',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'patients receive a single infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 475,\n",
       "  'nctid': 'NCT04328480',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The colchicine dosage schedule will vary according to the following scenarios:\\n\\nIn patients not receiving Lopinavir/Ritonavir\\n\\nLoading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)\\nThe next day 0.5 mg bid for 14 days or until discharge.\\n\\nIn patients receiving Lopinavir/Ritonavir\\n\\nLoading dose of 0.5 mg (day 1)\\nAfter 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.\\n\\nPatients under treatment with Colchicine that are starting with Lopinavir/Ritonavir\\n\\nDose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.\\nContinue with 0.5 mg every 72 hours for 14 days or until discharge.\\n\\nOnly the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 480,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered for minimum of 5 days, up to 14 days if supply available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 481,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered for minimum of 5 days, up to 14 days if supply available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 482,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered for minimum of 5 days, up to 14 days if supply available',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 483,\n",
       "  'nctid': 'NCT04328012',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 484,\n",
       "  'nctid': 'NCT04387240',\n",
       "  'interventionname': 'Artemisinin / Artesunate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 486,\n",
       "  'nctid': 'NCT04341207',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 200 mg 3 times a day for 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 487,\n",
       "  'nctid': 'NCT04341207',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 492,\n",
       "  'nctid': 'NCT04335552',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 493,\n",
       "  'nctid': 'NCT04335552',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 494,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Enoxaparin Prophylactic Dose',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):\\n\\nIf eGFR ≥30 mL/min (stable kidney function):\\n\\nBMI < 40 kg/m2: Enoxaparin 40 mg SC daily\\nBMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h\\nBMI > 50 kg/m2: Enoxaparin 60 mg SC q12h',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 495,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Heparin Infusion',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 496,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Heparin SC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 497,\n",
       "  'nctid': 'NCT04367831',\n",
       "  'interventionname': 'Enoxaparin/Lovenox Intermediate Dose',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 500,\n",
       "  'nctid': 'NCT04311177',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Losartan; 25 mg daily; oral administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 503,\n",
       "  'nctid': 'NCT04347382',\n",
       "  'interventionname': 'Honey',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '30ml Natural Honey orally BD',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 504,\n",
       "  'nctid': 'NCT04347382',\n",
       "  'interventionname': 'Nigella Sativa / Black Cumin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Capsule 2gm seed powder orally BD',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 505,\n",
       "  'nctid': 'NCT04347382',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Empty capsule with 250ml of distilled water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 507,\n",
       "  'nctid': 'NCT04273646',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 509,\n",
       "  'nctid': 'NCT04374552',\n",
       "  'interventionname': 'Hydroxychloroquine sulfate &Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug - Hydroxychloroquine sulfate &Azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 510,\n",
       "  'nctid': 'NCT04374552',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug - placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 513,\n",
       "  'nctid': 'NCT04382040',\n",
       "  'interventionname': 'ArtemiC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment will be sprayed orally twice a day for the first 2 days in the treatment period',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 514,\n",
       "  'nctid': 'NCT04382040',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment will be sprayed orally twice a day for the first 2 days in the treatment period',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 518,\n",
       "  'nctid': 'NCT04344756',\n",
       "  'interventionname': 'Tinzaparin or unfractionated heparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 519,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'DAS181',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'DAS181 4.5mg nebulized qd x 7 OR 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 520,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo nebulized qd x 7 OR 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 521,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'DAS181 COVID-19',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'DAS181 4.5mg nebulized q12h/day x 7 OR 10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 522,\n",
       "  'nctid': 'NCT03808922',\n",
       "  'interventionname': 'DAS181 OL',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days < 40kg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 523,\n",
       "  'nctid': 'NCT04321174',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 526,\n",
       "  'nctid': 'NCT04334460',\n",
       "  'interventionname': 'BLD-2660',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 529,\n",
       "  'nctid': 'NCT04343651',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 530,\n",
       "  'nctid': 'NCT04343651',\n",
       "  'interventionname': 'Leronlimab (700mg)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 537,\n",
       "  'nctid': 'NCT04353037',\n",
       "  'interventionname': 'Group A HCQ',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Enrolled participants randomized in Group A receive the HCQ drug',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 538,\n",
       "  'nctid': 'NCT04353037',\n",
       "  'interventionname': 'Group B Control',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Enrolled participants randomized in Group B will receive a placebo drug',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 539,\n",
       "  'nctid': 'NCT04385186',\n",
       "  'interventionname': 'Inactivated convalescent plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol\\n\\nDay 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 540,\n",
       "  'nctid': 'NCT04385186',\n",
       "  'interventionname': 'Support treatment',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Day 0: Start of support treatment selected by medical staff according to each each institutional protocol',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 542,\n",
       "  'nctid': 'NCT04390464',\n",
       "  'interventionname': 'Ravulizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement‐mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 543,\n",
       "  'nctid': 'NCT04390464',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 546,\n",
       "  'nctid': 'NCT04334512',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with hydroxychloroquine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 547,\n",
       "  'nctid': 'NCT04334512',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 552,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '200 mg/12h for 5 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 553,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Ritonavir/lopinavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400/100 mg/12h for 7-10 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 554,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Tocilizumab Injection [Actemra]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '600 mg/day for 1-2 doses',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 555,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '500 mg/24h for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 556,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Corticosteroid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Corticosteroids (methylprednisolone/dexamethasone/prednisone)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 557,\n",
       "  'nctid': 'NCT04380818',\n",
       "  'interventionname': 'Low molecular weight heparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 559,\n",
       "  'nctid': 'NCT04366232',\n",
       "  'interventionname': 'Anakinra alone (stages 2b/3)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Anakinra 300 mg 1/d Intravenous 5 days then dose tapering',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 560,\n",
       "  'nctid': 'NCT04366232',\n",
       "  'interventionname': 'Anakinra and Ruxolitinib (overcome stage 3)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 563,\n",
       "  'nctid': 'NCT04367883',\n",
       "  'interventionname': 'ACE inhibitor',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If evolution is favorable in patients treated with ACE as assessed at the first step of the study, this treatment would be added in a random selection of new incoming patients suffering Covid19, and results would be compared to a control group of incoming patients.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 564,\n",
       "  'nctid': 'NCT04367883',\n",
       "  'interventionname': 'ARB',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If evolution is favorable in patients treated with ARB as assessed at the first step of the study, this treatment would be added in a random selection of new incoming patients suffering Covid19, and results would be compared to a control group of incoming patients.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 568,\n",
       "  'nctid': 'NCT04349098',\n",
       "  'interventionname': 'Selinexor',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive 20 mg of selinexor.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 570,\n",
       "  'nctid': 'NCT04379492',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 572,\n",
       "  'nctid': 'NCT04371523',\n",
       "  'interventionname': 'Apo-Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 573,\n",
       "  'nctid': 'NCT04371523',\n",
       "  'interventionname': 'Matched Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Matching Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 574,\n",
       "  'nctid': 'NCT04320277',\n",
       "  'interventionname': 'Baricitinib',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 575,\n",
       "  'nctid': 'NCT04342169',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 576,\n",
       "  'nctid': 'NCT04342169',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo to be taken on the same schedule as HCQ.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 578,\n",
       "  'nctid': 'NCT04339712',\n",
       "  'interventionname': 'Anakinra',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'In case of diagnosis of MAS treatment with anakinra',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 579,\n",
       "  'nctid': 'NCT04339712',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'In case of diagnosis of immune dysregulation treatment with tocilizumab',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 585,\n",
       "  'nctid': 'NCT04346797',\n",
       "  'interventionname': 'Eculizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous administration as follows:\\n\\nInduction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 586,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Ivermectine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 587,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine Sulfate 400mg/daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 588,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '(0.2 mg /kg=12 mg ) lactose single dose at once/ weekly',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 589,\n",
       "  'nctid': 'NCT04343092',\n",
       "  'interventionname': 'Azithromycin 500 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin capsules 500mg daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 591,\n",
       "  'nctid': 'NCT04392232',\n",
       "  'interventionname': 'Convalescent Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '• Investigational Product\\n\\no COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 592,\n",
       "  'nctid': 'NCT04312009',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Losartan; 50 mg daily; oral administration',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 595,\n",
       "  'nctid': 'NCT04333654',\n",
       "  'interventionname': 'Hydroxychloroquine SAR321068',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Pharmaceutical form:Tablet Route of administration: Oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 596,\n",
       "  'nctid': 'NCT04333654',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Pharmaceutical form:Tablet Route of administration: Oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 598,\n",
       "  'nctid': 'NCT04354155',\n",
       "  'interventionname': 'Enoxaparin Prefilled Syringe [Lovenox]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 599,\n",
       "  'nctid': 'NCT04399980',\n",
       "  'interventionname': 'Mavrilimumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 600,\n",
       "  'nctid': 'NCT04399980',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 606,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Ascorbic Acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive ascorbic acid and folic acid therapy.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 607,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 608,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 609,\n",
       "  'nctid': 'NCT04354428',\n",
       "  'interventionname': 'Folic Acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Eligible participants in a household will receive folic acid and an additional intervention drug',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 611,\n",
       "  'nctid': 'NCT04401293',\n",
       "  'interventionname': 'Enoxaparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Full Dose LMWH anticoagulation therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 612,\n",
       "  'nctid': 'NCT04401293',\n",
       "  'interventionname': 'Prophylactic/Intermediate Dose Enoxaparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Prophylactic/Intermediate Dose LMWH or UFH therapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 613,\n",
       "  'nctid': 'NCT04388709',\n",
       "  'interventionname': 'Peginterferon Lambda-1A',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 618,\n",
       "  'nctid': 'NCT04372589',\n",
       "  'interventionname': 'Heparin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).\\n\\nUnfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 619,\n",
       "  'nctid': 'NCT04341935',\n",
       "  'interventionname': 'Linagliptin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '5 mg Linagliptin administered by mouth once daily',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 620,\n",
       "  'nctid': 'NCT04341935',\n",
       "  'interventionname': 'Insulin regimen',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care insulin regimen as per hospital protocol',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 621,\n",
       "  'nctid': 'NCT04357730',\n",
       "  'interventionname': 'Alteplase 50 MG [Activase]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hours. Immediately following the Alteplase infusion, 5000 IU of unfracionated heparin (UFH) will be delivered intravenously and the heparin drip will be continued to maintain the activated partial thromboplastin time at 60-80sec (2.0 to 2.5 times the upper limit of normal).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 622,\n",
       "  'nctid': 'NCT04357730',\n",
       "  'interventionname': 'Alteplase 100 MG [Activase]',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients randomized to Alteplase-100 group will receive 100 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 90 mgs over a total time of 2 hours. Immediately following the Alteplase infusion, 5000 IU of unfracionated heparin (UFH) will be delivered intravenously and the heparin drip will be continued to maintain the activated partial thromboplastin time at 60-80sec (2.0 to 2.5 times the upper limit of normal).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 623,\n",
       "  'nctid': 'NCT04357366',\n",
       "  'interventionname': 'Anakinra',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 624,\n",
       "  'nctid': 'NCT04357366',\n",
       "  'interventionname': 'trimethoprim/sulfamethoxazole',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Treatment with 80/400 mgTrimethoprime/sulfamethoxazole orally once daily for ten days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 627,\n",
       "  'nctid': 'NCT04380935',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'According to national or hospital guidelines \"COVID-19 Management Protocol\"',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 629,\n",
       "  'nctid': 'NCT04390139',\n",
       "  'interventionname': 'XCEL-UMC-BETA',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administration on top of the standard administered treatment',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 633,\n",
       "  'nctid': 'NCT04372628',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine 200 mg tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 634,\n",
       "  'nctid': 'NCT04372628',\n",
       "  'interventionname': 'Lopinavir/ritonavir 400 mg/100 mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'lopinavir/ritonavir tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 637,\n",
       "  'nctid': 'NCT04345614',\n",
       "  'interventionname': 'CM4620-Injectable Emulsion',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'CM4620-IE 2.0 mg/kg on Day 1 and then 1.6 mg/kg on Days 2 and 3. All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 638,\n",
       "  'nctid': 'NCT04391179',\n",
       "  'interventionname': 'Dipyridamole 100 Milligram(mg)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Drug will be given for 14 days while in the hospital.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 639,\n",
       "  'nctid': 'NCT04391179',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo will be given for 14 days while in the hospital.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 641,\n",
       "  'nctid': 'NCT04328272',\n",
       "  'interventionname': 'Hydroxychloroquine 200 Mg Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine administered orally with water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 642,\n",
       "  'nctid': 'NCT04328272',\n",
       "  'interventionname': 'Azithromycin 500Mg Oral Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Azithromycin administered orally with water',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 645,\n",
       "  'nctid': 'NCT04346446',\n",
       "  'interventionname': 'Convalescent Plasma Transfusion',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Convalescent Plasma Transfusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 647,\n",
       "  'nctid': 'NCT04346446',\n",
       "  'interventionname': 'Random Donor Plasma',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 650,\n",
       "  'nctid': 'NCT04397497',\n",
       "  'interventionname': 'Mavrilimumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'human monoclonal antibody targeting GM-CSF receptor-alpha',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 651,\n",
       "  'nctid': 'NCT04397497',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'matching volume of diluent',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 652,\n",
       "  'nctid': 'NCT04323592',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 656,\n",
       "  'nctid': 'NCT04251871',\n",
       "  'interventionname': 'Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.\\n\\nTraditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 657,\n",
       "  'nctid': 'NCT04251871',\n",
       "  'interventionname': 'Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 658,\n",
       "  'nctid': 'NCT04363827',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 659,\n",
       "  'nctid': 'NCT04359329',\n",
       "  'interventionname': 'Estradiol patch',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 660,\n",
       "  'nctid': 'NCT04306705',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Administered as an intravenous infusion.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 663,\n",
       "  'nctid': 'NCT04363437',\n",
       "  'interventionname': 'Colchicine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 664,\n",
       "  'nctid': 'NCT04363437',\n",
       "  'interventionname': 'Usual Care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 669,\n",
       "  'nctid': 'NCT04338126',\n",
       "  'interventionname': 'Tranexamic acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'previously described',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 670,\n",
       "  'nctid': 'NCT04338126',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'previously described',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 671,\n",
       "  'nctid': 'NCT03648372',\n",
       "  'interventionname': 'TAK-981',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous infusion.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 672,\n",
       "  'nctid': 'NCT03648372',\n",
       "  'interventionname': 'Standard of care',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care for COVID-19.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 673,\n",
       "  'nctid': 'NCT04373824',\n",
       "  'interventionname': 'Ivermectin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ivermectin 200 to 400 mcg per kg body weight',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 674,\n",
       "  'nctid': 'NCT04328467',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine; 200mg tablet; oral',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 678,\n",
       "  'nctid': 'NCT04350450',\n",
       "  'interventionname': 'Hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '400 mg tablet',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 679,\n",
       "  'nctid': 'NCT04381364',\n",
       "  'interventionname': 'Ciclesonide Inhalation Aerosol',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ciclesonide 320 µg twice daily for 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 680,\n",
       "  'nctid': 'NCT04357782',\n",
       "  'interventionname': 'L-ascorbic acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 686,\n",
       "  'nctid': 'NCT04366089',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 687,\n",
       "  'nctid': 'NCT04366089',\n",
       "  'interventionname': 'hydroxychloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'dose: 200 mg, 1 cp x 2 / day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 688,\n",
       "  'nctid': 'NCT04393792',\n",
       "  'interventionname': 'Povidone-Iodine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.23% three times daily (tds) for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 689,\n",
       "  'nctid': 'NCT04393792',\n",
       "  'interventionname': 'Normal saline',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.9% three times daily (tds) for 3 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 690,\n",
       "  'nctid': 'NCT04358081',\n",
       "  'interventionname': 'HCQ',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine Monotherapy',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 691,\n",
       "  'nctid': 'NCT04358081',\n",
       "  'interventionname': 'HCQ+AZT',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Hydroxychloroquine with azithromycin',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 692,\n",
       "  'nctid': 'NCT04358081',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 693,\n",
       "  'nctid': 'NCT04333914',\n",
       "  'interventionname': 'Chloroquine analog (GNS651)',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cohort 1 (arm B): 200mg bid loading dose for 2 days then, 200 qd orally for 14 consecutive days.\\n\\nCohorte 2 (arm E): 200mg bid loading dose for 2 days then, 200 qd/day orally, per os, for 14 consecutive days.\\n\\nIf for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 694,\n",
       "  'nctid': 'NCT04333914',\n",
       "  'interventionname': 'Nivolumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cohorte 1 (arm C): 0.3mg/Kg, intravenously, single infusion at Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 695,\n",
       "  'nctid': 'NCT04333914',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cohorte 2 (arm F): 400mg flat dose, intravenously, single infusion at Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 697,\n",
       "  'nctid': 'NCT04402060',\n",
       "  'interventionname': 'APL-9',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Complement (C3) Inhibitor',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 700,\n",
       "  'nctid': 'NCT04343963',\n",
       "  'interventionname': 'Pyridostigmine Bromide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One 60mg tablet P.O. once per day for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 701,\n",
       "  'nctid': 'NCT04343963',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'One tablet P.O. once per day for 14 days',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 703,\n",
       "  'nctid': 'NCT04371393',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 704,\n",
       "  'nctid': 'NCT04345276',\n",
       "  'interventionname': 'Danoprevir+Ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 705,\n",
       "  'nctid': 'NCT04365153',\n",
       "  'interventionname': 'Canakinumab Injection 600mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients </= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 706,\n",
       "  'nctid': 'NCT04365153',\n",
       "  'interventionname': 'Canakinumab Injection 300mg',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients </= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 707,\n",
       "  'nctid': 'NCT04365153',\n",
       "  'interventionname': 'Placebos',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '250 mL of 5% dextrose infused IV over 2 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 709,\n",
       "  'nctid': 'NCT04306393',\n",
       "  'interventionname': 'Nitric Oxide Gas',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.\\n\\nWeaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 718,\n",
       "  'nctid': 'NCT04344184',\n",
       "  'interventionname': 'L-ascorbic acid',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '100 mg/kg intravenous vitamin C infusion every 8 hours for up to 72 hours',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 722,\n",
       "  'nctid': 'NCT04363502',\n",
       "  'interventionname': 'Clazakizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 723,\n",
       "  'nctid': 'NCT04363502',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 733,\n",
       "  'nctid': 'NCT04349371',\n",
       "  'interventionname': 'Chloroquine',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 734,\n",
       "  'nctid': 'NCT04349371',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 741,\n",
       "  'nctid': 'NCT04388826',\n",
       "  'interventionname': 'Veru-111',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Respiratory Distress Syndrome, Adult',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 744,\n",
       "  'nctid': 'NCT04279197',\n",
       "  'interventionname': 'N-acetylcysteine+ Fuzheng Huayu Tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 745,\n",
       "  'nctid': 'NCT04279197',\n",
       "  'interventionname': 'N-acetylcysteine+Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The subjects will be taking 1 N-acetylcysteine capcule and 4 Placebo tablets three times a day for 24 weeks.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 747,\n",
       "  'nctid': 'NCT04374474',\n",
       "  'interventionname': 'corticosteroid nasal irrigation',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 758,\n",
       "  'nctid': 'NCT04342650',\n",
       "  'interventionname': 'Chloroquine Diphosphate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '150mg tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 759,\n",
       "  'nctid': 'NCT04342650',\n",
       "  'interventionname': 'Placebo oral tablet',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '150mg placebo tablets',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 761,\n",
       "  'nctid': 'NCT04343729',\n",
       "  'interventionname': 'Methylprednisolone Sodium Succinate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'injectable solution at a dose of 0.5mg/kg',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 762,\n",
       "  'nctid': 'NCT04343729',\n",
       "  'interventionname': 'Placebo solution',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'injectable saline solution',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 765,\n",
       "  'nctid': 'NCT04340557',\n",
       "  'interventionname': 'Losartan',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 766,\n",
       "  'nctid': 'NCT04254874',\n",
       "  'interventionname': 'Abidol hydrochloride',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '0.2g once, 3 times a day,two weeks',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 767,\n",
       "  'nctid': 'NCT04254874',\n",
       "  'interventionname': 'Abidol Hydrochloride combined with Interferon atomization',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 768,\n",
       "  'nctid': 'NCT04261270',\n",
       "  'interventionname': 'ASC09F+Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 769,\n",
       "  'nctid': 'NCT04261270',\n",
       "  'interventionname': 'Ritonavir+Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 770,\n",
       "  'nctid': 'NCT04261270',\n",
       "  'interventionname': 'Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '75mg ,once a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 771,\n",
       "  'nctid': 'NCT04336410',\n",
       "  'interventionname': 'INO-4800',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'INO-4800 will be administered ID on Day 0 and Week 4.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 775,\n",
       "  'nctid': 'NCT04255017',\n",
       "  'interventionname': 'Abidol hydrochloride',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 776,\n",
       "  'nctid': 'NCT04255017',\n",
       "  'interventionname': 'Oseltamivir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 777,\n",
       "  'nctid': 'NCT04255017',\n",
       "  'interventionname': 'Lopinavir/ritonavir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 778,\n",
       "  'nctid': 'NCT04263402',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 779,\n",
       "  'nctid': 'NCT04263402',\n",
       "  'interventionname': 'Methylprednisolone',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 780,\n",
       "  'nctid': 'NCT04334265',\n",
       "  'interventionname': 'Anluohuaxian',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '6g each time, twice a day',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 781,\n",
       "  'nctid': 'NCT04355637',\n",
       "  'interventionname': 'Inhaled budesonide',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'adding budesonide to standard of care for pneumonia in COVID19 positive patients',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 786,\n",
       "  'nctid': 'NCT04323527',\n",
       "  'interventionname': 'Chloroquine diphosphate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '150mg chloroquine diphosphate tablets.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 787,\n",
       "  'nctid': 'NCT04401150',\n",
       "  'interventionname': 'Vitamin C',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 788,\n",
       "  'nctid': 'NCT04401150',\n",
       "  'interventionname': 'Control',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 792,\n",
       "  'nctid': 'NCT04380961',\n",
       "  'interventionname': 'Sirukumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive sirukumab 5 mg/kg IV single dose infusion on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 793,\n",
       "  'nctid': 'NCT04380961',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Participants will receive placebo IV single dose infusion on Day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 795,\n",
       "  'nctid': 'NCT04264533',\n",
       "  'interventionname': 'VC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 796,\n",
       "  'nctid': 'NCT04264533',\n",
       "  'interventionname': 'Sterile Water for Injection',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 802,\n",
       "  'nctid': 'NCT04275245',\n",
       "  'interventionname': 'Meplazumab for Injection',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'humanized MAb against CD147',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 805,\n",
       "  'nctid': 'NCT04333589',\n",
       "  'interventionname': 'Favipiravir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 806,\n",
       "  'nctid': 'NCT04310228',\n",
       "  'interventionname': 'Favipiravir Combined With Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\\n\\nTocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 807,\n",
       "  'nctid': 'NCT04310228',\n",
       "  'interventionname': 'Favipiravir',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 808,\n",
       "  'nctid': 'NCT04310228',\n",
       "  'interventionname': 'Tocilizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 809,\n",
       "  'nctid': 'NCT04341727',\n",
       "  'interventionname': 'Hydroxychloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'anti-rheumatic drug (DMARD)',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 810,\n",
       "  'nctid': 'NCT04341727',\n",
       "  'interventionname': 'Azithromycin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antibiotic',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 811,\n",
       "  'nctid': 'NCT04341727',\n",
       "  'interventionname': 'Chloroquine Sulfate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Antimalarial',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 812,\n",
       "  'nctid': 'NCT04392219',\n",
       "  'interventionname': 'EIDD-2801',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Part 1:\\n\\nSubjects will be randomized to receive a single oral dose of EIDD-2801 or Placebo.\\n\\nPart 2:\\n\\nTwo single oral doses of EIDD-2801 will be administered to subjects, in an open-label manner.\\n\\nPart 3:\\n\\nSubjects will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 813,\n",
       "  'nctid': 'NCT04392219',\n",
       "  'interventionname': 'Placebo',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Part 1:\\n\\nSubjects will be randomized to receive a single oral dose of EIDD-2801 or Placebo.\\n\\nPart 3:\\n\\nSubjects will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 826,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': 'Cisplatin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 827,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': 'Carboplatin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 828,\n",
       "  'nctid': 'NCT03323463',\n",
       "  'interventionname': '5Fluorouracil',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 830,\n",
       "  'nctid': 'NCT03680274',\n",
       "  'interventionname': 'Vitamin C',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 834,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'Voraxaze',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 835,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'Methotrexate',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': '(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m^2',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 836,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'Rituximab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will be treated with rituximab 500 mg/m^2.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 837,\n",
       "  'nctid': 'NCT03684980',\n",
       "  'interventionname': 'leucovorin',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 846,\n",
       "  'nctid': 'NCT03398135',\n",
       "  'interventionname': 'risankizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'subcutaneous (SC) injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 847,\n",
       "  'nctid': 'NCT03398135',\n",
       "  'interventionname': 'placebo for risankizumab',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'subcutaneous (SC) injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 848,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Placebo for Risankizumab SC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo for Risankizumab SC Subcutaneous (SC) Injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 849,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Risankizumab IV',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Risankizumab IV Intravenous (IV) infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 850,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Placebo for Risankizumab IV',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Placebo for Risankizumab IV Intravenous (IV) infusion',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 851,\n",
       "  'nctid': 'NCT03105102',\n",
       "  'interventionname': 'Risankizumab SC',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'Risankizumab SC Subcutaneous (SC) injection',\n",
       "  'statusDate': '05/26/2020'},\n",
       " {'index': 857,\n",
       "  'nctid': 'NCT04278404',\n",
       "  'interventionname': 'The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:',\n",
       "  'interventiontype': 'Drug',\n",
       "  'interventiondesc': 'The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.',\n",
       "  'statusDate': '05/26/2020'}]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_int_query = engine.execute(\"Select * From Interventions Where interventiontype = 'Drug'\")\n",
    "d, a = {}, []\n",
    "for rowproxy in drug_int_query:\n",
    "    # rowproxy.items() returns an array like [(key0, value0), (key1, value1)] > thank you stackoverflow!\n",
    "    for column, value in rowproxy.items():\n",
    "        # build up the dictionary\n",
    "        d = {**d, **{column: value}}\n",
    "    a.append(d)\n",
    "connection.close()\n",
    "a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "446"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(a)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>nctid</th>\n",
       "      <th>interventionname</th>\n",
       "      <th>interventiontype</th>\n",
       "      <th>interventiondesc</th>\n",
       "      <th>statusDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>NCT04332380</td>\n",
       "      <td>Plasma</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Day 1: CP-COVID19, 250 milliliters. Day 2: CP-...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>Plasma</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Day 1: CP-COVID19, 250 milliliters. Day 2: CP-...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>400 milligrams each 12 hours for 10 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>7</td>\n",
       "      <td>NCT04341441</td>\n",
       "      <td>Hydroxychloroquine - Daily Dosing</td>\n",
       "      <td>Drug</td>\n",
       "      <td>The daily hydroxychloroquine treatment arm wil...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>8</td>\n",
       "      <td>NCT04341441</td>\n",
       "      <td>Hydroxychloroquine - Weekly Dosing</td>\n",
       "      <td>Drug</td>\n",
       "      <td>The once weekly randomized treatment arm will ...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   index        nctid                    interventionname interventiontype  \\\n",
       "0      0  NCT04332380                              Plasma             Drug   \n",
       "1      2  NCT04332835                              Plasma             Drug   \n",
       "2      3  NCT04332835                  Hydroxychloroquine             Drug   \n",
       "3      7  NCT04341441   Hydroxychloroquine - Daily Dosing             Drug   \n",
       "4      8  NCT04341441  Hydroxychloroquine - Weekly Dosing             Drug   \n",
       "\n",
       "                                    interventiondesc  statusDate  \n",
       "0  Day 1: CP-COVID19, 250 milliliters. Day 2: CP-...  05/26/2020  \n",
       "1  Day 1: CP-COVID19, 250 milliliters. Day 2: CP-...  05/26/2020  \n",
       "2           400 milligrams each 12 hours for 10 days  05/26/2020  \n",
       "3  The daily hydroxychloroquine treatment arm wil...  05/26/2020  \n",
       "4  The once weekly randomized treatment arm will ...  05/26/2020  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_int_df = pd.DataFrame(a)\n",
    "drug_int_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count         446\n",
       "unique        276\n",
       "top       Placebo\n",
       "freq           38\n",
       "Name: interventionname, dtype: object"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_int_df['interventionname'].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Plasma', 'Hydroxychloroquine',\n",
       "       'Hydroxychloroquine - Daily Dosing',\n",
       "       'Hydroxychloroquine - Weekly Dosing', 'Nitric Oxide',\n",
       "       'Suspension of heat killed (autoclaved) Mycobacterium w',\n",
       "       'Standard therapy of COVID-19', 'Indomethacin',\n",
       "       'Zithromax Oral Product',\n",
       "       'ACE Inhibitors and Calcium Channel Blockers', 'Standard of care',\n",
       "       'Naltrexone', 'Ketamine',\n",
       "       'MCN (Methylene blue, vitamin C, N-acetyl cysteine)',\n",
       "       'Darunavir and Cobicistat', 'Colchicine', 'Placebo oral tablet',\n",
       "       'Standard of Care', 'Azithromycin',\n",
       "       'Hydoxychloroquine or Chloroquine', 'Interferon-Beta',\n",
       "       'Dexamethasone', 'PUL-042 Inhalation Solution', 'Placebo',\n",
       "       'Lopinavir / Ritonavir Pill',\n",
       "       'Retrospective case-control analysis', 'Convalescent Plasma',\n",
       "       'Chloroquine phosphate', 'Povidone-Iodine Nasal Spray and Gargle',\n",
       "       'Silymarin', 'Duvelisib', 'Losartan',\n",
       "       'Hydroxychloroquine and azithromycin treatment',\n",
       "       'Peginterferon Lambda-1a', 'Hidroxicloroquine',\n",
       "       'Lopinavir/ritonavir', 'Imatinib tablets',\n",
       "       'Baricitinib Oral Tablet',\n",
       "       'Traditional Chinese Medicine Prescription', 'AT-001',\n",
       "       'Levamisole', 'Isoprinosine', 'Levamisole and Isoprinosine',\n",
       "       'Zanubrutinib', 'Supportive Care', 'FT516', 'Ruxolitinib',\n",
       "       'Baricitinib', 'HCQ + Intravenous Famotidine', 'HCQ + Placebo',\n",
       "       'Hydroxychloroquine Pre-Exposure Prophylaxis',\n",
       "       'Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :',\n",
       "       'metenkefalin + tridecactide', 'The standard of care',\n",
       "       'BCG Vaccine', '0.9%NaCl', 'HB-adMSC',\n",
       "       'Angiotensin Receptor Blockers', 'Tocilizumab',\n",
       "       'Vazegepant (BHV-3500)', 'Hydroxychloroquine Sulfate',\n",
       "       'Ascorbic Acid', 'NORS (Nitric Oxide Releasing Solution)',\n",
       "       'Atovaquone/Azithromycin', 'Canakinumab',\n",
       "       'Hydroxychloroquine Sulfate 400 mg twice a day',\n",
       "       'Hydroxychloroquine Sulfate 600 mg twice a day',\n",
       "       'Hydroxychloroquine Sulfate 600 mg once a day',\n",
       "       'TCM prescriptions', 'Sirolimus 1 MG/ML', 'Plitidepsin 1.5 mg/day',\n",
       "       'Plitidepsin 2.0 mg/day', 'Plitidepsin 2.5 mg/day', 'Leflunomide',\n",
       "       'N-acetylcysteine',\n",
       "       'High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma',\n",
       "       'Sarilumab',\n",
       "       'Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.',\n",
       "       'Dapagliflozin 10 MG', 'Hydroxychloroquine sulfate',\n",
       "       'Baricitinib (janus kinase inhibitor)',\n",
       "       'Hydroxychloroquine Sulfate 200 MG', 'Placebos', 'CD24Fc',\n",
       "       'Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment',\n",
       "       'Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment',\n",
       "       'Standard treatment',\n",
       "       'Peginterferon lambda alfa-1a subcutaneous injection',\n",
       "       'Chemotherapy', 'Hydroxychloroquine (HCQ)',\n",
       "       'Bicalutamide 150 Mg Oral Tablet', 'Ivermectin 3Mg Tab',\n",
       "       'Remdesivir', 'Telmisartan 40mg', 'Placebo Administration',\n",
       "       'Acalabrutinib', 'Degarelix', 'Prazosin',\n",
       "       'ACE inhibitor, angiotensin receptor blocker', 'favipiravir',\n",
       "       'Standard of care therapy', 'remdesivir', 'Fluoxetine',\n",
       "       'Sildenafil citrate tablets', 'Enoxaparin Higher Dose',\n",
       "       'Lower-dose prophylactic anticoagulation', 'Zinc Sulfate',\n",
       "       'Doxycycline', 'Tacrolimus', 'Methylprednisolone',\n",
       "       'Clarithromycin', 'Leronlimab (700mg)',\n",
       "       'Pegylated interferon lambda', 'Etoposide', 'Low-dose chloroquine',\n",
       "       'Mid-dose chloroquine', 'High-dose chloroquine',\n",
       "       'Tocilizumab (TCZ)', 'Saline oral/nasal rinse',\n",
       "       '0.5% Povidone/Iodine oral/nasal rinse',\n",
       "       '0.12% Chlorhexidine oral/nasal rinse', 'Mannitol',\n",
       "       'Colchicine Tablets', 'Sirolimus', 'Nitric Oxide Gas',\n",
       "       'SnPP Protoporphyrin', 'Sulfonatoporphyrin(TPPS)', 'LY3127804',\n",
       "       'Tranexamic acid tablets', 'Clazakizumab', 'Bevacizumab', 'AT-527',\n",
       "       'Chloroquine or Hydroxychloroquine', 'Lopinavir/Ritonavir',\n",
       "       'Rivaroxaban', 'Thromboprophylaxis', 'Candesartan',\n",
       "       'non-RAS blocking antihypertensives', 'placebo for clazakizumab',\n",
       "       'Fluvoxamine', 'MSTT1041A', 'MSTT1041A-matched Placebo',\n",
       "       'UTTR1147A', 'UTTR1147A-matched Placebo', 'Clazakizumab 25 mg',\n",
       "       'Clazakizumab 12.5 mg', 'Inhaled nitric oxide (iNO)',\n",
       "       'Nitrogen gas', 'Oxygen gas', 'Galidesivir', 'Progesterone 100 MG',\n",
       "       'Ivermectin', 'BMS-986253', 'EDP1815', 'Dapagliflozin',\n",
       "       'Ambrisentan', 'Peginterferon Lambda-1A',\n",
       "       'Chloroquine or hydroxychloroquine', 'Gimsilumab', 'TJ003234',\n",
       "       'lopinavir/ritonavir', 'Artemisinin / Artesunate',\n",
       "       'Enoxaparin Prophylactic Dose', 'Heparin Infusion', 'Heparin SC',\n",
       "       'Enoxaparin/Lovenox Intermediate Dose', 'Honey',\n",
       "       'Nigella Sativa / Black Cumin',\n",
       "       'Hydroxychloroquine sulfate &Azithromycin', 'ArtemiC',\n",
       "       'Tinzaparin or unfractionated heparin', 'DAS181',\n",
       "       'DAS181 COVID-19', 'DAS181 OL', 'BLD-2660', 'Group A HCQ',\n",
       "       'Group B Control', 'Inactivated convalescent plasma',\n",
       "       'Support treatment', 'Ravulizumab', 'Ritonavir/lopinavir',\n",
       "       'Tocilizumab Injection [Actemra]', 'Corticosteroid',\n",
       "       'Low molecular weight heparin', 'Anakinra alone (stages 2b/3)',\n",
       "       'Anakinra and Ruxolitinib (overcome stage 3)', 'ACE inhibitor',\n",
       "       'ARB', 'Selinexor', 'Apo-Hydroxychloroquine', 'Matched Placebo',\n",
       "       'Anakinra', 'Eculizumab', 'Ivermectine', 'Azithromycin 500 mg',\n",
       "       'Hydroxychloroquine SAR321068',\n",
       "       'Enoxaparin Prefilled Syringe [Lovenox]', 'Mavrilimumab',\n",
       "       'Folic Acid', 'Enoxaparin',\n",
       "       'Prophylactic/Intermediate Dose Enoxaparin', 'Heparin',\n",
       "       'Linagliptin', 'Insulin regimen', 'Alteplase 50 MG [Activase]',\n",
       "       'Alteplase 100 MG [Activase]', 'trimethoprim/sulfamethoxazole',\n",
       "       'XCEL-UMC-BETA', 'Lopinavir/ritonavir 400 mg/100 mg',\n",
       "       'CM4620-Injectable Emulsion', 'Dipyridamole 100 Milligram(mg)',\n",
       "       'Hydroxychloroquine 200 Mg Oral Tablet',\n",
       "       'Azithromycin 500Mg Oral Tablet',\n",
       "       'Convalescent Plasma Transfusion', 'Random Donor Plasma',\n",
       "       'Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules',\n",
       "       'Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)',\n",
       "       'Estradiol patch', 'Usual Care', 'Tranexamic acid', 'TAK-981',\n",
       "       'Ciclesonide Inhalation Aerosol', 'L-ascorbic acid',\n",
       "       'hydroxychloroquine', 'Povidone-Iodine', 'Normal saline', 'HCQ',\n",
       "       'HCQ+AZT', 'Chloroquine analog (GNS651)', 'Nivolumab', 'APL-9',\n",
       "       'Pyridostigmine Bromide', 'Danoprevir+Ritonavir',\n",
       "       'Canakinumab Injection 600mg', 'Canakinumab Injection 300mg',\n",
       "       'Chloroquine', 'Veru-111',\n",
       "       'N-acetylcysteine+ Fuzheng Huayu Tablet',\n",
       "       'N-acetylcysteine+Placebo', 'corticosteroid nasal irrigation',\n",
       "       'Chloroquine Diphosphate', 'Methylprednisolone Sodium Succinate',\n",
       "       'Placebo solution', 'Abidol hydrochloride',\n",
       "       'Abidol Hydrochloride combined with Interferon atomization',\n",
       "       'ASC09F+Oseltamivir', 'Ritonavir+Oseltamivir', 'Oseltamivir',\n",
       "       'INO-4800', 'Anluohuaxian', 'Inhaled budesonide',\n",
       "       'Chloroquine diphosphate', 'Vitamin C', 'Control', 'Sirukumab',\n",
       "       'VC', 'Sterile Water for Injection', 'Meplazumab for Injection',\n",
       "       'Favipiravir', 'Favipiravir Combined With Tocilizumab',\n",
       "       'Chloroquine Sulfate', 'EIDD-2801', 'Cisplatin', 'Carboplatin',\n",
       "       '5Fluorouracil', 'Voraxaze', 'Methotrexate', 'Rituximab',\n",
       "       'leucovorin', 'risankizumab', 'placebo for risankizumab',\n",
       "       'Placebo for Risankizumab SC', 'Risankizumab IV',\n",
       "       'Placebo for Risankizumab IV', 'Risankizumab SC',\n",
       "       'The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_int_df['interventionname'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_list = ['Hydroxychloroquine', 'chloroquine', 'Remdesivir', 'Favilavir', 'Lopinavir-ritonavir', 'Convalescent plasma']\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_list = []\n",
    "for drug in drug_list:\n",
    "    query = engine.execute(f\"Select * From Interventions Where interventionname LIKE '%{drug}%'\")\n",
    "    d, a = {}, []\n",
    "    for rowproxy in query:\n",
    "        # rowproxy.items() returns an array like [(key0, value0), (key1, value1)] > thank you stackoverflow!\n",
    "        for column, value in rowproxy.items():\n",
    "            # build up the dictionary\n",
    "            d = {**d, **{column: value}}\n",
    "        a.append(d)\n",
    "    a_df = pd.DataFrame(a)\n",
    "    df_list.append(a_df)\n",
    "connection.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "specific_drug_df = pd.concat(df_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>nctid</th>\n",
       "      <th>interventionname</th>\n",
       "      <th>interventiontype</th>\n",
       "      <th>interventiondesc</th>\n",
       "      <th>statusDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>400 milligrams each 12 hours for 10 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>7</td>\n",
       "      <td>NCT04341441</td>\n",
       "      <td>Hydroxychloroquine - Daily Dosing</td>\n",
       "      <td>Drug</td>\n",
       "      <td>The daily hydroxychloroquine treatment arm wil...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>8</td>\n",
       "      <td>NCT04341441</td>\n",
       "      <td>Hydroxychloroquine - Weekly Dosing</td>\n",
       "      <td>Drug</td>\n",
       "      <td>The once weekly randomized treatment arm will ...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>29</td>\n",
       "      <td>NCT04344457</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>200 mg PO BID 5 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>51</td>\n",
       "      <td>NCT04345692</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>oral tablet administered by hospital staff or ...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>25</td>\n",
       "      <td>591</td>\n",
       "      <td>NCT04392232</td>\n",
       "      <td>Convalescent Plasma</td>\n",
       "      <td>Drug</td>\n",
       "      <td>• Investigational Product\\n\\no COVID-19 conval...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>26</td>\n",
       "      <td>626</td>\n",
       "      <td>NCT04380935</td>\n",
       "      <td>Convalescent plasma</td>\n",
       "      <td>Biological</td>\n",
       "      <td>Convalescent plasma of recovered COVID-19 pati...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>27</td>\n",
       "      <td>645</td>\n",
       "      <td>NCT04346446</td>\n",
       "      <td>Convalescent Plasma Transfusion</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Convalescent Plasma Transfusion</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>28</td>\n",
       "      <td>799</td>\n",
       "      <td>NCT04376034</td>\n",
       "      <td>Convalescent Plasma 1 Unit</td>\n",
       "      <td>Biological</td>\n",
       "      <td>Each adult recipient will receive 1 units of p...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>29</td>\n",
       "      <td>800</td>\n",
       "      <td>NCT04376034</td>\n",
       "      <td>Convalescent Plasma 2 Units</td>\n",
       "      <td>Biological</td>\n",
       "      <td>Those that meet severe or critical criteria wi...</td>\n",
       "      <td>05/26/2020</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>163 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    index        nctid                    interventionname interventiontype  \\\n",
       "0       3  NCT04332835                  Hydroxychloroquine             Drug   \n",
       "1       7  NCT04341441   Hydroxychloroquine - Daily Dosing             Drug   \n",
       "2       8  NCT04341441  Hydroxychloroquine - Weekly Dosing             Drug   \n",
       "3      29  NCT04344457                  Hydroxychloroquine             Drug   \n",
       "4      51  NCT04345692                  Hydroxychloroquine             Drug   \n",
       "..    ...          ...                                 ...              ...   \n",
       "25    591  NCT04392232                 Convalescent Plasma             Drug   \n",
       "26    626  NCT04380935                 Convalescent plasma       Biological   \n",
       "27    645  NCT04346446     Convalescent Plasma Transfusion             Drug   \n",
       "28    799  NCT04376034          Convalescent Plasma 1 Unit       Biological   \n",
       "29    800  NCT04376034         Convalescent Plasma 2 Units       Biological   \n",
       "\n",
       "                                     interventiondesc  statusDate  \n",
       "0            400 milligrams each 12 hours for 10 days  05/26/2020  \n",
       "1   The daily hydroxychloroquine treatment arm wil...  05/26/2020  \n",
       "2   The once weekly randomized treatment arm will ...  05/26/2020  \n",
       "3                                200 mg PO BID 5 days  05/26/2020  \n",
       "4   oral tablet administered by hospital staff or ...  05/26/2020  \n",
       "..                                                ...         ...  \n",
       "25  • Investigational Product\\n\\no COVID-19 conval...  05/26/2020  \n",
       "26  Convalescent plasma of recovered COVID-19 pati...  05/26/2020  \n",
       "27                    Convalescent Plasma Transfusion  05/26/2020  \n",
       "28  Each adult recipient will receive 1 units of p...  05/26/2020  \n",
       "29  Those that meet severe or critical criteria wi...  05/26/2020  \n",
       "\n",
       "[163 rows x 6 columns]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "specific_drug_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>count</td>\n",
       "      <td>163.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>mean</td>\n",
       "      <td>336.546012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>std</td>\n",
       "      <td>224.737246</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>min</td>\n",
       "      <td>3.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>25%</td>\n",
       "      <td>154.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>50%</td>\n",
       "      <td>302.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>75%</td>\n",
       "      <td>542.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>max</td>\n",
       "      <td>811.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            index\n",
       "count  163.000000\n",
       "mean   336.546012\n",
       "std    224.737246\n",
       "min      3.000000\n",
       "25%    154.000000\n",
       "50%    302.000000\n",
       "75%    542.500000\n",
       "max    811.000000"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "specific_drug_df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count                    163\n",
       "unique                    50\n",
       "top       Hydroxychloroquine\n",
       "freq                      66\n",
       "Name: interventionname, dtype: object"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "specific_drug_df['interventionname'].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Hydroxychloroquine', 'Hydroxychloroquine - Daily Dosing',\n",
       "       'Hydroxychloroquine - Weekly Dosing',\n",
       "       'Hydroxychloroquine and azithromycin treatment',\n",
       "       'Hydroxychloroquine Pre-Exposure Prophylaxis',\n",
       "       'Hydroxychloroquine Sulfate',\n",
       "       'Hydroxychloroquine Sulfate 400 mg twice a day',\n",
       "       'Hydroxychloroquine Sulfate 600 mg twice a day',\n",
       "       'Hydroxychloroquine Sulfate 600 mg once a day',\n",
       "       'Hydroxychloroquine sulfate', 'Hydroxychloroquine Sulfate 200 MG',\n",
       "       'Hydroxychloroquine (HCQ)',\n",
       "       'Hydroxychloroquine Sulfate + Azithromycin',\n",
       "       'Chloroquine or Hydroxychloroquine',\n",
       "       'Chloroquine or hydroxychloroquine',\n",
       "       'Hydroxychloroquine sulfate &Azithromycin',\n",
       "       'Apo-Hydroxychloroquine', 'Hydroxychloroquine SAR321068',\n",
       "       'Hydroxychloroquine 200 Mg Oral Tablet', 'hydroxychloroquine',\n",
       "       'Hydoxychloroquine or Chloroquine', 'Chloroquine phosphate',\n",
       "       'Low-dose chloroquine', 'Mid-dose chloroquine',\n",
       "       'High-dose chloroquine', 'Chloroquine analog (GNS651)',\n",
       "       'Chloroquine', 'Chloroquine Diphosphate',\n",
       "       'Chloroquine diphosphate', 'Chloroquine Sulfate', 'Remdesivir',\n",
       "       'remdesivir',\n",
       "       'Multiple Doses of Anti-SARS-CoV-2 convalescent plasma',\n",
       "       'COVID-19 Convalescent Plasma',\n",
       "       'Convalescent Plasma from COVID-19 donors',\n",
       "       'anti-SARS-CoV-2 convalescent plasma', 'Convalescent Plasma',\n",
       "       'SARS-CoV-2 convalescent plasma',\n",
       "       'pathogen reduced SARS-CoV-2 convalescent plasma',\n",
       "       'Convalescent Plasma (anti-SARS-CoV-2 plasma)',\n",
       "       'convalescent plasma', 'Non-convalescent Plasma (control plasma)',\n",
       "       'Convalescent plasma',\n",
       "       'High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma',\n",
       "       'Convalescent plasma (CP)',\n",
       "       'High-Titer COVID-19 Convalescent Plasma (HT-CCP)',\n",
       "       'Inactivated convalescent plasma',\n",
       "       'Convalescent Plasma Transfusion', 'Convalescent Plasma 1 Unit',\n",
       "       'Convalescent Plasma 2 Units'], dtype=object)"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "specific_drug_df.interventionname.unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "query = engine.execute(f\"Select * From Interventions Where interventionname LIKE '%{drug}%'\")\n",
    "d, a = {}, []\n",
    "for rowproxy in query:\n",
    "    # rowproxy.items() returns an array like [(key0, value0), (key1, value1)] > thank you stackoverflow!\n",
    "    for column, value in rowproxy.items():\n",
    "        # build up the dictionary\n",
    "        d = {**d, **{column: value}}\n",
    "    a.append(d)\n",
    "a_df = pd.DataFrame(a)\n",
    "df_list.append(a_df)\n",
    "connection.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "def query_handler(query_execution):\n",
    "    d, a = {}, []\n",
    "    for rowproxy in query_execution:\n",
    "        # rowproxy.items() returns an array like [(key0, value0), (key1, value1)] > thank you stackoverflow!\n",
    "        for column, value in rowproxy.items():\n",
    "            # build up the dictionary\n",
    "            d = {**d, **{column: value}}\n",
    "        a.append(d)\n",
    "    a_df = pd.DataFrame(a)\n",
    "    connection.close()\n",
    "    return a_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "query = engine.execute(f\"Select * From Inclusion_Criteria\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>nctid</th>\n",
       "      <th>inclusion_criteria</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>4</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>9</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>11</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7494</td>\n",
       "      <td>14996</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Pregnant (any plurality) delivering at or afte...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7495</td>\n",
       "      <td>14997</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>16 years or older</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7496</td>\n",
       "      <td>14998</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Low-income socioeconomic status (publicly fund...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7497</td>\n",
       "      <td>14999</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Ability to speak and read English or Spanish</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7498</td>\n",
       "      <td>15000</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Established patient at the Northwestern Medici...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>7499 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      index        nctid                                 inclusion_criteria\n",
       "0         2  NCT04395924  All pregnant women SARS-Cov-2 positive during ...\n",
       "1         3  NCT04395924                          Informed consent obtained\n",
       "2         4  NCT04395924                               18 years to 48 years\n",
       "3         9  NCT04372004  • Male or female over 18 years of age at the t...\n",
       "4        11  NCT04372004  Current symptoms of COVID-19 ; fever alone or ...\n",
       "...     ...          ...                                                ...\n",
       "7494  14996  NCT03922334  Pregnant (any plurality) delivering at or afte...\n",
       "7495  14997  NCT03922334                                  16 years or older\n",
       "7496  14998  NCT03922334  Low-income socioeconomic status (publicly fund...\n",
       "7497  14999  NCT03922334       Ability to speak and read English or Spanish\n",
       "7498  15000  NCT03922334  Established patient at the Northwestern Medici...\n",
       "\n",
       "[7499 rows x 3 columns]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "inclusion_df = query_handler(query)\n",
    "inclusion_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>nctid</th>\n",
       "      <th>exclusion_criteria</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Pregnant women without SARS-Cov-2 infection ( ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>curatorship patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>4</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Refusal to participate to the study</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>7</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Unwilling to provide informed consent</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>9</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Unwilling to undergo bi-weekly serological tes...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9933</td>\n",
       "      <td>13779</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Intent to transfer care to an outside institution</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9934</td>\n",
       "      <td>13780</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>HIV (as these patients already receive intensi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9935</td>\n",
       "      <td>13781</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior pregnancy in which individual declined p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9936</td>\n",
       "      <td>13782</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior enrollment in NNM2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9937</td>\n",
       "      <td>13783</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Enrollment in a concurrent research study that...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>9938 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      index        nctid                                 exclusion_criteria\n",
       "0         2  NCT04395924  Pregnant women without SARS-Cov-2 infection ( ...\n",
       "1         3  NCT04395924                              curatorship patients.\n",
       "2         4  NCT04395924                Refusal to participate to the study\n",
       "3         7  NCT04372004            • Unwilling to provide informed consent\n",
       "4         9  NCT04372004  Unwilling to undergo bi-weekly serological tes...\n",
       "...     ...          ...                                                ...\n",
       "9933  13779  NCT03922334  Intent to transfer care to an outside institution\n",
       "9934  13780  NCT03922334  HIV (as these patients already receive intensi...\n",
       "9935  13781  NCT03922334  Prior pregnancy in which individual declined p...\n",
       "9936  13782  NCT03922334                           Prior enrollment in NNM2\n",
       "9937  13783  NCT03922334  Enrollment in a concurrent research study that...\n",
       "\n",
       "[9938 rows x 3 columns]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query = engine.execute(f\"Select * From Exclusion_Criteria\")\n",
    "exclusion_df = query_handler(query)\n",
    "exclusion_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "inclusion_df = inclusion_df.drop(['index'], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "exclusion_df = exclusion_df.drop(['index'], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>inclusion_criteria</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7494</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Pregnant (any plurality) delivering at or afte...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7495</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>16 years or older</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7496</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Low-income socioeconomic status (publicly fund...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7497</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Ability to speak and read English or Spanish</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7498</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Established patient at the Northwestern Medici...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>7499 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            nctid                                 inclusion_criteria\n",
       "0     NCT04395924  All pregnant women SARS-Cov-2 positive during ...\n",
       "1     NCT04395924                          Informed consent obtained\n",
       "2     NCT04395924                               18 years to 48 years\n",
       "3     NCT04372004  • Male or female over 18 years of age at the t...\n",
       "4     NCT04372004  Current symptoms of COVID-19 ; fever alone or ...\n",
       "...           ...                                                ...\n",
       "7494  NCT03922334  Pregnant (any plurality) delivering at or afte...\n",
       "7495  NCT03922334                                  16 years or older\n",
       "7496  NCT03922334  Low-income socioeconomic status (publicly fund...\n",
       "7497  NCT03922334       Ability to speak and read English or Spanish\n",
       "7498  NCT03922334  Established patient at the Northwestern Medici...\n",
       "\n",
       "[7499 rows x 2 columns]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "inclusion_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>exclusion_criteria</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Pregnant women without SARS-Cov-2 infection ( ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>curatorship patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Refusal to participate to the study</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Unwilling to provide informed consent</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Unwilling to undergo bi-weekly serological tes...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9933</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Intent to transfer care to an outside institution</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9934</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>HIV (as these patients already receive intensi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9935</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior pregnancy in which individual declined p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9936</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior enrollment in NNM2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9937</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Enrollment in a concurrent research study that...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>9938 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            nctid                                 exclusion_criteria\n",
       "0     NCT04395924  Pregnant women without SARS-Cov-2 infection ( ...\n",
       "1     NCT04395924                              curatorship patients.\n",
       "2     NCT04395924                Refusal to participate to the study\n",
       "3     NCT04372004            • Unwilling to provide informed consent\n",
       "4     NCT04372004  Unwilling to undergo bi-weekly serological tes...\n",
       "...           ...                                                ...\n",
       "9933  NCT03922334  Intent to transfer care to an outside institution\n",
       "9934  NCT03922334  HIV (as these patients already receive intensi...\n",
       "9935  NCT03922334  Prior pregnancy in which individual declined p...\n",
       "9936  NCT03922334                           Prior enrollment in NNM2\n",
       "9937  NCT03922334  Enrollment in a concurrent research study that...\n",
       "\n",
       "[9938 rows x 2 columns]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "exclusion_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "exclusion_df['label'] = \"__label__1\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>exclusion_criteria</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Pregnant women without SARS-Cov-2 infection ( ...</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>curatorship patients.</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Refusal to participate to the study</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Unwilling to provide informed consent</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Unwilling to undergo bi-weekly serological tes...</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9933</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Intent to transfer care to an outside institution</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9934</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>HIV (as these patients already receive intensi...</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9935</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior pregnancy in which individual declined p...</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9936</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior enrollment in NNM2</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9937</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Enrollment in a concurrent research study that...</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>9938 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            nctid                                 exclusion_criteria  \\\n",
       "0     NCT04395924  Pregnant women without SARS-Cov-2 infection ( ...   \n",
       "1     NCT04395924                              curatorship patients.   \n",
       "2     NCT04395924                Refusal to participate to the study   \n",
       "3     NCT04372004            • Unwilling to provide informed consent   \n",
       "4     NCT04372004  Unwilling to undergo bi-weekly serological tes...   \n",
       "...           ...                                                ...   \n",
       "9933  NCT03922334  Intent to transfer care to an outside institution   \n",
       "9934  NCT03922334  HIV (as these patients already receive intensi...   \n",
       "9935  NCT03922334  Prior pregnancy in which individual declined p...   \n",
       "9936  NCT03922334                           Prior enrollment in NNM2   \n",
       "9937  NCT03922334  Enrollment in a concurrent research study that...   \n",
       "\n",
       "           label  \n",
       "0     __label__1  \n",
       "1     __label__1  \n",
       "2     __label__1  \n",
       "3     __label__1  \n",
       "4     __label__1  \n",
       "...          ...  \n",
       "9933  __label__1  \n",
       "9934  __label__1  \n",
       "9935  __label__1  \n",
       "9936  __label__1  \n",
       "9937  __label__1  \n",
       "\n",
       "[9938 rows x 3 columns]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "exclusion_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>inclusion_criteria</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7494</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Pregnant (any plurality) delivering at or afte...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7495</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>16 years or older</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7496</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Low-income socioeconomic status (publicly fund...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7497</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Ability to speak and read English or Spanish</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7498</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Established patient at the Northwestern Medici...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>7499 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            nctid                                 inclusion_criteria  \\\n",
       "0     NCT04395924  All pregnant women SARS-Cov-2 positive during ...   \n",
       "1     NCT04395924                          Informed consent obtained   \n",
       "2     NCT04395924                               18 years to 48 years   \n",
       "3     NCT04372004  • Male or female over 18 years of age at the t...   \n",
       "4     NCT04372004  Current symptoms of COVID-19 ; fever alone or ...   \n",
       "...           ...                                                ...   \n",
       "7494  NCT03922334  Pregnant (any plurality) delivering at or afte...   \n",
       "7495  NCT03922334                                  16 years or older   \n",
       "7496  NCT03922334  Low-income socioeconomic status (publicly fund...   \n",
       "7497  NCT03922334       Ability to speak and read English or Spanish   \n",
       "7498  NCT03922334  Established patient at the Northwestern Medici...   \n",
       "\n",
       "           label  \n",
       "0     __label__0  \n",
       "1     __label__0  \n",
       "2     __label__0  \n",
       "3     __label__0  \n",
       "4     __label__0  \n",
       "...          ...  \n",
       "7494  __label__0  \n",
       "7495  __label__0  \n",
       "7496  __label__0  \n",
       "7497  __label__0  \n",
       "7498  __label__0  \n",
       "\n",
       "[7499 rows x 3 columns]"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "inclusion_df['label']='__label__0'\n",
    "inclusion_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>__label__0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid                               eligibility_criteria       label\n",
       "0  NCT04395924  All pregnant women SARS-Cov-2 positive during ...  __label__0\n",
       "1  NCT04395924                          Informed consent obtained  __label__0\n",
       "2  NCT04395924                               18 years to 48 years  __label__0\n",
       "3  NCT04372004  • Male or female over 18 years of age at the t...  __label__0\n",
       "4  NCT04372004  Current symptoms of COVID-19 ; fever alone or ...  __label__0"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "inclusion_df = inclusion_df.rename(columns={'inclusion_criteria':'eligibility_criteria'})\n",
    "exclusion_df = exclusion_df.rename(columns={'exclusion_criteria':'eligibility_criteria'})\n",
    "inclusion_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>count</td>\n",
       "      <td>17437</td>\n",
       "      <td>17437</td>\n",
       "      <td>17437</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>unique</td>\n",
       "      <td>1630</td>\n",
       "      <td>15386</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>top</td>\n",
       "      <td>NCT04376476</td>\n",
       "      <td>Pregnancy</td>\n",
       "      <td>__label__1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>freq</td>\n",
       "      <td>97</td>\n",
       "      <td>76</td>\n",
       "      <td>9938</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              nctid eligibility_criteria       label\n",
       "count         17437                17437       17437\n",
       "unique         1630                15386           2\n",
       "top     NCT04376476            Pregnancy  __label__1\n",
       "freq             97                   76        9938"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligibility_criteria_df = pd.concat([inclusion_df, exclusion_df])\n",
    "eligibility_criteria_df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>label</th>\n",
       "      <th>elig_split</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[All, pregnant, women, SARS-Cov-2, positive, d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Informed, consent, obtained]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[18, years, to, 48, years]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[•, Male, or, female, over, 18, years, of, age...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Current, symptoms, of, COVID-19, ;, fever, al...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid                               eligibility_criteria       label  \\\n",
       "0  NCT04395924  All pregnant women SARS-Cov-2 positive during ...  __label__0   \n",
       "1  NCT04395924                          Informed consent obtained  __label__0   \n",
       "2  NCT04395924                               18 years to 48 years  __label__0   \n",
       "3  NCT04372004  • Male or female over 18 years of age at the t...  __label__0   \n",
       "4  NCT04372004  Current symptoms of COVID-19 ; fever alone or ...  __label__0   \n",
       "\n",
       "                                          elig_split  \n",
       "0  [All, pregnant, women, SARS-Cov-2, positive, d...  \n",
       "1                      [Informed, consent, obtained]  \n",
       "2                         [18, years, to, 48, years]  \n",
       "3  [•, Male, or, female, over, 18, years, of, age...  \n",
       "4  [Current, symptoms, of, COVID-19, ;, fever, al...  "
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligibility_criteria_df['elig_split'] = [x.split() for x in eligibility_criteria_df['eligibility_criteria']]\n",
    "eligibility_criteria_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "•\n",
      ";\n",
      ".\n",
      "-\n",
      "&\n",
      "-\n",
      "-\n",
      ")\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      "•\n",
      "•\n",
      ";\n",
      ";\n",
      "-\n",
      "•\n",
      "-\n",
      "•\n",
      "-\n",
      "-\n",
      "-\n",
      "(\n",
      "&\n",
      "&\n",
      "(\n",
      "(\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      "(\n",
      "-\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "(\n",
      ",\n",
      "-\n",
      "-\n",
      "•\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "&\n",
      "-\n",
      ")\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ")\n",
      "-\n",
      "-\n",
      ")\n",
      "&\n",
      "-\n",
      "(\n",
      "-\n",
      "-\n",
      "&\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ")\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "-\n",
      ".\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "•\n",
      "-\n",
      "(\n",
      "•\n",
      ".\n",
      ",\n",
      ";\n",
      "(\n",
      "-\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      ")\n",
      "-\n",
      ")\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "&\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "&\n",
      "&\n",
      "(\n",
      "-\n",
      "-\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "-\n",
      "-\n",
      "-\n",
      "•\n",
      "(\n",
      "(\n",
      "(\n",
      ")\n",
      "-\n",
      "-\n",
      ".\n",
      "-\n",
      "&\n",
      "-\n",
      "-\n",
      "-\n",
      "•\n",
      "&\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "-\n",
      "-\n",
      "-\n",
      "(\n",
      "•\n",
      ".\n",
      ",\n",
      "-\n",
      ";\n",
      ";\n",
      "-\n",
      "-\n",
      ".\n",
      ".\n",
      "-\n",
      "-\n",
      "•\n",
      ",\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "-\n",
      "•\n",
      ".\n",
      ".\n",
      ".\n",
      ".\n",
      "&\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "&\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "•\n",
      "-\n",
      "-\n",
      "-\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "&\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      ",\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "(\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      ";\n",
      "-\n",
      "-\n",
      ",\n",
      "-\n",
      "-\n",
      ",\n",
      ".\n",
      ",\n",
      "-\n",
      "-\n",
      ";\n",
      "-\n",
      "&\n",
      "&\n",
      "&\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ")\n",
      "&\n",
      "•\n",
      ",\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ";\n",
      "•\n",
      "-\n",
      ".\n",
      ".\n",
      ".\n",
      "-\n",
      "-\n",
      "-\n",
      ")\n",
      "-\n",
      "•\n",
      "•\n",
      "-\n",
      ".\n",
      ".\n",
      ".\n",
      "-\n",
      "-\n",
      ".\n",
      "-\n",
      "-\n",
      "-\n",
      ")\n",
      "-\n",
      "-\n",
      ",\n",
      "•\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n",
      ".\n",
      "•\n",
      "-\n",
      "-\n",
      ".\n",
      "-\n",
      "-\n",
      "-\n",
      "-\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>label</th>\n",
       "      <th>elig_split</th>\n",
       "      <th>elig_split_attempt</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[All, pregnant, women, SARS-Cov-2, positive, d...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Informed, consent, obtained]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[18, years, to, 48, years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[•, Male, or, female, over, 18, years, of, age...</td>\n",
       "      <td>[None]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Current, symptoms, of, COVID-19, ;, fever, al...</td>\n",
       "      <td>[None]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid                               eligibility_criteria       label  \\\n",
       "0  NCT04395924  All pregnant women SARS-Cov-2 positive during ...  __label__0   \n",
       "1  NCT04395924                          Informed consent obtained  __label__0   \n",
       "2  NCT04395924                               18 years to 48 years  __label__0   \n",
       "3  NCT04372004  • Male or female over 18 years of age at the t...  __label__0   \n",
       "4  NCT04372004  Current symptoms of COVID-19 ; fever alone or ...  __label__0   \n",
       "\n",
       "                                          elig_split elig_split_attempt  \n",
       "0  [All, pregnant, women, SARS-Cov-2, positive, d...                 []  \n",
       "1                      [Informed, consent, obtained]                 []  \n",
       "2                         [18, years, to, 48, years]                 []  \n",
       "3  [•, Male, or, female, over, 18, years, of, age...             [None]  \n",
       "4  [Current, symptoms, of, COVID-19, ;, fever, al...             [None]  "
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "listofsymbols = [\"•\", \"&\", \".\", \",\", \"-\", \"(\", \")\", \";\"]\n",
    "eligibility_criteria_df['elig_split_attempt'] = [[print(symbol) for symbol in listofsymbols if symbol in cell] for cell in eligibility_criteria_df['elig_split']]\n",
    "\n",
    "eligibility_criteria_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>label</th>\n",
       "      <th>elig_split</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[All, pregnant, women, SARS-Cov-2, positive, d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Informed, consent, obtained]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[18, years, to, 48, years]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[•, Male, or, female, over, 18, years, of, age...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Current, symptoms, of, COVID-19, ;, fever, al...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9933</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Intent to transfer care to an outside institution</td>\n",
       "      <td>__label__1</td>\n",
       "      <td>[Intent, to, transfer, care, to, an, outside, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9934</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>HIV (as these patients already receive intensi...</td>\n",
       "      <td>__label__1</td>\n",
       "      <td>[HIV, (as, these, patients, already, receive, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9935</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior pregnancy in which individual declined p...</td>\n",
       "      <td>__label__1</td>\n",
       "      <td>[Prior, pregnancy, in, which, individual, decl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9936</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Prior enrollment in NNM2</td>\n",
       "      <td>__label__1</td>\n",
       "      <td>[Prior, enrollment, in, NNM2]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9937</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Enrollment in a concurrent research study that...</td>\n",
       "      <td>__label__1</td>\n",
       "      <td>[Enrollment, in, a, concurrent, research, stud...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>17437 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            nctid                               eligibility_criteria  \\\n",
       "0     NCT04395924  All pregnant women SARS-Cov-2 positive during ...   \n",
       "1     NCT04395924                          Informed consent obtained   \n",
       "2     NCT04395924                               18 years to 48 years   \n",
       "3     NCT04372004  • Male or female over 18 years of age at the t...   \n",
       "4     NCT04372004  Current symptoms of COVID-19 ; fever alone or ...   \n",
       "...           ...                                                ...   \n",
       "9933  NCT03922334  Intent to transfer care to an outside institution   \n",
       "9934  NCT03922334  HIV (as these patients already receive intensi...   \n",
       "9935  NCT03922334  Prior pregnancy in which individual declined p...   \n",
       "9936  NCT03922334                           Prior enrollment in NNM2   \n",
       "9937  NCT03922334  Enrollment in a concurrent research study that...   \n",
       "\n",
       "           label                                         elig_split  \n",
       "0     __label__0  [All, pregnant, women, SARS-Cov-2, positive, d...  \n",
       "1     __label__0                      [Informed, consent, obtained]  \n",
       "2     __label__0                         [18, years, to, 48, years]  \n",
       "3     __label__0  [•, Male, or, female, over, 18, years, of, age...  \n",
       "4     __label__0  [Current, symptoms, of, COVID-19, ;, fever, al...  \n",
       "...          ...                                                ...  \n",
       "9933  __label__1  [Intent, to, transfer, care, to, an, outside, ...  \n",
       "9934  __label__1  [HIV, (as, these, patients, already, receive, ...  \n",
       "9935  __label__1  [Prior, pregnancy, in, which, individual, decl...  \n",
       "9936  __label__1                      [Prior, enrollment, in, NNM2]  \n",
       "9937  __label__1  [Enrollment, in, a, concurrent, research, stud...  \n",
       "\n",
       "[17437 rows x 4 columns]"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligibility_criteria_df.drop(['elig_split_attempt'], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>label</th>\n",
       "      <th>elig_split</th>\n",
       "      <th>elig_split_attempt</th>\n",
       "      <th>elig_split_str_concat</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[All, pregnant, women, SARS-Cov-2, positive, d...</td>\n",
       "      <td>[]</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Informed, consent, obtained]</td>\n",
       "      <td>[]</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[18, years, to, 48, years]</td>\n",
       "      <td>[]</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[•, Male, or, female, over, 18, years, of, age...</td>\n",
       "      <td>[None]</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Current, symptoms, of, COVID-19, ;, fever, al...</td>\n",
       "      <td>[None]</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid                               eligibility_criteria       label  \\\n",
       "0  NCT04395924  All pregnant women SARS-Cov-2 positive during ...  __label__0   \n",
       "1  NCT04395924                          Informed consent obtained  __label__0   \n",
       "2  NCT04395924                               18 years to 48 years  __label__0   \n",
       "3  NCT04372004  • Male or female over 18 years of age at the t...  __label__0   \n",
       "4  NCT04372004  Current symptoms of COVID-19 ; fever alone or ...  __label__0   \n",
       "\n",
       "                                          elig_split elig_split_attempt  \\\n",
       "0  [All, pregnant, women, SARS-Cov-2, positive, d...                 []   \n",
       "1                      [Informed, consent, obtained]                 []   \n",
       "2                         [18, years, to, 48, years]                 []   \n",
       "3  [•, Male, or, female, over, 18, years, of, age...             [None]   \n",
       "4  [Current, symptoms, of, COVID-19, ;, fever, al...             [None]   \n",
       "\n",
       "                               elig_split_str_concat  \n",
       "0  All pregnant women SARS-Cov-2 positive during ...  \n",
       "1                          Informed consent obtained  \n",
       "2                               18 years to 48 years  \n",
       "3  • Male or female over 18 years of age at the t...  \n",
       "4  Current symptoms of COVID-19 ; fever alone or ...  "
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligibility_criteria_df['elig_split_str_concat'] = [' '.join(cell) for cell in eligibility_criteria_df['elig_split']]\n",
    "eligibility_criteria_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>label</th>\n",
       "      <th>elig_split</th>\n",
       "      <th>elig_split_attempt</th>\n",
       "      <th>elig_split_str_concat</th>\n",
       "      <th>lowercase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[All, pregnant, women, SARS-Cov-2, positive, d...</td>\n",
       "      <td>[]</td>\n",
       "      <td>All pregnant women SARS-Cov-2 positive during ...</td>\n",
       "      <td>all pregnant women sars-cov-2 positive during ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Informed, consent, obtained]</td>\n",
       "      <td>[]</td>\n",
       "      <td>Informed consent obtained</td>\n",
       "      <td>informed consent obtained</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[18, years, to, 48, years]</td>\n",
       "      <td>[]</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[•, Male, or, female, over, 18, years, of, age...</td>\n",
       "      <td>[None]</td>\n",
       "      <td>• Male or female over 18 years of age at the t...</td>\n",
       "      <td>• male or female over 18 years of age at the t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>[Current, symptoms, of, COVID-19, ;, fever, al...</td>\n",
       "      <td>[None]</td>\n",
       "      <td>Current symptoms of COVID-19 ; fever alone or ...</td>\n",
       "      <td>current symptoms of covid-19 ; fever alone or ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid                               eligibility_criteria       label  \\\n",
       "0  NCT04395924  All pregnant women SARS-Cov-2 positive during ...  __label__0   \n",
       "1  NCT04395924                          Informed consent obtained  __label__0   \n",
       "2  NCT04395924                               18 years to 48 years  __label__0   \n",
       "3  NCT04372004  • Male or female over 18 years of age at the t...  __label__0   \n",
       "4  NCT04372004  Current symptoms of COVID-19 ; fever alone or ...  __label__0   \n",
       "\n",
       "                                          elig_split elig_split_attempt  \\\n",
       "0  [All, pregnant, women, SARS-Cov-2, positive, d...                 []   \n",
       "1                      [Informed, consent, obtained]                 []   \n",
       "2                         [18, years, to, 48, years]                 []   \n",
       "3  [•, Male, or, female, over, 18, years, of, age...             [None]   \n",
       "4  [Current, symptoms, of, COVID-19, ;, fever, al...             [None]   \n",
       "\n",
       "                               elig_split_str_concat  \\\n",
       "0  All pregnant women SARS-Cov-2 positive during ...   \n",
       "1                          Informed consent obtained   \n",
       "2                               18 years to 48 years   \n",
       "3  • Male or female over 18 years of age at the t...   \n",
       "4  Current symptoms of COVID-19 ; fever alone or ...   \n",
       "\n",
       "                                           lowercase  \n",
       "0  all pregnant women sars-cov-2 positive during ...  \n",
       "1                          informed consent obtained  \n",
       "2                               18 years to 48 years  \n",
       "3  • male or female over 18 years of age at the t...  \n",
       "4  current symptoms of covid-19 ; fever alone or ...  "
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligibility_criteria_df['lowercase'] = [cell.lower() for cell in eligibility_criteria_df['elig_split_str_concat']]\n",
    "eligibility_criteria_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>label</th>\n",
       "      <th>lowercase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>all pregnant women sars-cov-2 positive during ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>informed consent obtained</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>• male or female over 18 years of age at the t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>current symptoms of covid-19 ; fever alone or ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid       label                                          lowercase\n",
       "0  NCT04395924  __label__0  all pregnant women sars-cov-2 positive during ...\n",
       "1  NCT04395924  __label__0                          informed consent obtained\n",
       "2  NCT04395924  __label__0                               18 years to 48 years\n",
       "3  NCT04372004  __label__0  • male or female over 18 years of age at the t...\n",
       "4  NCT04372004  __label__0  current symptoms of covid-19 ; fever alone or ..."
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligibility_criteria_df = eligibility_criteria_df.drop(['eligibility_criteria', 'elig_split', 'elig_split_attempt', 'elig_split_str_concat'], axis=1)\n",
    "eligibility_criteria_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>label</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>all pregnant women sars-cov-2 positive during ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>informed consent obtained</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>• male or female over 18 years of age at the t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>current symptoms of covid-19 ; fever alone or ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid       label                               eligibility_criteria\n",
       "0  NCT04395924  __label__0  all pregnant women sars-cov-2 positive during ...\n",
       "1  NCT04395924  __label__0                          informed consent obtained\n",
       "2  NCT04395924  __label__0                               18 years to 48 years\n",
       "3  NCT04372004  __label__0  • male or female over 18 years of age at the t...\n",
       "4  NCT04372004  __label__0  current symptoms of covid-19 ; fever alone or ..."
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "eligibility_criteria_df = eligibility_criteria_df.rename(columns={'lowercase':'eligibility_criteria'})\n",
    "eligibility_criteria_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>label</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>index</th>\n",
       "      <th>interventionname</th>\n",
       "      <th>interventiontype</th>\n",
       "      <th>interventiondesc</th>\n",
       "      <th>statusDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>all pregnant women sars-cov-2 positive during ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>informed consent obtained</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>18 years to 48 years</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>• male or female over 18 years of age at the t...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>NCT04372004</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>current symptoms of covid-19 ; fever alone or ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid       label                               eligibility_criteria  \\\n",
       "0  NCT04395924  __label__0  all pregnant women sars-cov-2 positive during ...   \n",
       "1  NCT04395924  __label__0                          informed consent obtained   \n",
       "2  NCT04395924  __label__0                               18 years to 48 years   \n",
       "3  NCT04372004  __label__0  • male or female over 18 years of age at the t...   \n",
       "4  NCT04372004  __label__0  current symptoms of covid-19 ; fever alone or ...   \n",
       "\n",
       "   index interventionname interventiontype interventiondesc statusDate  \n",
       "0    NaN              NaN              NaN              NaN        NaN  \n",
       "1    NaN              NaN              NaN              NaN        NaN  \n",
       "2    NaN              NaN              NaN              NaN        NaN  \n",
       "3    NaN              NaN              NaN              NaN        NaN  \n",
       "4    NaN              NaN              NaN              NaN        NaN  "
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "joined_df = eligibility_criteria_df.join(specific_drug_df.set_index('nctid'), on='nctid')\n",
    "joined_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "joined_df = joined_df.dropna()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>label</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>index</th>\n",
       "      <th>interventionname</th>\n",
       "      <th>interventiontype</th>\n",
       "      <th>interventiondesc</th>\n",
       "      <th>statusDate</th>\n",
       "      <th>full_concat</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>55</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>fulfilling all the following criteria</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>400 milligrams each 12 hours for 10 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "      <td>Hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>55</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>fulfilling all the following criteria</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>400 milligrams each 12 hours for 10 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "      <td>Hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>56</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>aged between 18 and 60 years, male or female.</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>400 milligrams each 12 hours for 10 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "      <td>Hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>56</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>aged between 18 and 60 years, male or female.</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>400 milligrams each 12 hours for 10 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "      <td>Hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>57</td>\n",
       "      <td>NCT04332835</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hospitalized participants with diagnosis of co...</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Hydroxychloroquine</td>\n",
       "      <td>Drug</td>\n",
       "      <td>400 milligrams each 12 hours for 10 days</td>\n",
       "      <td>05/26/2020</td>\n",
       "      <td>Hydroxychloroquine . hospitalized participants...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          nctid       label  \\\n",
       "55  NCT04332835  __label__0   \n",
       "55  NCT04332835  __label__0   \n",
       "56  NCT04332835  __label__0   \n",
       "56  NCT04332835  __label__0   \n",
       "57  NCT04332835  __label__0   \n",
       "\n",
       "                                 eligibility_criteria  index  \\\n",
       "55              fulfilling all the following criteria    3.0   \n",
       "55              fulfilling all the following criteria    3.0   \n",
       "56      aged between 18 and 60 years, male or female.    3.0   \n",
       "56      aged between 18 and 60 years, male or female.    3.0   \n",
       "57  hospitalized participants with diagnosis of co...    3.0   \n",
       "\n",
       "      interventionname interventiontype  \\\n",
       "55  Hydroxychloroquine             Drug   \n",
       "55  Hydroxychloroquine             Drug   \n",
       "56  Hydroxychloroquine             Drug   \n",
       "56  Hydroxychloroquine             Drug   \n",
       "57  Hydroxychloroquine             Drug   \n",
       "\n",
       "                            interventiondesc  statusDate  \\\n",
       "55  400 milligrams each 12 hours for 10 days  05/26/2020   \n",
       "55  400 milligrams each 12 hours for 10 days  05/26/2020   \n",
       "56  400 milligrams each 12 hours for 10 days  05/26/2020   \n",
       "56  400 milligrams each 12 hours for 10 days  05/26/2020   \n",
       "57  400 milligrams each 12 hours for 10 days  05/26/2020   \n",
       "\n",
       "                                          full_concat  \n",
       "55  Hydroxychloroquine . fulfilling all the follow...  \n",
       "55  Hydroxychloroquine . fulfilling all the follow...  \n",
       "56  Hydroxychloroquine . aged between 18 and 60 ye...  \n",
       "56  Hydroxychloroquine . aged between 18 and 60 ye...  \n",
       "57  Hydroxychloroquine . hospitalized participants...  "
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "joined_df['full_concat'] = joined_df['interventionname'] + ' . ' + joined_df['eligibility_criteria']\n",
    "joined_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label</th>\n",
       "      <th>full_concat</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>55</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>Hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>55</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>Hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>56</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>Hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>56</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>Hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>57</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>Hydroxychloroquine . hospitalized participants...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         label                                        full_concat\n",
       "55  __label__0  Hydroxychloroquine . fulfilling all the follow...\n",
       "55  __label__0  Hydroxychloroquine . fulfilling all the follow...\n",
       "56  __label__0  Hydroxychloroquine . aged between 18 and 60 ye...\n",
       "56  __label__0  Hydroxychloroquine . aged between 18 and 60 ye...\n",
       "57  __label__0  Hydroxychloroquine . hospitalized participants..."
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clean_elig_df = joined_df[[\"label\", \"full_concat\"]]\n",
    "clean_elig_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "clean_elig_df = clean_elig_df.reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "clean_elig_df = clean_elig_df.drop(['index'], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "clean_elig_df['full_concat'] = [cell.lower() for cell in clean_elig_df['full_concat']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label</th>\n",
       "      <th>full_concat</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . hospitalized participants...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        label                                        full_concat\n",
       "0  __label__0  hydroxychloroquine . fulfilling all the follow...\n",
       "1  __label__0  hydroxychloroquine . fulfilling all the follow...\n",
       "2  __label__0  hydroxychloroquine . aged between 18 and 60 ye...\n",
       "3  __label__0  hydroxychloroquine . aged between 18 and 60 ye...\n",
       "4  __label__0  hydroxychloroquine . hospitalized participants..."
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clean_elig_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "clean_elig_df = clean_elig_df.rename(columns={'full_concat':'eligibility_criteria'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>0</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . fulfilling all the follow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . aged between 18 and 60 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4</td>\n",
       "      <td>__label__0</td>\n",
       "      <td>hydroxychloroquine . hospitalized participants...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        label                               eligibility_criteria\n",
       "0  __label__0  hydroxychloroquine . fulfilling all the follow...\n",
       "1  __label__0  hydroxychloroquine . fulfilling all the follow...\n",
       "2  __label__0  hydroxychloroquine . aged between 18 and 60 ye...\n",
       "3  __label__0  hydroxychloroquine . aged between 18 and 60 ye...\n",
       "4  __label__0  hydroxychloroquine . hospitalized participants..."
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clean_elig_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>count</td>\n",
       "      <td>2446</td>\n",
       "      <td>2446</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>unique</td>\n",
       "      <td>2</td>\n",
       "      <td>1416</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>top</td>\n",
       "      <td>__label__1</td>\n",
       "      <td>hydroxychloroquine . pregnancy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>freq</td>\n",
       "      <td>1489</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             label            eligibility_criteria\n",
       "count         2446                            2446\n",
       "unique           2                            1416\n",
       "top     __label__1  hydroxychloroquine . pregnancy\n",
       "freq          1489                              10"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clean_elig_df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
